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Abstract		
	
Coeliac	disease	 is	 a	 systemic	 autoimmune	disease	 associated	with	 gastrointestinal	 and	extra-
gastrointestinal	 symptoms,	 triggered	by	gluten	 in	genetically	 susceptible	 individuals.	 It	affects		
1%	of	the	general	population	(1,	2),	although	75%	remain	undiagnosed	(3).	Delayed	diagnosis	can	
lead	to	a	poor	quality	of	life	and	complications	(3).		The	under-detection	could	be	due	to	non-
specific	symptoms	and	under-utilisation	of	serological	testing	(4).	Several	point	of	care	tests	for	
coeliac	disease	have	been	developed	in	the	past	decade,	which	may	potentially	help	to	improve	
case	detection.	
	
A	 few	 recent	 studies	 have	 shown	 that	 Simtomax,	 a	 point	 of	 care	 test	 detecting	 IgA-/IgG-
deamidated	gliadin	peptide	antibodies	(IgA/IgG-DGP),	appeared	to	have	comparable	sensitivities	
to	 conventional	 serology.	 However,	 further	 studies	 are	 required	 to	 validate	 the	 diagnostic	
performance	of	Simtomax.	
	
The	null	 hypothesis	of	my	 thesis	 is	 that	 a	point	of	 care	 test	has	no	 role	 in	 the	diagnosis	 and	
management	 of	 coeliac	 disease.	 We	 aimed	 to	 evaluate	 the	 sensitivities,	 utility	 and	 cost	
effectiveness	of	the	point	of	care	test,	Simtomax,	in	various	domains:	
	
Study	1:	To	assess	the	role	of	Simtomax	as	a	primary	care	case	finding	tool	for	coeliac	disease	in	
high	risk	individuals	in	community	pharmacies.		
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Study	 2:	 To	 demonstrate	 the	 diagnostic	 accuracy	 of	 Simtomax	 in	 secondary	 care,	 in	 patients	
referred	with	gastrointestinal	symptoms	or	self-reported	gluten	sensitivity.	
	
Study	3:	To	establish	the	diagnostic	accuracy	of	Simtomax	and	its	cost	effectiveness	of	coeliac	
testing	in	patients	with	iron	deficiency	anaemia	in	the	endoscopy	setting.		
	
Study	 4:	 To	 investigate	 whether	 Simtomax	 is	 a	 reliable	 surrogate	 marker	 for	 predicting	
histological	remission	in	patients	with	known	coeliac	disease	on	a	gluten	free	diet.		
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1.1:	Introduction	to	Coeliac	Disease	
1.1.1:	The	history	of	coeliac	disease	
Coeliac	disease	 is	 a	 systemic	 autoimmune	disease	 associated	with	 gastrointestinal	 and	extra-
gastrointestinal	symptoms,	affecting	1%	of	the	general	population	worldwide	(1,	5).	 It	 is	1.5-2	
times	more	prevalent	in	females	(1,	3,	6).	The	disease	is	triggered	by	dietary	gluten,	a	ubiquitous	
protein	complex	found	in	staple	foods	made	of	wheat,	barley	and	rye	in	genetically	susceptible	
individuals	(7).	Although	this	condition	of	gluten	intolerance	may	appear	to	be	a	modern	disease,	
it	 was	 in	 fact	 described	 since	 ancient	 times.	 Humans	 had	 been	 hunter	 gatherers	 since	 the	
beginning	of	humankind	2.5	million	years	ago,	until	wheat	cultivation	methods	were	first	adopted	
in	Gobleki	Tepe	in	south	eastern	Turkey,	known	as	the	Fertile	Crescent,	from	10th	century	CE.	This	
Neolithic	agricultural	revolution	transformed	humankind’s	way	of	life	from	hunter	gatherers	to	
securing	 a	 stable	 food	 supply.	 Consequently,	wheat	 cultivation	 generated	antigens	 that	were	
previously	unknown	 to	humans,	 and	 those	who	were	unable	 to	adapt	would	develop	 coeliac	
disease.		
	
During	the	2nd	century	CE	a	Greek	physician	named	Aretaeus	of	Cappadocia,	who	lived	in	eastern	
Turkey,	identified	this	malabsorptive	syndrome	of	steatorrhea,	weight	loss	and	pallor,	and	named	
it	 ‘koiliakos’,	 meaning	 abdominal.	 Centuries	 later	 in	 1887,	 Samuel	 Gee,	 a	 leading	 English	
paediatrician,	 provided	 the	 first	 comprehensive	 modern	 description	 of	 this	 chronic	
malabsorptive	disorder	that	could	be	treated	by	dietetic	measures,	for	which	he	named	as	coeliac	
disease,	concluding	‘if	the	patient	can	be	cured	at	all,	it	must	be	by	means	of	diet’,	although	the	
causative	agent	was	not	known	at	the	time.		
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In	1924,	the	famous	banana	diet	was	championed	by	an	American	physician,	Sidney	Haas	(8).	The	
diet	excluded	other	carbohydrates	such	as	bread,	cereals,	crackers	and	potatoes,	which	benefited	
many	children	for	decades	based	on	eliminating	wheat	grains.	A	significant	discovery	was	made	
after	the	second	World	War	in	1950,	confirming	the	Dutch	paediatrician,	William	Dicke’s	previous	
clinical	 observation	 of	 wheat	 being	 the	 culprit	 of	 coeliac	 disease.	 Dicke	 recognised	 that	 the	
shortage	of	bread	towards	the	end	of	World	War	two,	the	so	called	‘winter	of	starvation’,	resulted	
in	clinical	improvement	in	children	who	were	fed	other	foods	such	as	rice	and	maize.	And	when	
bread	was	 airdropped	 in	Holland,	 the	 children	 rapidly	 deteriorated	 again.	 The	 toxic	 effect	 of	
wheat	was	supported	by	objective	measurements	of	growth	curves	and	faecal	fat	quantification	
related	 to	 wheat	 exposure.	 His	 subsequent	 collaborative	 studies	 found	 that	 the	 gliadin	
component	of	wheat	was	responsible	for	the	fat	malabsorption	in	coeliac	patients	(9).	
	
A	major	breakthrough	in	coeliac	disease	pathology	was	made	in	1954	when	an	English	physician	
John	 Paulley	 discovered	 the	 characteristic	 small	 bowel	 mucosal	 flattening	 in	 patients	 with	
steatorrhoea	 through	 intestinal	 sampling	 during	 laparotomies.	 Small	 intestinal	 sampling	 was	
subsequently	made	less	invasive	by	the	invention	of	a	flexible	biopsy	tube	which	took	duodenal	
biopsies	per	orally	with	fluoroscopic	guidance	in	1956.	This	was	later	superseded	by	the	Crosby	
capsule	in	1957,	which	allowed	jejunal	biopsy	sampling	by	suctioning	the	mucosa	and	triggering	
a	spring	activated	knife	to	obtain	the	biopsy.	This	technique	was	widely	used	until	the	advent	of	
fibreoptic	endoscopes	in	the	1990’s.	
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1.1.2:	Clinical	presentation	
The	presenting	features	of	coeliac	disease	are	variable	and	can	be	non-specific.	According	to	the	
Oslo	definitions,	the	presentation	of	coeliac	disease	can	be	categorised	into	two	main	groups-	
‘classical’	 and	 ‘non	 classical’	 (10).	 Historically,	 coeliac	 disease	was	 considered	 a	 rare	 disease,	
featuring	 ‘classical’	 symptoms	 of	malabsorption	 including	 chronic	 diarrhoea,	 weight	 loss	 and	
failure	to	thrive	(11).	It	is	important	to	note	that	the	term	‘classical	coeliac	disease’	does	not	imply	
that	it	is	the	commoner	form	of	presentation.	In	fact,	since	the	1980s,	there	has	been	a	gradual	
recognition	 that	 coeliac	 disease	 often	 presents	 insidiously,	 with	 the	 majority	 of	 patients	
presenting	with	‘non	classical’	features	such	as	irritable	bowel	type	symptoms,	anaemia,	chronic	
fatigue,	change	in	bowel	habit,	abdominal	pain,	osteoporosis	and	neurological	symptoms	(11-15).	
Epidemiological	studies	also	showed	that	coeliac	disease	affects	a	far	more	diverse	population	
worldwide	among	different	races	than	previously	recognised	(16-19).	
	
1.1.3:	Epidemiology	
Epidemiological	 studies	 have	 demonstrated	 that	 the	 true	 prevalence	 of	 coeliac	 disease	 is	
approximately	 1%	 in	 Western	 countries	 (1,	 5),	 with	 a	 female	 preponderance	 of	 1.5-2	 fold	
compared	to	males	(1,	3,	6).	The	incidence	of	coeliac	disease	has	been	on	the	rise,	through	the	
combination	of	the	advent	of	serological	testing,	heightened	awareness	of	coeliac	disease	and	a	
genuine	 increase	 in	 incidence.	 A	 recent	 Norwegian	 study	 found	 a	 three-fold	 increase	 in	 the	
incidence	of	biopsy	proven	coeliac	disease	in	children	from	2000	to	2010	(20).	A	similar	trend	has	
also	 been	 observed	 in	 adults	 where	 a	 Finnish	 group	 found	 the	 prevalence	 to	 have	 doubled	
between	1978-80	and	2000-01	(21).	The	authors	concluded	that	there	was	a	true	increase	in	the	
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incidence	 of	 coeliac	 disease,	 as	 the	 prevalence	 of	 unrecognised	 coeliac	 disease	 increased	
proportionately	with	the	recognised	cases	over	the	two	decades.	If	the	increased	rate	was	purely	
due	to	a	heightened	awareness,	then	one	would	expect	a	drop	in	the	proportion	of	undetected	
cases.	
	
Apart	 from	 improved	 case	detection	 from	 raised	 awareness,	 there	 are	other	 factors	 that	 are	
postulated	 to	 cause	 the	 true	 rise	 in	 incidence.	 The	 increasing	 incidence	 of	 coeliac	 disease	 is	
parallel	to	the	steady	rise	of	other	autoimmune	diseases	and	allergies,	with	growing	evidence	to	
support	the	hygiene	theory	as	one	of	the	possible	contributing	factors	to	this	phenomenon	(22).		
	
Furthermore,	gluten	is	ubiquitous	in	the	Western	diet	and	processed	foods,	which	may	also	play	
a	 part	 in	 the	 growing	 incidence	 of	 coeliac	 disease.	 Mounting	 evidence	 revealed	 that	 the	
prevalence	 of	 coeliac	 disease	 in	 Asia	 is	 climbing	 with	 an	 increasingly	 Westernised	 diet.	 The	
seroprevalence	of	coeliac	disease	was	found	to	be	1.6%	in	Asia	(Iran,	Turkey,	Israel	and	India)	
(23).	 Similar	 figures	 have	 been	observed	 in	 population	 screening	 studies	 in	Argentina	 (0.95%	
biopsy	proven)	(24),	Malaysia	(1.25%	seroprevalence)	(25)	and	Saudi	Arabia	(1%	biopsy	proven)	
(26).	
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1.1.4:	Genetics	
Genetic	predisposition	plays	a	key	role	in	the	pathogenesis	of	coeliac	disease.	Virtually	all	patients	
with	 coeliac	 disease	 carry	 the	 human	 leucocyte	 antigen	 (HLA)	 class	 II	 genes:	 the	 HLA-DQ2	
haplotype	is	expressed	in	95%	of	patients,	and	the	HLA-DQ8	haplotype	in	the	remaining	5%.	The	
absence	of	these	genotypes	therefore	effectively	rules	out	coeliac	disease	(27).	These	HLA	class	
II	genes	are	not	exclusive	to	patients	with	coeliac	disease	however,	as	they	are	also	expressed	in	
30%	of	 the	general	population	where	 coeliac	disease	 is	prevalent.	 Interestingly,	only	2-5%	of	
individuals	 carrying	 these	class	 II	major	histocompatibility	 complex	molecules	develop	coeliac	
disease,	implicating	that	environmental	factors	also	play	a	part	(28).	
	
1.1.5:	Pathogenesis	
Gliadin	is	a	glycoprotein	extract	from	gluten	that	is	unusually	proline	rich,	a	residue	that	is	very	
resistant	to	degradation	by	luminal	and	brush	border	peptidase	(29).	Long	fragments	of	gliadin	
trigger	 the	 release	of	 zonulin,	a	physiological	modulator	of	 tight	 junctions,	allowing	gliadin	 to	
cross	the	intestinal	epithelial	barrier	through	increased	gut	permeability	(30).	(Figure	1)	
	
Adaptive	immune	response	
Once	in	the	lamina	propria,	gliadin	is	deamidated	to	negatively	charged	glutamic	acid	by	tissue	
transglutaminase	 (TTG),	 an	 enzyme	 normally	 involved	 in	 collagen	 cross-linking	 and	 tissue	
remodelling.	The	deamidated	gliadin	peptides	(DGP)	have	a	high	affinity	to	bind	to	HLA-DQ2	or	
HLA-DQ8	molecules	expressed	on	the	antigen	presenting	cells	(APC).	This	triggers	an	adaptive	
immune	response,	where	the	APC	interact	with	gliadin	specific	cluster	of	differentiation	4	(CD4)	
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T-helper	 1	 cells	 to	 produce	 inflammatory	 cytokines	 (31).	 Inflammatory	 cytokines	 such	 as	
interferon	 (IFN)-γ	 induce	 the	 activation	 and	 release	 of	 matrix	 metalloproteinases	 (MMP)	 by	
myofibroblasts,	resulting	in	mucosal	remodelling	and	villous	atrophy.	On	the	other	hand,	T-helper	
2	 cells	 drive	 the	 clonal	 expansion	 of	 B	 cells	 to	 produce	 anti-gliadin	 (AGA)	 and	 anti-TTG	 (32).	
(Figure	1)	
	
Innate	immune	response	
Gliadin	 also	 triggers	 an	 innate	 immune	 response	 involving	 an	 increased	 production	 of	 pro-
inflammatory	cytokines,	particularly	interleukin	(IL)-15.	IL-15	upregulates	the	natural-killer	group	
2	member	D	 (NKG2D)	 receptors	 on	 intraepithelial	 lymphocytes	 (IEL)	 and	 its	 epithelial	 ligand,	
inducing	epithelial	apoptosis	(28).	Intriguingly,	α-gliadin	peptides	unrecognised	by	intestinal	CD4	
T	cells	can	upregulate	IL-15	production,	suggesting	that	the	innate	response	in	the	epithelium	
may	occur	autonomously,	as	seen	in	patients	with	latent	coeliac	disease	prior	to	the	occurrence	
of	villous	atrophy	(33).	(Figure	1)	
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Figure	1:	The	pathogenesis	of	coeliac	disease.	Increased	gut	permeability	allows	gluten	peptides	(gliadin)	to	cross	
the	 intestinal	epithelial	barrier	and	enter	the	 lamina	propria.	Gliadin	 is	deamidated	by	TTG	which	enhances	 its	
binding	to	HLA	DQ2	and	HLA	DQ8	molecules	that	are	presented	on	APC.	This	complex	is	recognised	by	CD4	T	helper	
1	cells	which	produce	inflammatory	cytokines	such	as	IFN-γ,	inducing	mucosal	remodelling	and	villous	atrophy	by	
MMP	released	by	myofibroblasts.	T-helper	2	cells	drive	the	clonal	expansion	of	B	cells	to	produce	AGA	and	anti-
tissue	 transglutaminase	 (TG2	 in	 the	 figure).	 Gliadin	 also	 stimulates	 an	 innate	 immune	 response	 involving	 an	
increased	 production	 of	 pro-inflammatory	 cytokines	 such	 as	 IL-15	 in	 epithelial	 and	 dendritic	 cells,	 activating	
intraepithelial	lymphocytes	and	ultimately	causing	epithelial	apoptosis.	
	
 
 
 
	
	
Figure	reprinted	from	‘Celiac	Disease:	From	Pathogenesis	to	Novel	Therapies,	Schuppan	et	al.,	Gastroenterology	
Volume	137,	Issue	6,	December	2009,	Pages	1912–1933’,	Copyright	2016	with	permission	from	Elsevier.		
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1.1.6:	Complications	
Patients	living	with	undiagnosed	coeliac	disease	often	suffer	from	a	significantly	impaired	quality	
of	life	compared	to	those	who	have	been	diagnosed	and	treated	(health	outcome	measure	EQ-
5D	0.56	versus	0.84)	(34).	Anaemia	and	nutritional	deficiencies	in	iron,	vitamin	B12,	vitamin	D,	
folate,	and	calcium	are	common	at	diagnosis	(35).	The	prevalence	of	metabolic	bone	disease	and	
premature	osteoporosis	is	more	than	twice	than	that	of	the	general	population	(36).	Although	
there	is	a	moderate	increased	risk	of	fractures	in	patients	with	coeliac	disease	(hazard	ratio	[HR]	
1.31	for	any	fractures)	compared	to	the	general	population,	the	absolute	fracture	risk	is	small	
(3.19	 per	 1000	 person-years)	 (37).	 Extra-gastrointestinal	 complications	 such	 as	 subfertility,	
adverse	foetal	outcomes	(38,	39)	and	neuropsychiatric	symptoms	(e.g.	headaches,	depression)	
(40,	41)	are	not	uncommon.	
	
A	small	proportion	of	patients	will	develop	non-responsive	coeliac	disease,	defined	as	failure	of	
symptomatic	or	histological	 improvement	following	presumed	adherence	to	a	gluten	free	diet	
(primary	non-response	if	no	response	after	12	months	of	a	gluten	free	diet;	and	secondary	non-
response	if	symptoms	relapse	after	initial	response	to	a	gluten	free	diet).	The	commonest	cause	
for	 non-responsiveness	 is	 gluten	 exposure,	 whether	 inadvertently	 or	 not	 (42),	 due	 to	 the	
restrictiveness	 of	 a	 gluten	 free	 diet	 and	 the	 ubiquity	 of	 gluten	 in	 processed	 foods.	 Dietary	
adherence	 has	 been	 reported	 to	 be	 36%-96%,	 and	 is	 influenced	 by	 a	 variety	 of	 cognitive,	
emotional	and	socio-cultural	factors	(43,	44).	Other	causes	for	persistent	symptoms	should	be	
ruled	 out,	 such	 as	 microscopic	 colitis,	 pancreatic	 insufficiency	 and	 small	 bowel	 bacterial	
overgrowth.	
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In	patients	with	persistent	villous	atrophy	despite	a	confirmed	strict	gluten	free	diet	by	a	coeliac	
specialist	dietitian,	a	diagnosis	of	refractory	coeliac	disease	(RCD)	may	be	made	after	exclusion	
of	 other	 concomitant	 small	 intestinal	 conditions	 causing	 villous	 atrophy	 (e.g.	 small	 bowel	
bacterial	 overgrowth,	 giardiasis,	 tuberculosis,	 human	 immunodeficiency	 virus	 and	 Whipple’s	
disease).	RCD	is	a	rare	complication	defined	by	persistent	or	recurrent	malabsorptive	symptoms	
and	villous	atrophy	despite	strict	adherence	to	a	gluten	free	diet	for	at	least	6-12	months,	in	the	
absence	of	other	causes	of	non-responsive	treated	coeliac	disease	(45,	46).	The	true	incidence	of	
RCD	is	unknown	due	to	its	rarity.	Within	the	coeliac	cohort,	the	prevalence	has	been	reported	to	
be	0.7%	in	a	UK	study,	and	cumulative	incidence	of	1.47%	in	a	US	study	(47,	48).	Symptoms	are	
often	severe	and	patients	often	require	pharmacological	therapies	in	addition	to	a	strict	gluten	
free	diet.		
	
RCD	can	be	divided	into	two	types	based	on	the	presence	or	absence	of	aberrant	IELs	in	the	small	
bowel	mucosa.	Type	1	RCD	is	clinically	and	histologically	indistinguishable	from	uncomplicated	
active	coeliac	disease.	It	could	represent	patients	who	are	super	sensitive	to	even	trace	levels	of	
gluten,	or	those	with	a	slow	response	to	gluten	withdrawal.		Type	1	RCD	generally	have	a	more	
benign	course	compared	to	type	2,	although	the	rate	of	complications	and	mortality	is	still	much	
higher	than	uncomplicated	coeliac	disease	(45,	49).	In	type	2	RCD,	severe	complications	such	as	
ulcerative	jejunitis	and	enteropathy	associated	T	cell	lymphoma	(EATL)	can	develop.	There	is	a	
marked	difference	in	the	five	year	survival	rate	between	type	1	and	type	2	RCD	(96%	vs	58%),	
which	is	largely	explained	by	the	high	frequency	of	development	of	EATL	in	patients	with	type	2	
RCD	(52%)	within	4-6	years	of	diagnosis	(49,	50).	EATL	carries	a	grave	prognosis,	with	a	five	year	
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survival	of	only	11%	despite	aggressive	treatment	(51-53).		
	
Due	to	the	rarity	of	RCD,	evidence	for	therapeutic	interventions	for	RCD	are	based	on	case	reports	
and	open	 label	observational	studies.	 Immunosuppressants	such	as	prednisolone,	budesonide	
and/or	azathioprine	have	been	shown	to	be	effective	 in	 inducing	and	maintaining	clinical	and	
histological	 remission	 in	most	 type	 1	 RCD	 patients	 (54-56).	 In	 contrast,	 there	 is	 no	 effective	
treatment	 for	 type	 2	 RCD.	 The	 only	 drug	 that	 was	 shown	 to	 induce	 clinical	 and	 histological	
improvement	 with	 a	 significant	 decrease	 in	 the	 number	 of	 aberrant	 clonal	 IELs	 is	 an	
antimetabolite,	 cladribine.	Nevertheless,	 41%	of	 patients	 still	 died	 of	 EATL	 despite	 cladribine	
therapy	(57).	The	risk	of	lymphoproliferative	malignancies	such	as	EATL	has	been	shown	to	be	
increased	in	patients	with	persistent	villous	atrophy	compared	to	those	with	mucosal	healing	(HR	
2.26)	 (58).	 Fortunately,	 EATL	 is	 a	 rare	 complication	 of	 coeliac	 disease,	 as	 demonstrated	 in	 a	
nationwide	 Swedish	 study	 showing	 an	 absolute	 rate	 of	 lymphoproliferative	 malignancies	 in	
coeliac	disease	of	70.3	per	100,000	person-years	(59).	
	
1.1.7:	Diagnosis	
The	 diagnosis	 of	 coeliac	 disease	 has	 evolved	 considerably	 over	 the	 last	 few	 decades	 as	 our	
understanding	of	its	pathophysiology	came	to	light.	According	to	the	current	British	Society	of	
Gastroenterology	 (BSG)	 (35)	and	National	 Institute	 for	Health	and	Care	Excellence	 (NICE)	 (60)	
guidelines,	a	diagnosis	of	coeliac	disease	is	made	based	on	a	positive	coeliac	serology	with	Marsh	
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grade	3	histology,	consisting	of	 raised	 IELs	 (>25	per	100	enterocytes),	 crypt	hypertrophy,	and	
villous	atrophy	(Figure	2).	
	
	
	
	
	
	
	
	
	
	
	
Historically,	 case	 detection	 was	 an	 arduous	 three	 phase	 process	 based	 on	 the	 presence	 of	
‘classical	 symptoms’	 of	 malabsorption,	 with	 non-specific	 tests	 assessing	 for	 small	 bowel	
absorption,	such	as	faecal	fat,	and	a	confirmatory	jejunal	biopsy	showing	villous	atrophy.	Because	
there	are	other	 causes	 for	 villous	atrophy	apart	 from	coeliac	disease,	a	 relationship	between	
gluten	and	the	small	bowel	mucosa	had	to	be	demonstrated.	This	consisted	of	phase	two	showing	
symptom	resolution	on	a	gluten	free	diet	and	a	second	biopsy	showing	mucosal	healing.	A	third	
biopsy	 was	 performed	 in	 phase	 three	 after	 a	 period	 of	 gluten	 challenge	 to	 demonstrate	 a	
recurrence	of	symptoms	and	mucosal	damage	on	histology.		
	
Figure	2:	Duodenal	histology	findings	in	coeliac	disease.	From	left	to	right-	Marsh	1:	Normal	villous	architecture	
with	increased	intraepithelial	lymphocytes	(IELs);	Marsh	3a:	Increased	IELs,	crypt	hyperplasia	and	mild	villous	
atrophy;	Marsh	3b:	Increased	IELs,	crypt	hyperplasia	and	moderate	villous	atrophy;	Marsh	3c:	Increased	IELs,	
crypt	hyperplasia	and	total	villous	atrophy.	Stained	with	haematoxylin	and	eosin,	×100.	Marsh	2	histology	
(Normal	villous	architecture	with	increased	IELs	and	crypt	hyperplasia)	is	not	illustrated	here.	
	
	
		 	
	
Reproduced	from	‘Coeliac	disease:	An	update	for	pathologists,	Dickson	et	al.,	J	Clin	Pathol.	2006	Oct;	59(10):	1008–
1016.’	Copyright	2016	with	permission	from	BMJ	Publishing	Group	Ltd.	
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The	advent	of	serological	testing	revolutionised	the	diagnostic	methods	for	coeliac	disease	(61).	
A	Swiss	immunologist	Berger	detected	antigliadin	antibodies	(AGA)	in	1964.	However,	AGA	has	a	
low	specificity	giving	a	high	number	of	false	positives	(62),	therefore	it	is	no	longer	recommended	
for	 the	 diagnosis	 of	 coeliac	 disease.	 In	 1983,	 a	 Polish	 dermatologist	 Chorzelski	 discovered	
endomysial	 antibodies	 (EMA)	 and	 dermatitis	 herpetiformis	 in	 children	 with	 coeliac	 disease.	
Although	EMA	is	highly	specific,	its	sensitivity	is	low.	Moreover,	EMA	testing	is	labour	intensive,	
costly	and	its	interpretation	is	subjective.	The	test	is	performed	by	Indirect	immunofluorescence	
using	rhesus	monkey	oesophagus	as	the	substrate,	with	the	endomysium	of	the	smooth	muscle	
bundles	serving	as	the	antigen.	The	sections	are	incubated	with	dilutions	of	the	patient’s	sera	
and	 fluorescein	 conjugated	 anti-IgA.	 The	 slides	 are	 then	 screened	and	 read	manually	 using	 a	
fluorescent	microscope,	and	fluorescent	activity	is	graded	against	control	slides.	The	complexity	
and	subjectivity	of	EMA	testing	encouraged	efforts	to	develop	TTG	testing,	which	uses	enzyme	
linked	immunosorbent	assay	(ELISA)	technique	that	further	transformed	the	diagnostic	process	
(63).		In	principle,	ELISA	involves	adding	diluted	patient	sera	to	microwells	that	are	pre-coated	
with	recombinant	human	TTG	antigen.	Autoantibodies	recognise	the	TTG	antigen	and	bind	to	it,	
giving	a	blue	reaction	for	positivity	after	a	substrate	is	added.		The	optical	density	is	read	at	450nm	
using	an	automated	and	calibrated	microplate	reader,	giving	a	TTG	titre	that	corresponds	to	the	
intensity	 of	 the	 colour.	 The	 introduction	of	 TTG	has	 largely	 replaced	AGA	due	 to	 its	 superior	
sensitivity	and	specificity	(64).		
	
The	BSG	and	NICE	guidelines	recommend	screening	high	risk	adults	with	TTG	as	a	first	line	test	in	
view	of	its	excellent	sensitivity,	followed	by	EMA	for	those	with	a	positive	TTG	(useful	in	cases	
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where	 TTG	has	 a	mildly	 raised	 titre	which	may	be	 a	 false	 positive	 if	 EMA	 is	 negative),	 and	 a	
confirmatory	duodenal	biopsy	for	those	with	a	positive	EMA.	On	the	other	hand,	the	European	
Society	 for	 Paediatric	 Gastroenterology	 Hepatology	 and	 Nutrition	 (ESPGHAN)	 guidelines	
recommend	that	paediatric	patients	no	longer	require	biopsies	to	confirm	the	diagnosis	of	coeliac	
disease	if	they	have	TTG	levels	10	times	over	the	upper	limit	of	normal,	positive	EMA	and	the	
presence	 of	HLA-DQ2	or	HLA-DQ8	 genotype.	 This	was	 based	 on	 a	 few	 studies	 showing	 good	
predictability	of	coeliac	disease	at	such	high	TTG	titres	(65).		
	
1.1.8:	Management	
	
At	present,	 a	gluten	 free	diet	 for	 life	 is	 the	only	effective	and	available	 treatment	 for	 coeliac	
disease.	Small	bowel	absorption	should	be	assessed	by	testing	for	full	blood	count,	ferritin,	folate	
and	B12.	Liver	function	tests	should	also	be	performed	as	coeliac	disease	can	be	associated	with	
deranged	 liver	 enzymes.	 A	 recent	 study	 showed	 that	 liver	 function	 was	 deranged	 in	 40.6%	
patients	with	coeliac	disease	at	diagnosis,	which	normalised	in	78%	patients	1.5	years	after	gluten	
exclusion.	Those	without	any	improvement	in	liver	function	should	be	tested	for	any	co-existing	
liver	 disease	 (66).	 Calcium,	 vitamin	 D	 and	 alkaline	 phosphatase	 should	 be	 monitored	 and	
supplemented	accordingly.	 Those	with	additional	 risk	 factors	 for	osteoporosis	or	 age	over	55	
should	have	a	baseline	bone	density	scan	at	one	year	after	commencement	of	a	gluten	free	diet.	
Other	 co-existing	autoimmune	diseases	 should	be	 screened	 for,	 such	as	 autoimmune	 thyroid	
disease	and	type	1	diabetes.	Functional	hyposplenism	is	seen	in	patients	with	coeliac	disease,	
which	may	lead	to	impaired	immunity	to	encapsulated	bacteria.	Data	showed	a	modest	increase	
in	pneumococcal	sepsis	in	patients	with	coeliac	disease	compared	to	the	general	population	(HR	
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2.6),	therefore	annual	pneumococcal	vaccination	is	recommended	(67).		
	
	
The	goal	of	treatment	is	to	relieve	symptoms,	achieve	mucosal	healing	and	prevent	complications	
through	a	strict	gluten	free	diet.	Therefore,	assessment	of	adherence	and	disease	remission	are	
key	aspects	of	management	(68).	The	assessment	of	adherence	incorporates	a	combination	of	
dietetic	evaluation	by	a	coeliac	specialist	dietitian,	symptom	assessment,	serological	testing	and	
repeat	 duodenal	 biopsy	 to	 assess	 for	mucosal	 healing.	Monitoring	 of	 complications	 includes	
haematological	 and	 biochemical	 evaluation	 for	 anaemia	 and	 nutritional	 deficiencies,	 bone	
density	 scans	 for	 osteoporosis,	 and	 vaccinations	 against	 Pneumococcus	 for	 functional	
hyposplenism	 (35).	Any	suspicion	of	 serious	complications	 such	as	RCD,	ulcerative	 jejunitis	or	
EATL	 should	 be	 urgently	 investigated	 endoscopically	 with	 small	 intestinal	 biopsies	 and	 small	
bowel	 capsule	 endoscopy.	 Immunosuppressants	 and	 artificial	 nutritional	 support	 may	 be	
indicated	in	RCD.	
	
Novel	pharmacological	therapies	for	coeliac	disease	are	on	the	horizon,	although	only	several	
have	 undergone	 phase	 2	 clinical	 trials.	 Gliadin	 is	 known	 to	 increase	 the	 secretion	 of	 a	 tight	
junction	modulator,	zonulin,	which	increases	intestinal	permeability.	This	facilitates	the	transport	
of	gliadin	into	the	lamina	propria	through	the	compromised	epithelial	barrier,	thereby	triggering	
an	inflammatory	process.	Phase	2	randomised	controlled	trials	on	a	zonulin	inhibitor,	larazotide	
acetate	 (AT-1001),	 have	 shown	 conflicting	 results	 regarding	 the	 preservation	 of	 intestinal	
epithelial	integrity	to	gluten	exposure,	although	patients	in	the	larazotide	group	experienced	less	
symptoms	on	a	gluten	challenge	(69-71).		
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Another	 therapeutic	option	 is	detoxifying	gluten	by	degradation	of	gluten	peptides	which	are	
highly	resistant	to	enzymatic	proteolysis	 in	the	gut.	Phase	2	randomised	controlled	trials	have	
demonstrated	that	pre-treating	gluten	with	bacterial	endoproteases	(ALV003	and	AN-PEP)	led	to	
significantly	less	mucosal	injury	and	T	cell	response	(72-74).		
	
A	therapeutic	vaccine	designed	to	induce	immunotolerance	to	gluten	has	been	developed	based	
on	three	frequently	recognised	immunogenic	peptides	(gliadin,	hordein	and	secalin)	identified	in	
patients	with	coeliac	disease.	Regular	administration	of	the	vaccine	in	mouse	models	have	shown	
a	dose	dependent	decrease	in	T	cell	proliferation	on	gluten	exposure.	Phase	1	trials	have	shown	
that	the	Nexvax2	vaccine	when	given	in	gradual	escalation	of	doses	over	7-9	weeks	(with	dose	
intervals	 of	 once	 every	 3-4	 days)	 was	 safe	 and	well	 tolerated	without	 immune	 activation	 or	
serious	adverse	effects	(75).	Nexvax2	will	now	enter	phase	2	trials	to	be	studied	as	an	adjunct	to	
a	gluten-free	diet.	There	are	a	number	of	other	therapeutic	options	being	studied,	but	they	are	
still	 in	 their	 infancy	 in	 preclinical	 phases.	 If	 the	 aforementioned	 therapies	 are	 proven	 to	 be	
efficacious,	it	is	foreseeable	that	they	will	act	as	adjuncts	to	a	gluten	free	diet	perhaps	in	a	subset	
of	patients	who	have	difficulty	in	inducing	or	maintaining	remission,	rather	than	as	a	replacement	
of	a	gluten	free	diet	given	the	potentially	high	cost.	
	
1.2:	Point	of	Care	Tests	for	Coeliac	Disease	
1.2.1:	Why	do	we	need	a	point	of	care	test	for	coeliac	disease?	
The	fact	that	76%	of	patients	with	coeliac	disease	remain	undiagnosed	suggests	that	the	current	
case	finding	strategies	with	serological	testing	may	be	inadequate.	Despite	national	guidelines,	it	
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has	been	revealed	that	coeliac	serology	was	only	performed	in	31.8%	of	patients	with	symptoms	
suggestive	 of	 coeliac	 disease	 who	 were	 undergoing	 a	 gastroscopy	 with	 duodenal	 biopsies,	
implying	that	serological	testing	was	underused	(4).	Conventional	serological	testing	is	a	sensitive	
screening	tool	for	coeliac	disease,	although	it	is	not	without	drawbacks.		
	
Serology	 testing	 requires	 venepuncture	 by	 a	 health	 care	 professional	 and	 can	 be	 difficult	 in	
children.	It	is	performed	in	central	laboratories,	and	results	usually	take	several	days	to	a	week	
to	become	available.	Moreover,	EMA	testing	is	labour	intensive,	time	consuming	and	costly,	and	
is	also	prone	to	subjective	interpretation	of	results.		Serological	testing	usually	requires	multiple	
healthcare	 visits	 and	 can	 lead	 to	 a	 delay	 in	 the	 patient	 undergoing	 a	 gastroscopy	 to	 obtain	
duodenal	biopsies	for	confirmation	of	the	diagnosis	and	initiation	of	treatment.	
	
The	 advantages	 of	 point	 of	 care	 tests	 are	 manifold:	 point	 of	 care	 tests	 do	 not	 require	
venepuncture	 nor	 laboratory	 processing,	 thus	 operate	 at	 a	 relatively	 low	 cost	 compared	 to	
conventional	 serology.	 A	 cost	 benefit	 analysis	 showed	 that	 by	 replacing	 current	 serological	
testing	with	a	point	of	care	test,	Simtomax,	in	patients	with	suspected	coeliac	disease	in	primary	
care,	a	potential	cost	saving	of	over	£7	million	per	year	could	be	made	for	the	National	Health	
Service	(NHS)	(76).	As	previously	mentioned,	serology	results	were	only	available	in	one	third	of	
patients	with	suspected	coeliac	disease	who	were	attending	for	a	gastroscopy	(4).	The	lack	of	a	
serological	result	commits	the	endoscopist	to	taking	duodenal	biopsies	routinely	for	patients	with	
symptoms	suggestive	of	coeliac	disease,	which	is	an	expensive	method	for	case	detection.	Most	
importantly,	 point	of	 care	 tests	 can	be	performed	 in	 an	ambulatory	 care	 setting	with	 rapidly	
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available	results,	which	could	facilitate	the	clinician’s	immediate	decision	making	to	streamline	
the	diagnostic	process.	
	
1.2.2:	The	commercially	available	point	of	care	tests	for	coeliac	disease	
A	point	of	care	test,	also	known	as	a	rapid	test	or	near	patient	test,	is	a	test	that	can	be	performed	
near	the	patient,	providing	rapid	results	without	the	need	for	laboratory	processing.	Point	of	care	
tests	for	coeliac	disease	have	evolved	considerably	in	the	past	two	decades.	One	of	the	first	point	
of	care	tests	was	a	dot	 immunobinding	assay	strip	detecting	AGA,	with	results	available	 in	30	
minutes	(77,	78).	With	the	discovery	of	TTG	being	identified	as	an	antigen	in	coeliac	disease	(31),	
several	point	of	care	tests	detecting	TTG	have	since	been	developed.	Early	point	of	care	tests	by	
dot	blot	immunoassay	test	strips	(Figure	3)	(79-81)	have	been	superseded	by	more	user	friendly,	
commercially	available	point	of	care	test	kits	using	lateral	flow	immunochromatography,	giving	
rapid	results	in	10	minutes	(Figure	4).	The	commercially	available	POCTs	are	listed	in	table	1.	
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Figure	3:	An	early	rapid	test	by	dot	blot	
immunoassay	test	strips.		
	
A	red	blot	at	the	control	line	denotes	a	
correctly	functioning	test	strip.	A	red	
blot	at	the	test	line	indicates	a	positive	
TTG	result.	Test	strips	1,	4,	6,	7	and	9	
are	positive	samples,	and	2,	3,	5,	8	and	
10	are	negative	samples.	
	
	
	
	
Reprinted	 from	 The	 Lancet,	 Vol	 359,	
March	16,	2002,	 Sorell	 et	al.,	One-step	
immunochromatographic	 assay	 for	
screening	 of	 coeliac	 disease,	 p945.		
Copyright	(2016),	with	permission	from	
Elsevier.	 	 Also	 Lancet	 special	 credit	 -	
"Reprinted	 from	 Vol	 359,	 March	 16,	
2002,	 Sorell	 et	 al.,	 One-step	
immunochromatographic	 assay	 for	
screening	 of	 coeliac	 disease,	 p945.	
Copyright	(2016),	with	permission	from	
Elsevier.	
	
Figure	 4:	 A	 commercially	 available	 point	 of	 care	
test,	using	Simtomax	as	an	example.		
	
A	drop	of	blood	from	a	finger	prick	is	drawn	with	a	
pipette	(top	 left),	which	 is	 then	applied	to	the	test	
device	 followed	by	 5	 drops	 of	 the	 provided	 buffer	
solution	(top	right).	(a)	Results	can	be	read	within	10	
minutes.	(b)	A	red	test	line	A	indicates	a	positive	test	
result,	 a	 red	 test	 line	 B	 indicates	 the	 presence	 of	
immunoglobulin	A	 (IgA),	 and	an	 inbuilt	 red	control	
line	 CT	 ensures	 that	 the	 device	 is	 functioning	
correctly.	(c)	shows	a	negative	Simtomax	test.	
	
	
				
	
	
Reprinted	 with	 the	 permission	 from	 Augurix	
Diagnostics.	
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Table	1:	The	commercially	available	POCTs.	
	
POCT	 Substrate	 Antibody	 Control	
line	
Available	
in	the	UK	
Available	 for	
purchase	 by	 the	
public	 or	 health	
care	 professionals	
(HCP	only)	
BiocardA	 Whole	blood	 IgA	TTG	 Yes	 Yes	 Public	and	HCP	
Stick	CD1B	 Serum	 IgA/IgG	TTG	 No	 No	 HCP	only	
Stick	CD2B	 Serum	 IgA	TTG	and	AGA	 No	 No	 HCP	only	
Simple	
CD1WB	B	
Whole	blood	 IgA/IgG/IgM	TTG	 Yes	 No	 HCP	only	
Simple	
CD2WB	B	
Whole	blood	 IgA	TTG	and	AGA	 Yes	 No	 HCP	only	
Celiac	 Quick	
TestC	
Whole	blood	 IgA/IgG/IgM	TTG	 Yes	 Yes	 HCP	only	
Celiac	 Screen	
ProfessionalD	
Whole	blood	 IgA/IgG	TTG	 Yes	 Yes	 HCP	only	
Xeliac	 Test	
ProE	
Whole	blood	 IgA/IgG	TTG	 Yes	 Yes	 Public	and	HCP	
SimtomaxF	 Whole	blood,	
serum,	and	
heparinised	
EDTA	plasma	
IgA/IgG	 DGP,	
total	IgA	
Yes	 Yes	 HCP	only	
	
A:	 Ani	 Biotech	 Oy,	 Finland;	 B:	 Operon	 S.A.,	 Spain;	 C:	 Biohit	 Healthcare,	 UK;	 D:	 Personal	
Diagnostics,	UK;	E:	Eurospital,	Italy;	F:	Augurix	Diagnostics,	Switzerland	
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1.2.3:	Current	evidence	for	point	of	care	tests	for	coeliac	disease	
The	main	 body	 of	 work	 on	 point	 of	 care	 tests	 has	 been	 focussed	 on	 Biocard,	 which	 initially	
appeared	to	perform	well	with	sensitivities	over	90%.	However,	common	flaws	in	the	methods	
used	seemed	to	have	overestimated	its	efficacy.	Firstly,	most	studies	only	biopsied	patients	with	
a	positive	serology	or	point	of	care	test.	For	 instance,	Raivio’s	group	examined	the	diagnostic	
accuracy	of	Biocard	in	150	high	risk	patients	(82).	All	patients	had	a	Biocard	test	alongside	EMA	
and	TTG.	Only	those	with	positive	serology	(n=44)	had	duodenal	biopsies	which	confirmed	coeliac	
disease.	The	sensitivity	and	specificity	of	Biocard	 in	concordance	 to	serology	were	95.5%	and	
97.1%	respectively.	The	fact	that	only	those	with	positive	serology	were	biopsied,	together	with	
the	 high	 coeliac	 disease	 prevalence	 of	 29.9%,	 would	 contribute	 to	 the	 apparently	 high	
sensitivities	 of	 Biocard,	 as	 false	 negatives	 would	 be	missed.	 Additionally,	 the	 sensitivity	 and	
specificity	 of	 Biocard	were	 compared	 against	 serology	 rather	 than	 duodenal	 histology	 as	 the	
reference	standard,	meaning	that	the	true	performance	of	Biocard	was	not	reflected.	Appendix	
1	contains	details	of	all	the	point	of	care	studies	to	date,	including	their	study	limitations.		
	
Secondly,	a	common	issue	is	an	inherent	high	pre-test	probability	due	to	tertiary	referral	bias.	
The	coeliac	disease	prevalence	of	the	case	finding	and	case	control	studies	ranged	from	1.5-65.4%	
(median	38.5%),	in	contrast	with	0.24-0.79%	in	population	screening	studies	(see	appendix	1).	
These	 limitations	could	overestimate	the	sensitivity	of	Biocard.	As	an	example,	Raivio’s	group	
conducted	a	subsequent	similar	but	 larger	study	evaluating	Biocard	using	stored	whole	blood	
samples	 from	 139	 patients	 with	 coeliac	 disease	 and	 103	 controls	 (83).	 The	 sensitivity	 and	
specificity	of	Biocard	were	found	to	be	93%	and	94%.	However,	we	must	take	into	account	the	
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significantly	 high	 coeliac	 disease	 prevalence	 at	 57.4%,	 which	 would	 cause	 a	 positive	
ascertainment	bias	through	the	high	pre-test	probability,	thereby	potentially	falsely	inflating	the	
sensitivities	of	Biocard.			
	
When	Biocard	was	compared	against	duodenal	histology	as	the	reference	standard	in	all	patients,	
its	 sensitivities	 disappointingly	 fell	 to	 70-80%	 (84,	 85).	 Mooney’s	 group	 evaluated	 the	
performance	of	Biocard	in	adults	with	suspected	coeliac	disease	attending	for	a	gastroscopy.	All	
patients	underwent	EMA,	TTG,	Biocard	and	duodenal	biopsies	irrespective	of	serology	or	Biocard	
results.	The	prevalence	of	coeliac	disease	was	moderately	high	at	22.4%	due	to	a	tertiary	referral	
bias,	 but	 even	 so,	 the	 sensitivity	 dropped	 to	 70.1%	 (84).	 The	 low	 sensitivity	 of	 Biocard	 was	
mirrored	in	another	prospective	case	finding	study	in	a	paediatric	population	in	India	when	the	
all-biopsy	 method	 was	 employed	 (85).	 They	 tested	 Biocard	 on	 124	 patients	 referred	 to	 the	
tertiary	care	centre	with	suspected	coeliac	disease,	with	a	very	high	prevalence	of	coeliac	disease	
at	64.7%.	Nevertheless,	the	sensitivity	and	specificity	still	fell	to	83%	and	90%	respectively	when	
compared	against	histology.	
	
It	is	noteworthy	that	the	sensitivity	of	Biocard	evaluated	by	a	Finnish	group	(sensitivity	93%)	(83,	
86)	was	higher	than	the	above	mentioned	studies	(sensitivities	70-80%)	(84,	85,	87),	even	though	
they	all	used	serology	and	duodenal	histology	as	 the	reference	standard.	This	could	partly	be	
explained	by	the	difference	in	the	method	of	blood	sample	collection,	where	the	Finnish	group	
used	stored	whole	blood	samples	 from	the	 laboratory	 instead	of	a	 fresh	whole	blood	sample	
from	 a	 finger	 prick	 in	 the	 latter	 two	 groups.	 Because	 Biocard	 depends	 on	 the	 liberation	 of	
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endogenous	TTG	from	red	blood	cells	to	act	as	the	autoantigen	for	the	test,	insufficient	red	cells	
from	a	finger	prick	may	liberate	insufficient	TTG	to	generate	a	positive	result.	Hence	it	is	possible	
that	the	sensitivity	of	Biocard	may	be	lower	if	a	capillary	finger	prick	sample	is	being	used	instead	
of	a	venous	blood	sample.	
	
Other	point	of	 care	 tests	 detecting	 TTG	 such	as	Celiac	Quick	 Test,	 Stick	CD1/CD2	and	 Simple	
CD1WB/CD2WB	appeared	to	be	comparable	to	serology,	but	there	are	only	a	handful	of	studies	
assessing	 their	 diagnostic	 accuracy,	 with	 similar	 limitations	 as	 those	 of	 Biocard.	 Therefore,	
caution	should	be	taken	when	interpreting	these	results.	Although	Simtomax	likewise	has	not	
been	extensively	investigated,	it	has	emerged	to	be	the	better	performing	point	of	care	test,	with	
sensitivities	of	92.7-100%	and	specificities	of	85.2-95%	 (87-90).	However,	only	one	study	 (87)	
biopsied	all	patients	irrespective	of	their	point	of	care	test	or	serology	results;	two	of	the	studies	
compared	Simtomax	against	serology	rather	than	duodenal	histology	(87-90);	and	all	four	studies	
had	a	high	pre-test	probability	(9.6%-65.4%).	Thus,	the	results	may	not	be	truly	reflective	of	the	
performance	of	Simtomax	in	clinical	practice.	Nevertheless,	Simtomax	was	shown	to	be	the	best	
point	of	care	test	in	a	head	to	head	trial	in	the	UK	comparing	Celiac	Quick	Test,	Biocard,	Simtomax	
and	IgA	TTG	in	55	patients	referred	with	a	positive	EMA	(87).	 	The	prevalence	was	expectedly	
high	at	65.4%,	and	the	sensitivity	was	77.8%	for	Celiac	Quick	Test,	72.2%	for	Biocard,	94.4%	for	
Simtomax	and	97.2%	for	TTG.		
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1.2.4:	Gaps	in	the	current	literature		
Simtomax	has	been	shown	to	be	a	promising	point	of	care	test	for	coeliac	disease.	However,	most	
study	methods	had	limitations	which	could	affect	the	true	efficacy	of	Simtomax	in	clinical	practice.	
Moreover,	the	prevalence	of	coeliac	disease	tended	to	be	high	in	these	studies	due	to	tertiary	
referral	bias.	The	sensitivities	of	Simtomax	may	drop	when	applied	to	a	lower	disease	prevalence	
population.	There	is	a	lack	of	data	in	the	current	literature	on	the	true	diagnostic	performance	of	
Simtomax	without	positive	ascertainment	bias	or	tertiary	referral	bias.	
	
1.2.5:	Simtomax-	a	point	of	care	test	detecting	IgA	and	IgG	deamidated	peptide	antibodies	
Simtomax	stands	out	from	the	other	point	of	care	tests	in	which	it	detects	IgA/IgG-DGP	rather	
than	 IgA-TTG,	 as	 well	 as	 the	 presence	 of	 IgA.	 As	 previously	 mentioned,	 gliadin	 in	 gluten	 is	
deamidated	 by	 TTG	 to	 DGP,	 a	 process	 that	 enhances	 its	 binding	 to	 HLA	 DQ2	 and	 HLA	 DQ8	
receptors,	which	triggers	a	gut	derived	T	cell	immune	response	(31,	91,	92).	DGP	can	be	detected	
by	Simtomax	via	different	types	of	blood	samples	such	as	venous	or	finger	prick	capillary	whole	
blood,	serum	and	plasma.	It	is	manufactured	by	Augurix	in	Swizterland,	and	is	currently	available	
for	order	by	health	care	professionals	in	the	UK	through	its	UK	distributor,	Tillotts	Pharma.	There	
are	 four	 reports	 so	 far	 on	 Simtomax,	 all	 of	 them	 being	 case	 finding	 studies	 (87-90).	 Details	
regarding	how	Simtomax	is	used	is	described	in	the	methods	section	in	chapter	two.	
	
	
	
	 37	
1.3:	Summary		
	
Coeliac	disease	is	a	common	yet	under	diagnosed	condition.	One	of	the	reasons	may	be	due	to	
deficiencies	in	case	finding	strategies	with	serological	testing.	If	Simtomax	can	be	shown	to	have	
diagnostic	accuracy	comparable	to	conventional	serology,	 it	may	offer	a	more	convenient	and	
potentially	more	cost	effective	way	of	detecting	and	managing	coeliac	disease.	
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Chapter	2:	Framework	of	thesis	
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2.1:	Null	hypothesis			
	
The	null	hypothesis	is	that	a	point	of	care	test	has	no	role	in	the	diagnosis	and	management	of	
coeliac	disease.	In	order	to	reject	the	null	hypothesis,	we	will	evaluate	the	utilisation	of	a	point	
of	care	test,	Simtomax,	in	four	studies,	which	will	form	the	chapters	of	my	thesis.		
	
2.2:	Aims	
 
	
Study	1:	To	assess	the	role	of	Simtomax	as	a	primary	care	case	finding	tool	for	coeliac	disease	in	
high	risk	individuals	in	community	pharmacies.	(chapter	3)	
	
Study	2:	To	demonstrate	the	diagnostic	accuracy	of	Simtomax	in	secondary	care,	by	recruiting	
patients	with	gastrointestinal	symptoms	or	self-reported	gluten	sensitivity	who	were	referred	to	
secondary	 care.	 The	 sensitivities	 of	 Simtomax	were	 compared	 to	 conventional	 serology	with	
duodenal	 histology	 as	 the	 reference	 standard.	 Patient	 acceptability	 of	 Simtomax	 and	 inter-
observer	agreement	of	the	Simtomax	results	were	also	evaluated.	(chapter	4)	
	
Study	3:	To	establish	the	diagnostic	accuracy	of	Simtomax	and	its	cost	effectiveness	of	coeliac	
testing	in	patients	with	iron	deficiency	anaemia	in	the	endoscopy	setting.	(chapter	5)	
	
Study	 4:	 To	 investigate	 whether	 Simtomax	 is	 a	 reliable	 surrogate	 marker	 for	 predicting	
histological	remission	in	patients	with	known	coeliac	disease	on	a	gluten	free	diet.	(chapter	6)	
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2.3:	General	methodology	
	
The	methodology	for	all	chapters	involving	Simtomax,	coeliac	serology	and	duodenal	biopsies	are	
described	here	to	avoid	repetition	in	subsequent	chapters.	Any	additional	methodological	details	
will	be	provided	in	individual	chapters.	
	
2.3.1:	The	point	of	care	test,	Simtomax	
	
The	DGP	based	point	of	care	test	 for	celiac	disease,	Simtomax,	was	manufactured	by	Augurix	
Diagnostics,	 Rheinfelden,	 Switzerland.	 It	 detects	 both	 IgA/IgG-DGP	 antibodies,	 as	well	 as	 the	
presence	of	IgA.	The	assay	is	based	on	lateral	flow	immunochromatography	using	colloidal	gold	
antihuman	 antibodies	 as	 a	 signal	 detector.	 A	 sample	 of	 25μl	 of	 capillary	 venous	 blood	 was	
obtained	through	a	simple	finger	prick	technique.	The	blood	sample	was	then	applied	to	the	test	
device,	followed	by	the	application	of	five	drops	of	the	provided	buffer	solution.	The	result	was	
available	after	ten	minutes.	Positive	results	were	indicated	by	the	presence	of	a	solid	red	band	
for	IgA/IgG-DGP	positivity.	A	second	single	red	band	indicated	the	presence	of	IgA.	A	third	in-built	
red	control	band	ensured	a	correctly	functioning	test.	See	figure	5	for	illustration	of	the	point	of	
care	test.	
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	Figure	5.	How	to	perform	a	Simtomax	test.		
	
From	left	to	right	from	the	top	down:	The	test	kit	comprises	of	an	alcohol	wipe,	a	lancet,	a	pipette,	
a	test	device,	buffer	solution	and	a	plaster.	The	fingertip	is	pricked	using	the	lancet,	producing	a	
droplet	of	blood.	Capillary	venous	blood	is	drawn	using	the	pipette	until	the	blood	reaches	the	
black	line	on	the	pipette	(25μl).	The	blood	sample	is	expelled	from	the	pipette	and	deposited	into	
the	outer	window	of	the	test	device.	After	30	seconds,	the	test	device	lid	is	lifted	and	five	drops	
of	the	buffer	solution	is	added	to	the	circular	port.	Allow	the	test	to	run	on	a	flat	surface	and	wait	
10	minutes	before	reading	the	results.	The	lid	should	not	be	closed	while	running	the	test.	Positive	
results	are	indicated	by	the	presence	of	a	solid	red	band	(A)	for	IgA/IgG-DGP	positivity.	A	second	
single	red	band	(B)	indicates	the	presence	of	IgA.	A	third	in-built	red	control	band	(C)	ensures	a	
correctly	functioning	test.	The	test	result	on	the	left	is	negative	and	the	one	on	the	right	is	positive.	
	
										
	
	
The	above	photos	were	taken	by	myself.	
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2.3.2:	Coeliac	serology	
IgA-TTG	was	 previously	 assayed	 using	 ELISA	 kit	 (Aesku	Diagnostics,	Wendelsheim,	 Germany).	
Since	2014,	IgA-TTG	has	been	assayed	using	fluorescence	enzyme	immunoassay	(Thermo	Fisher	
Immunocap	EliA,	UK).	A	TTG	titre	of	>7	U/ml	was	regarded	as	positive	as	per	the	manufacturer’s	
guidance.	
	
IgA-EMA	was	detected	by	immunofluorescence	on	primate	oesophagus	sections	(Binding	Site,	
Birmingham,	UK).	Total	 IgA	was	measured	on	a	Behring	BN2	nephelometer	 (Haywards	Heath,	
West	Sussex,	UK).		
	
2.3.3:	Histological	evaluation	
In	total,	at	least	five	biopsies	were	taken	from	the	duodenum	with	a	single	bite	per	pass	technique,	
including	 at	 least	 one	 biopsy	 from	 the	 duodenal	 bulb	 and	 four	 quadrantic	 biopsies	 from	 the	
second	part	of	the	duodenum.	Each	biopsy	was	fixed	in	formalin	at	the	time	of	the	gastroscopy.	
Specimens	were	 then	processed,	orientated	and	embedded	 in	paraffin	wax	by	 the	pathology	
department.	Standard	3μm	thick	sections	at	 three	 levels	were	stained	with	haematoxylin	and	
eosin,	and	reported	by	gastrointestinal	histopathologists	without	knowledge	of	the	point	of	care	
test	or	serology	results.	Villous	atrophy	was	graded	according	to	the	modified	Marsh	criteria	(93).		
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2.4:	Statistical	analysis	
 
	
Data	were	summarised	by	descriptive	statistics,	including	counts	and	percentages	for	categorical	
data,	and	medians	and	ranges	for	continuous	parameters.	The	diagnostic	accuracies	of	Simtomax,	
IgA-TTG	and	IgA-EMA	were	presented	with	sensitivity,	specificity,	PPV	and	NPV.	Clopper-Pearson	
method	was	used	to	calculate	the	confidence	intervals	(CI)	for	the	sensitivities.		
Statistical	analysis	was	performed	using	IBM	SPSS	statistics	version	24.	
	
2.5:	Definitions	of	diagnoses	
 
 
The	definition	of	coeliac	disease	was	based	on	positive	serology	(positive	TTG	and/or	EMA)	with	
Marsh	3	villous	atrophy.		
	
Seronegative	coeliac	disease	was	based	on	Marsh	3	villous	atrophy	on	a	normal	gluten	containing	
diet,	 positive	HLA	DQ2	or	DQ8,	 and	 other	 supporting	 information	 such	 as	 family	 history	 and	
response	 to	 a	 gluten	 free	 diet.	 Non-coeliac	 causes	 of	 seronegative	 villous	 atrophy	 were	
extensively	 investigated	 for,	 including	 giardiasis,	 tuberculosis,	Whipple’s	 disease,	 small	 bowel	
bacterial	 overgrowth,	 helicobacter	 pylori,	 human	 immunodeficiency	 virus,	 autoimmune	
enteropathy	and	drug	related	causes.		
	
Potential	coeliac	disease	was	defined	as	positive	serology	with	no	villous	atrophy	(Marsh	0-2),	
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with	supporting	information	such	as	positive	HLA	DQ2	or	DQ8	and	family	history.		
	
Non-coeliac	gluten	sensitivity	was	diagnosed	 in	patients	who	self-report	 symptoms	related	 to	
gluten,	with	negative	 serology,	 absence	of	 villous	 atrophy,	 and	 symptom	 induction	by	 gluten	
challenge.	
	
2.6:	Reference	standard	
	
The	reference	standard	for	the	diagnostic	performance	of	coeliac	serology	and	Simtomax:	Marsh	
3	villous	atrophy	secondary	to	coeliac	disease	(includes	seronegative	coeliac	disease	after	other	
causes	of	seronegative	villous	atrophy	were	ruled	out)	
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Chapter	3:	The	role	of	a	point	of	care	test	in	primary	care:	a	case	
finding	feasibility	study	
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3.1:	Abstract	
	
Background:	Coeliac	disease	affects	1%	of	the	population,	but	75%	remain	undiagnosed.	This	is	
partly	 due	 to	 coeliac	 serology	 being	 under-utilised,	 suggesting	 insufficiencies	 in	 current	 case	
finding	strategies.	The	aim	was	to	evaluate	the	case	detection	rate	using	a	point	of	care	test	in	
primary	care,	and	the	uptake	rate	of	Simtomax	and	subsequent	gastroscopies.	
	
Methods:	A	prospective	study	was	performed	in	six	community	pharmacies	across	Sheffield,	UK,	
using	a	point	of	care	test,	Simtomax	(IgA/IgG-deamidated	gliadin	peptide).	Pharmacy	customers	
with	 symptoms	 suggestive	 of	 or	 risk	 factors	 for	 coeliac	 disease	 were	 tested	with	 Simtomax.	
Positive	 individuals	 were	 referred	 for	 a	 gastroscopy	 with	 duodenal	 biopsies	 alongside	
conventional	 serology.	 Individuals	with	 known	 coeliac	disease,	 those	on	a	 gluten	 free	diet	or	
those	who	were	investigated	for	coeliac	disease	were	excluded.		
	
Results:	A	total	of	802	customers	were	approached.	Eight	customers	(1.1%)	already	had	a	coeliac	
disease	diagnosis	and	were	therefore	excluded.	Five	hundred	customers	who	met	the	inclusion	
criteria	participated	in	the	study	and	were	tested	with	Simtomax	(369	females,	73.8%;	age	range	
18-87,	median	age	49),	with	a	positive	rate	of	7.2%	(36/500).	The	Simtomax	uptake	rate	was	63%	
(500/794).	Twenty-seven	 positive	 participants	 (75%)	 underwent	 a	 gastroscopy	with	 duodenal	
biopsies	 and	 serology.	 Two	 participants	 were	 diagnosed	 with	 coeliac	 disease,	 and	 one	 with	
potential	coeliac	disease,	with	a	case	detection	rate	of	0.6%.		
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Conclusion:	There	was	good	uptake	for	point	of	care	testing,	although	the	case	detection	rate	
was	much	 lower	 than	 anticipated.	 Therefore,	 it	 has	 a	 limited	 role	 as	 a	 case	 finding	 tool	 in	 a	
community	pharmacy	setting	in	our	cohort.	
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3.2:	Introduction	
	
One	of	the	major	challenges	with	coeliac	disease	is	that	a	considerable	proportion	of	patients	are	
undiagnosed	despite	it	being	a	prevalent	condition.	Sanders	et	al.	reported	that	approximately	one	
third	of	patients	were	seen	by	other	medical	or	surgical	specialties	with	coeliac	related	symptoms	
before	being	diagnosed,	and	the	mean	delay	in	diagnosis	in	the	Sheffield	cohort	was	4.9	years	(14).	
In	the	past	two	decades,	there	has	been	an	increasing	recognition	of	the	changing	presentation	of	
coeliac	disease,	where	patients	can	exhibit	subtler	signs,	such	as	fatigue	and	anaemia.	Thus	there	
has	been	a	drive	to	test	for	coeliac	disease	in	at	risk	individuals	in	primary	care.		
	
Previous	primary	care	case	finding	studies	have	shown	improvement	in	case	detection	rates	through	
screening	high	 risk	patients	with	serology.	Sanders’	group	 found	12	new	cases	of	coeliac	disease	
when	screening	1200	patients	with	fatigue,	anaemia	and	irritable	bowel	syndrome	(94).	Hin	et	al.	
screened	1000	high	risk	patients	and	newly	diagnosed	30	patients	with	coeliac	disease	(prevalence	
3%).	They	quoted	a	fourfold	increase	in	new	cases	compared	to	seven	new	cases	diagnosed	in	a	local	
district	 general	 hospital	 in	 the	 previous	 year	 (95).	 Similarly,	 Catassi’s	 group	 found	 a	 2.3%	 case	
detection	rate	in	976	high	risk	patients,	increasing	the	diagnostic	rate	from	0.27	to	11.6	per	1000	
visits	when	compared	to	the	preceding	12	months	(16).	
	
Nevertheless,	despite	the	national	guidelines	to	test	for	coeliac	disease	in	patients	with	suggestive	
symptoms	or	risk	factors,	it	appears	that	clinicians	do	not	uniformly	follow	this	practice.	This	was	
previously	demonstrated	 in	our	multicentre	study,	where	we	collected	data	on	the	availability	of	
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coeliac	serology	prior	to	gastroscopy	with	duodenal	biopsies	in	934	anaemic	patients	from	four	UK	
hospitals	(Bradford,	Whipps	Cross,	Addenbrooke’s	and	Hull).	We	found	that	only	33.8%	of	patients	
had	 serology	 performed	 despite	 guideline	 recommendations	 (96).	 This	 result	 echoes	 the	 31.8%	
availability	rate	of	serology	in	patients	with	suspected	coeliac	disease	undergoing	a	gastroscopy	as	
demonstrated	by	Wiland’s	group	in	America	(4).	
	
Several	reasons	could	explain	the	lower	than	expected	usage	of	coeliac	serology.	The	main	reason	is	
probably	due	to	the	fact	that	coeliac	disease	presents	in	an	array	of	symptoms,	some	of	which	are	
vague	and	insidious.	This	makes	it	difficult	for	clinicians	to	recognise,	and	some	patients	accept	these	
symptoms	 as	 part	 of	 their	 health.	 Clinicians	 also	 fail	 to	 recognise	 opportunities	 for	 testing,	 as	
illustrated	 by	 Sanders’	 group	 where	 patients	 had	 sought	 help	 from	 multiple	 health	 care	
professionals,	 and	 some	 had	 had	 gastroscopies	 without	 duodenal	 biopsies	 taken	 before	 being	
diagnosed	with	coeliac	disease	years	 later	(14).	Moreover,	under	the	current	climate	of	the	NHS,	
increasingly	longer	waits	to	access	primary	care	are	not	uncommon.	Further	delay	is	encountered	
with	the	arrangement	of	a	blood	test	for	coeliac	serology,	obtaining	the	results,	and	referral	onwards	
for	a	gastroscopy.	All	these	issues	suggest	insufficiencies	in	our	current	case	finding	strategy.			
	
This	necessitates	an	alternative	approach	to	improve	case	detection.	A	point	of	care	test	offers	the	
advantage	of	rapid	result	availability	within	10	minutes,	making	it	suitable	for	use	in	a	community	
setting.	A	recent	proof	of	concept	study	demonstrated	that	screening	551	high	risk	individuals	with	
Simtomax	 in	 community	pharmacies	 led	 to	a	positive	 Simtomax	 test	 in	9.4%	of	 the	participants.	
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However,	there	was	no	data	pertaining	to	the	subsequent	follow	up	or	biopsy	results	to	confirm	the	
number	of	coeliac	disease	cases	detected	(97).	
	
3.3:	Methods	
	
Aims:		
To	 evaluate	 the	 role	 of	 Simtomax	 for	 the	 detection	 of	 coeliac	 disease	 in	 at	 risk	 or	 symptomatic	
individuals	in	a	primary	care	setting.		
	
Study	design	and	recruitment:		
A	prospective	case	finding	study	was	conducted	in	six	community	pharmacies	across	the	city	of	
Sheffield	 (Darnall,	 Foxhill,	 Manor	 Top,	 Wicker,	 Barnsley	 Road)	 over	 a	 four-month	 period.	
Recruitment	was	achieved	in	three	ways:		
1. Customers	 at	 the	 pharmacies	 were	 approached	 by	 the	 principal	 investigator	 (PI)	 i.e.	
myself	and	I	informed	them	about	the	study.	Those	who	were	interested	were	invited	to	
a	private	consultation	room	within	the	pharmacies	to	determine	eligibility	of	participation	
through	 completion	of	 a	participant’s	questionnaire	 (see	appendix	2).	Customers	with	
symptoms	or	risk	factors	for	coeliac	disease	indicated	for	coeliac	screening	by	the	NICE	
guidelines	(see	table	2)	were	recruited.	
	
	
	 51	
	
	
	
	
	
	
	
	
	
	
	
2. Customers	 obtaining	 relevant	 medications	 either	 through	 prescription	 or	 over	 the	
counter	 were	 approached	 by	 the	 pharmacists	 and	 referred	 to	 the	 PI	 for	 study	
participation.	 The	 relevant	medications	 included	 treatment	 for	 possible	 symptoms	 of	
coeliac	 disease	 (e.g.	 antispasmodics	 for	 irritable	 bowel)	 or	 conditions	 that	 may	 be	
associated	with	coeliac	disease	(e.g.	insulin	for	type	1	diabetes).	These	target	medications	
are	listed	in	table	3.		
3. Posters	advertising	for	the	study	were	in	place	in	all	pharmacies	which	customers	could	
enquire	further	for	study	participation	(see	appendix	3).		
	
Table	2:	Symptoms	of	and	risk	factors	for	coeliac	disease	that	fulfilled	the	inclusion	criteria	for	
the	study.	
	
	
Persistent	 unexplained	 abdominal	 or	
gastrointestinal	symptoms	
Coeliac	disease	in	first	degree	relatives		
Irritable	bowel	syndrome	 Metabolic	 bone	 disorders	 (osteomalacia/	
osteoporosis)	
Prolonged	fatigue	 Unexplained	 neurological	 symptoms	
(peripheral	neuropathy	or	ataxia)	
Unintentional	weight	loss	 Unexplained	 subfertility	 or	 recurrent	
miscarriage	
Severe	or	persistent	mouth	ulcers	 Persistently	 raised	 liver	 enzymes	 with	
unknown	cause	
Iron,	vitamin	B12	or	folate	deficiency	 Dental	enamel	defects	
Type	1	diabetes	 Autoimmune	thyroid	disease	
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Inclusion	criteria:		
Individuals	aged	18	or	over,	with	any	symptoms	or	risk	factors	 listed	 in	table	2,	and/or	taking	
medications	listed	in	table	3.	
	
Exclusion	criteria:		
Known	coeliac	disease,	being	on	a	gluten	free	diet,	previous	or	current	investigation	for	coeliac	
disease,	and	pregnancy.	
	
Table	3:	Types	of	medications	taken	by	an	individual	that	would	trigger	recruitment	into	the	study.	
	
Drug	group	 Example	drugs	 Association	with	coeliac	disease	
Antispasmodics	 Mebeverine,	buscopan,	spasmonal	 Irritable	bowel	syndrome	
Antacids	 Proton	 pump	 inhibitor,	 gaviscon,	
ranitidine	
Dyspepsia	
Anti-diarrhoeal	 Loperamide	 Diarrhoea	
Laxatives	 Senna,	movicol,	sodium	docusate	 Constipation	
Anti-emetic	 Domperidone,	metoclopramide	 Nausea	and	vomiting	
Supplements	 Ferrous	 sulphate,	 vitamin	 B12,	
folate	
Iron,	B12	and	folate	deficiencies	
Thyroid	medications	 Thyroxine,	carbimazole	 Autoimmune	thyroid	disease	
Insulin	 All	types	of	insulin	 Type	1	diabetes	
	
	
	 53	
Recruitment:		
Individuals	 who	 met	 the	 eligibility	 criteria	 were	 approached	 and	 consented	 for	 the	 study.	
Participants	were	given	background	information	about	coeliac	disease,	explained	the	process	of	
point	of	care	testing,	and	the	meaning	of	the	test	results.		
	
Simtomax	 testing	was	 performed	 in	 a	 private	 consultation	 room	within	 the	 pharmacies.	 The	
results	were	obtained	within	10	minutes	and	participants	were	informed	of	the	results	 in	real	
time.	Those	with	a	negative	test	were	advised	to	see	their	general	practitioner	if	necessary	or	if	
their	symptoms	persisted.	Those	with	a	positive	test	were	referred	for	further	investigations	at	
the	Royal	Hallamshire	Hospital,	Sheffield.		
	
Positive	participants	underwent	conventional	coeliac	serology	(IgA-TTG,	IgA-EMA)	and	total	IgA	
levels,	followed	by	a	gastroscopy	with	quadrantic	duodenal	biopsies	from	the	second	part	of	the	
duodenum	and	one	duodenal	bulb	biopsy.	A	diagnosis	of	coeliac	disease	was	made	based	on	
positive	coeliac	serology	(EMA+/-	TTG)	plus	villous	atrophy	on	duodenal	biopsies.	Participants	
with	coeliac	disease	ruled	out	were	 informed	of	 their	 results	and	discharged	to	primary	care.	
Those	 who	 were	 diagnosed	 with	 coeliac	 disease	 were	 offered	 a	 clinic	 appointment	 at	 the	
outpatient	department	at	the	Royal	Hallamshire	Hospital,	and	their	management	pathway	was	
as	per	standard.		
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Outcome	measures:		
The	 primary	 outcome	measure	 was	 the	 coeliac	 disease	 detection	 rate.	 Secondary	 outcomes	
included	the	uptake	rate	of	Simtomax	and	subsequent	investigations.	
	
Sample	size:		
The	sample	size	of	this	study	was	aimed	at	500.	The	estimated	prevalence	of	coeliac	disease	in	
this	 study	 cohort	was	 3%.	 This	 3%	prevalence	was	 based	 on	 previous	 case	 finding	 studies	 in	
primary	care:	Hin	et	al	demonstrated	a	3%	prevalence	of	coeliac	disease	in	patients	with	high	risk	
symptoms	(95);	and	Sanders	et	al	2002	found	a	3.3%	prevalence	of	coeliac	disease	in	participants	
with	irritable	bowel	syndrome	and	fatigue	in	South	Yorkshire	(14).	
	
Statistics:		
The	statistics	department	of	 the	University	of	Sheffield	was	consulted	regarding	 the	sample	size.	
Using	an	exact	binomial	test,	a	sample	size	of	500	would	have	88%	power	to	detect	the	difference	
between	the	estimated	3%	coeliac	disease	prevalence	 in	 the	study	cohort	and	the	estimated	1%	
prevalence	of	coeliac	disease	in	the	general	population.	
	
Ethics	approval:		
This	study	protocol	was	approved	by	the	Yorkshire	and	the	Humber	Research	Ethics	committee	
and	 registered	 with	 the	 local	 research	 and	 development	 department	 of	 Sheffield	 Teaching	
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Hospital	NHS	Foundation	Trust	under	 the	 registration	number	STH19172.	 (see	appendix	4	 for	
patient	information	sheet	and	appendix	5	for	consent	form)	
	
3.4:	Results	
Eight	hundred	and	two	pharmacy	customers	were	approached	for	the	study.	Eight	 individuals	
(1.1%)	 who	 were	 approached	 already	 had	 a	 coeliac	 disease	 diagnosis	 and	 were	 therefore	
excluded.	Five	hundred	individuals	met	the	eligibility	criteria	and	agreed	to	undertake	the	point	
of	care	test,	giving	a	point	of	care	test	uptake	rate	of	63%	(500/794).	There	were	369	females	
(73.8%),	 and	 the	 age	 range	 was	 18-87	 (median	 age	 49).	 Table	 4	 illustrates	 the	 participants’	
presenting	characteristics.	
	
Table	4:	Participants’	presenting	characteristics.	
Presenting	features	 Number	 of	
participants	
(n=500)	
%	
Persistent	unexplained	abdominal	or	gastrointestinal	symptoms	 441	 88.2	
Irritable	bowel	syndrome	 176	 35.2	
Prolonged	fatigue	 261	 52.2	
Unintentional	weight	loss	 48	 9.6	
Severe	or	persistent	mouth	ulcers	 68	 13.6	
Iron,	vitamin	B12	or	folate	deficiency	 47	 9.4	
Type	1	diabetes	 4	 0.8	
Autoimmune	thyroid	disease	 47	 9.4	
Coeliac	disease	in	first	degree	relatives	 21	 4.2	
Metabolic	bone	disorders	(osteomalacia/	osteoporosis)	 20	 4	
Unexplained	neurological	symptoms	(peripheral	neuropathy	or	ataxia)	 1	 0.2	
Unexplained	subfertility	or	recurrent	miscarriage	 9	 1.8	
Persistently	raised	liver	enzymes	with	unknown	cause	 2	 0.4	
	
	 56	
Thirty-six	 participants	 (36/500=7.2%)	 were	 tested	 positive,	 of	 which	 27	 (75%)	 subsequently	
underwent	 further	 evaluation	 with	 conventional	 serology	 and	 a	 gastroscopy	 with	 duodenal	
biopsies.	Of	 the	 remaining	nine	positive	participants	who	did	not	have	 further	 investigations,	
seven	participants	changed	their	mind	at	the	pharmacy	and	declined	further	investigations,	one	
participant	wanted	time	to	consider	further	tests	and	eventually	declined	a	gastroscopy,	and	one	
agreed	to	further	tests	but	did	not	attend	for	their	gastroscopy	appointments	and	subsequently	
declined	further	tests	over	follow	up	phone	calls.		
	
Of	 the	 27	 participants	 with	 positive	 Simtomax	 who	 underwent	 further	 investigations,	 two	
participants	were	diagnosed	with	coeliac	disease,	and	another	with	potential	coeliac	disease.	One	
was	a	classical	coeliac	disease	with	positive	EMA	and	TTG,	and	Marsh	3a	histology.	The	other	was	
a	seronegative	coeliac	disease	with	negative	EMA	and	TTG,	normal	IgA	levels,	Marsh	3b	histology	
and	positive	HLA	DQ2.	Other	causes	of	seronegative	villous	atrophy	were	excluded.	This	patient	
had	known	hypothyroidism,	and	presented	with	weight	loss	and	persistent	mouth	ulcers,	with	a	
first	degree	relative	with	coeliac	disease.	The	patient	with	potential	coeliac	disease	had	positive	
EMA	and	TTG	and	Marsh	0	histology.	She	was	commenced	on	a	gluten	free	diet	in	view	of	gluten	
related	symptoms.	The	remaining	24	participants	with	positive	Simtomax	had	negative	EMA	and	
TTG.	The	coeliac	disease	prevalence	was	0.6%	(3/500)	including	the	patient	with	potential	coeliac	
disease.		
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3.5:	Discussion	
	
This	is	the	first	study	to	demonstrate	both	the	feasibility	and	efficacy	of	using	a	point	of	care	test	in	
community	pharmacies	for	the	detection	of	coeliac	disease.	Allied	health	care	professionals	are	an	
asset	 for	 supporting	 and	 relieving	 the	workload	of	 clinicians.	 Existing	models	 of	 healthcare	have	
demonstrated	 that	 specialist	 nurses	 could	 provide	 effective	 care	 for	 patients	with	 inflammatory	
bowel	disease,	 for	 instance	 (98).	The	aim	of	offering	a	point	of	 care	 test	 to	at	 risk	 individuals	at	
community	 pharmacies	 was	 to	 increase	 the	 detection	 of	 coeliac	 disease	 and	 reduce	 delays	 in	
diagnosis	as	an	alternative	approach	in	primary	care.		
	
In	this	study	we	have	shown	that	there	was	a	good	response	from	pharmacy	customers	in	regards	
to	the	uptake	rate	of	the	point	of	care	test	and	subsequent	further	investigations	as	required.	The	
positive	 point	 of	 care	 test	 rate	was	 7.2%,	which	was	 similar	 to	 the	 9.4%	 positive	 rate	 from	 the	
previous	 proof	 of	 concept	 study	 using	 point	 of	 care	 testing	 in	 pharmacies	 by	 Urwin	 et	 al.	 (97),	
although	no	subsequent	investigations	were	undertaken	to	confirm	the	diagnosis	in	that	study.	
	
The	coeliac	disease	detection	rate	of	0.6%	in	our	study	was	however	much	lower	than	anticipated.	
There	are	several	possible	reasons	for	this.	One	of	the	reasons	could	be	because	the	existing	caseload	
of	coeliac	disease	is	higher	than	average	due	to	the	presence	of	our	tertiary	referral	centre	for	coeliac	
disease	 in	 Sheffield,	 and	 the	 heightened	 awareness	 for	 active	 coeliac	 testing	 by	 local	 general	
practitioners	because	of	that.	During	the	recruitment	period,	eight	pharmacy	customers	approached	
for	the	study	already	had	a	known	diagnosis	of	coeliac	disease,	giving	a	1.1%	known	coeliac	disease	
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prevalence	among	the	802	individuals	approached,	which	is	four	times	higher	than	the	UK	average	
detected	prevalence	of	0.24%	(3).	Nevertheless,	a	previous	point	of	care	test	case	finding	study	by	
Urwin	et	al.	based	in	15	pharmacies	across	England	(97)	had	a	similar	Simtomax	positive	rate	to	our	
study,	 indicating	that	the	low	yield	 in	primary	care	 is	probably	not	confined	to	our	 local	area	but	
beyond.	
	
Another	 potential	 factor	 which	may	 have	 contributed	 to	 the	 low	 detection	 rate	 is	 that	 25%	 of	
participants	who	 tested	positive	 did	 not	 proceed	 to	 further	 investigations	 to	 confirm	or	 exclude	
coeliac	disease.	Therefore,	it	is	possible	that	undiagnosed	cases	have	not	been	accounted	for.		
	
Lastly,	most	recruited	individuals	were	passively	approached	to	be	offered	point	of	care	testing,	as	
opposed	to	the	individual	actively	seeking	for	medical	advice	for	their	symptoms.	This	may	have	led	
to	the	inclusion	of	individuals	with	mild	or	insignificant	symptoms	which	they	would	not	have	sought	
for	medical	help	in	the	first	instance.	It	is	conceivable	that	the	case	detection	rate	may	possibly	be	
higher	if	the	point	of	care	tests	were	performed	in	individuals	with	symptoms	significant	enough	for	
them	to	actively	request	for	coeliac	testing	at	the	pharmacies.	
	
3.6:	Conclusion	
 
We	have	demonstrated	the	feasibility	of	using	a	point	of	care	test	for	the	detection	of	coeliac	
disease	in	the	primary	care	sector	in	community	pharmacies.	Although	there	was	good	uptake	
for	undertaking	the	point	of	care	test	among	pharmacy	customers,	the	point	of	care	test	did	not	
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increase	the	case	detection	rate	as	anticipated.	Therefore,	it	has	a	limited	role	as	a	case	finding	
tool	in	a	community	pharmacy	setting	in	our	cohort.		
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Chapter	4:	The	role	of	a	point	of	care	test	in	secondary	care:	a	
diagnostic	accuracy	study	
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4.1:	Abstract		
	
Background:	 Patients	 with	 gastrointestinal	 symptoms	 are	 frequently	 referred	 for	 specialist	
consult	in	secondary	care.	Moreover,	individuals	who	self-report	gluten	sensitivity	is	increasingly	
presenting	themselves	to	health	care	professionals.	Point	of	care	testing	in	secondary	care	could	
potentially	be	useful	 in	coeliac	disease	detection,	and	differentiating	between	coeliac	disease	
from	 non-coeliac	 gluten	 sensitivity.	 The	 aim	 of	 this	 study	 was	 to	 assess	 and	 compare	 the	
diagnostic	performance	of	Simtomax	 to	conventional	 serology	 (IgA-TTG	and	 IgA-EMA)	 for	 the	
detection	of	coeliac	disease	in	symptomatic	patients	(group	1),	and	in	patients	who	self-reported	
gluten	sensitivity	 (group	2).	Patient	acceptability	and	 inter-observer	variability	of	 the	point	of	
care	test	results	were	also	evaluated.	
	
Methods:	From	2013-2017,	patients	referred	to	secondary	care	with	gastrointestinal	symptoms,	
anaemia	 and/or	weight	 loss	 (group	 1)	 and	 patients	with	 self-reported	 gluten	 sensitivity	with	
unknown	 coeliac	 disease	 status	 (group	 2)	 were	 prospectively	 recruited.	 All	 patients	 had	
concurrent	 Simtomax,	 IgA-TTG,	 IgA-EMA,	 total	 IgA	 levels,	 and	 a	 gastroscopy	 with	 duodenal	
biopsies.	 Five	 hundred	 patients	 completed	 acceptability	 questionnaires,	 and	 inter-observer	
variability	of	the	Simtomax	results	was	compared	among	five	clinical	staff	for	400	cases.	
	
Results:	 Group	 1:	 1000	 patients,	 58.5%	 female,	 age	 range	 16-91,	 median	 age	 57.	 Forty-one	
patients	(4.1%)	were	diagnosed	with	coeliac	disease.	The	sensitivity	of	Simtomax,	IgA-TTG	and	
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IgA-EMA	were	82.9%,	78.1%	and	70.7%;	the	specificities	were	85.4%,	96.3%	and	99.8%.	Group	2:	
61	patients,	83%	female;	age	range	17-73,	median	age	35.	Simtomax	had	100%	sensitivity	and	
negative	predictive	value	(NPV)	in	detecting	coeliac	disease	in	group	2.	Most	patients	preferred	
Simtomax	to	venepuncture	(90.4%	vs	2.8%).	There	was	good	inter-observer	agreement	on	the	
Simtomax	results	with	a	Fleiss	Kappa	coefficient	of	0.895.	
	
Conclusion:	Simtomax	had	comparable	sensitivities	to	IgA-TTG,	and	correctly	identified	all	coeliac	
disease	cases	in	a	gluten	sensitive	cohort.	However,	its	low	specificity	may	increase	unnecessary	
investigations.		Despite	its	advantage	of	convenience	and	rapid	results,	Simtomax	may	not	add	
significant	value	to	case	finding	for	coeliac	disease	in	secondary	care.	
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4.2:	Introduction	
	
Coeliac	disease	has	an	increasingly	global	presence,	with	a	prevalence	of	0.3-2.4%	of	the	general	
population	worldwide	(2,	24,	26,	99-103).	It	affects	1	in	100	in	the	United	Kingdom,	but	only	24%	
are	detected	(3).	Similar	observations	are	also	apparent	in	Europe	(99),	the	United	States	(54)	
and	beyond	(104).	This	 is	partly	because	symptoms	of	coeliac	disease	can	be	non-specific	and	
difficult	for	clinicians	to	recognise.		
	
This	is	further	compounded	by	an	emerging	clinical	entity,	non-coeliac	gluten	sensitivity	(NCGS),	
which	is	clinically	indistinguishable	from	coeliac	disease	(105,	106).	NCGS	describes	individuals	
who	 complain	 of	 gastrointestinal	 (bloating,	 abdominal	 pain,	 diarrhoea)	 and/or	 non	
gastrointestinal	symptoms	(fatigue,	headaches,	foggy	mind)	related	to	gluten	ingestion,	where	
coeliac	disease	and	wheat	allergy	have	been	excluded	(107).	Although	the	Salerno	criteria	define	
NCGS	using	a	double	blinded	placebo	controlled	challenge	(108),	self-reported	gluten	sensitivity	
describes	 individuals	who	 complain	 of	 gastrointestinal	 and/or	 non	 gastrointestinal	 symptoms	
triggered	by	gluten	ingestion	and	present	to	physicians	accordingly.	There	is	a	paucity	of	data	on	
the	prevalence	of	NCGS,	but	it	has	been	reported	that	13%	of	the	general	population	in	the	UK	
self-report	gluten	sensitivity,	although	only	0.8%	had	a	diagnosis	of	coeliac	disease	(109).	The	
immunological	pathway	of	NCGS	is	not	yet	fully	elucidated.	Currently.	It	is	understood	that	NCGS	
is	associated	with	an	innate,	rather	than	adaptive	immune	response	triggered	by	gluten	(110),	
unlike	coeliac	disease	where	both	pathways	are	involved.	A	double	blinded,	placebo	controlled	
dietary	re-challenge	trial	showed	evidence	that	patients	with	NCGS	respond	to	a	gluten	free	diet.	
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However,	it	was	suggested	that	it	may	be	the	other	components	of	wheat	(fermentable,	oligo-,	
di-,	monosaccharides,	and	polyols)	that	contribute	to	the	symptoms	in	patients	with	NCGS,	rather	
than	gluten	 itself	 (111).	 Exclusion	of	 coeliac	disease	and	wheat	 allergy	 is	 fundamental	 in	 this	
group	of	patients.		
	
It	is	essential	to	distinguish	NCGS	from	coeliac	disease,	as	patients	with	NCGS	do	not	seem	to	be	
at	risk	of	the	complications	seen	in	coeliac	disease,	although	they	derive	symptomatic	benefit	
from	 a	 gluten	 free	 diet	 (112).	 Furthermore,	 any	 delays	 in	 coeliac	 testing	 before	 individuals	
embark	on	a	self-imposed	gluten	free	diet	could	cause	diagnostic	challenges.		
	
Early	diagnosis	of	coeliac	disease	is	important	for	the	improvement	of	patients’	quality	of	life	and	
the	 prevention	 of	 complications	 such	 as	 osteoporosis,	 hip	 fractures	 and	 lymphoproliferative	
malignancies.	It	has	been	shown	that	serological	testing	in	patients	with	high	risk	symptoms	in	a	
clinic	setting	yielded	3.3-4.7%	coeliac	disease	detection	(94).	Similar	 results	were	obtained	by	
other	 groups	 through	 case	 finding	 (95,	 113).	 On	 the	 other	 hand,	 a	 recent	 systematic	 review	
reported	insufficient	evidence	to	support	screening	for	asymptomatic	patients	at	present	(105,	
114-117).		
	
For	these	reasons,	case	finding	for	coeliac	disease	in	at	risk	individuals	has	been	recommended	
by	 international	 guidelines	 (35,	 36).	 However,	 serological	 testing	 for	 coeliac	 disease	 remains	
under-utilised	(4,	118).	This	could	be	due	to	a	multitude	of	factors,	including	a	lack	of	awareness	
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of	 the	 guidelines,	 inconvenience	 and	 cost.	 A	 finger	 prick	 point	 of	 care	 test	 that	 provides	
convenience	and	 rapid	 coeliac	 antibody	 results	may	have	a	 role	 in	 improving	 case	detection,	
particularly	 in	 secondary	 care	 consultations,	 where	 the	 results	 could	 potentially	 provide	
immediate	guidance	for	the	physician	on	the	need	for	duodenal	biopsies.		
	
4.3:	Methods	
	
Aims:		
To	assess	the	diagnostic	accuracy	of	Simtomax	in	the	detection	of	coeliac	disease	in	secondary	
care.	 The	 secondary	 aims	were	 to	 evaluate	 patient	 acceptability	 of	 Simtomax,	 and	 the	 inter-
observer	variability	of	test	result	interpretation.	
	
Study	design	and	recruitment:		
The	study	took	place	at	the	Royal	Hallamshire	Hospital,	Sheffield,	U.K.,	from	March	2013-January	
2017.	Patients	with	gastrointestinal	symptoms	who	were	referred	to	gastroenterology	for	further	
evaluation	 were	 prospectively	 recruited.	 The	 coeliac	 disease	 status	 of	 these	 patients	 was	
unknown.	All	patients	were	concurrently	tested	with	total	IgA	levels,	IgA-TTG,	IgA-EMA,	and	the	
point	of	care	test,	and	duodenal	biopsies	were	taken	in	all	patients	as	the	reference	standard.	
	
Inclusion	criteria:		
Group	1:	patients	presenting	to	secondary	care	with	gastrointestinal	symptoms	(abdominal	pain,	
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diarrhoea	and/or	dyspepsia),	anaemia	and/or	weight	loss.		
Group	 2:	 patients	 presenting	 to	 secondary	 care	 with	 self-reported	 gluten	 sensitivity,	 with	
gastrointestinal	and/or	extra-gastrointestinal	symptoms	related	to	gluten	ingestion.	Those	with	
reduced	 or	 no	 gluten	 intake	 were	 asked	 to	 undertake	 a	 six-week	 gluten	 challenge	 of	 10g	
gluten/day	prior	to	their	endoscopy	as	per	guidelines	(119,	120).		
	
Exclusion	criteria:		
For	groups	1	and	2,	patients	with	known	coeliac	disease	and	patients	on	a	self-imposed	gluten	
free	diet	who	declined	a	gluten	challenge	were	excluded.	Group	1	patients	who	were	referred	
with	positive	coeliac	serology	by	their	primary	care	physicians	were	excluded	from	the	study	so	
as	to	avoid	tertiary	referral	bias,	thus	providing	a	more	accurate	assessment	of	the	sensitivities	
of	the	point	of	care	test	that	is	reflective	of	clinical	practice.		
	
Patient	acceptability	of	the	point	of	care	test	
There	are	no	validated	patient	acceptability	questionnaires	in	the	literature	for	point	of	care	tests.	
Therefore,	a	questionnaire	consisting	of	five	questions	regarding	the	acceptability	of	the	point	of	
care	test	(comfort	level,	convenience	and	satisfaction	with	result	availability)	was	devised.	The	
questionnaires	were	filled	in	by	500	consecutive	patients	after	having	had	Simtomax	performed.	
They	were	asked	 to	 rate	on	a	 Likert	 scale	of	one	 to	 five	 for	each	question,	with	one	being	a	
negative	experience	and	five	being	a	positive	experience.	These	500	patients	all	had	previous	
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experience	of	a	venepuncture.	They	were	also	asked	to	state	their	preferred	mode	of	testing:	
point	 of	 care	 test,	 venepuncture,	 or	 no	 preference.	 A	 similar	 acceptability	 questionnaire	 for	
venepuncture	 was	 completed	 by	 a	 separate	 cohort	 of	 63	 patients	 after	 having	 had	 a	
venepuncture	to	act	as	controls.	These	questionnaires	were	given	out	to	both	groups	to	fill	 in	
independently	and	anonymously,	and	the	questionnaires	were	collected	by	a	member	of	staff	on	
completion.	(See	appendix	6	for	the	acceptability	questionnaires)	
	
Inter-observer	variability	of	the	point	of	care	test	results	
Inter-observer	variability	of	the	point	of	care	test	results	was	assessed	in	400	consecutive	patients	
in	group	1.	Each	observer	recorded	whether	there	was	a	definite	red	band,	a	faint	red	band,	or	
an	absence	of	a	 red	band.	There	were	 five	observers	 in	 total	 for	each	case,	consisting	of	one	
gastroenterologist	and	four	other	randomly	selected	allied	health	care	professionals	(for	example	
nurses).	All	observers	were	 trained	 to	 recognise	positive,	negative	and	 indeterminate	 results.	
Observation	of	the	results	was	carried	out	indoors	under	fluorescent	lighting.	
	
Ethics	approval:		
The	study	protocol	was	approved	by	the	Yorkshire	and	the	Humber	Research	Ethics	committee	
and	registered	with	the	local	research	and	development	department	of	Sheffield	Teaching	
Hospital	NHS	Foundation	Trust	under	the	registration	number	STH15416.	Written	consent	was	
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obtained	from	all	patients.	(See	appendix	7	for	patient	information	sheet	and	appendix	8	for	
consent	form)	
	
Statistical	analysis:	
Inter-observer	 variability	 was	 presented	 using	 Fleiss	 Kappa	 coefficient,	 where	 0	 indicates	 no	
agreement	and	1	indicates	perfect	agreement.	
		
Cohen’s	effect	size	(r)	for	patient	acceptability	between	Simtomax	and	venepuncture	groups	was	
measured	using	Mann-Whitney	U	test,	where	r=0.1,	0.3	and	0.5	 indicates	small,	medium	and	
large	effect	size	respectively.		
	
Receiving	operator	 characteristic	 (ROC)	 curves	were	 constructed	with	paired	 sensitivities	 and	
specificities	of	each	surrogate	marker,	and	the	area	under	the	curve	(AUC)	was	determined.		
	
4.4:	Results	
	
Patient	demographics	and	presenting	characteristics	 in	group	1	are	 illustrated	 in	 table	5.	One	
thousand	eligible	patients	who	consented	for	participation	entered	group	1	of	the	study.		There	
were	585/1000	females	(58.5%);	age	range	16-91,	median	age	57.		
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Forty-one	patients	(4.1%)	were	diagnosed	with	coeliac	disease.	IgA	deficiency	detected	by	total	
IgA	levels	from	the	laboratory	assay	was	found	in	28	patients	in	groups	one	and	two	combined	
(28/1061=2.6%).	Two	IgA	deficient	patients	were	diagnosed	with	coeliac	disease	(2/60=3.3%	of	
the	 total	 coeliac	 cohort	 i.e.	 groups	1+2),	 and	both	had	a	positive	 Simtomax	 test.	 Six	patients	
(6/60=10%)	had	seronegative	coeliac	disease,	with	three	patients	testing	positive	for	SImtomax	
and	one	of	whom	had	IgA	deficiency.	The	sensitivity	of	Simtomax	was	comparable	to	IgA-TTG	and	
IgA-EMA	(82.9%	vs	78.1%	vs	70.7%	respectively).	However,	its	specificity	was	significantly	lower	
than	IgA-TTG	and	IgA-EMA	(85.9%	vs	96.3%	vs	99.8%	respectively).		
	
The	diagnostic	performance	of	Simtomax,	IgA-TTG	and	IgA-EMA	for	group	one	are	displayed	in	
tables	6	and	7.	ROC	curves	for	the	aforementioned	tests	for	group	one	are	demonstrated	in	figure	
6.	
	
Table	5:	Group	one	patient	demographics	and	presenting	characteristics	table.	
	 No.	of	patients	 Coeliac	disease	yield	
Female	 585/1000	(58.5%)	 27/585	(4.6%)	
Male	 415/1000	(41.5%)	 14/415	(3.4%)	
Diarrhoea	 75/1000	(7.5%)	 8/75	(10.7%)	
Abdominal	pain	 159/1000	(15.9%)	 13/159	(8.2%)	
Weight	loss	 104/1000	(10.4%)	 6/104	(5.8%)	
Anaemia	 194/1000	(19.4%)	 9/194	(4.6%)	
Dyspepsia	 549/1000	(54.9%)	 8/549	(1.5%)	
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Table	6:	The	diagnostic	accuracy	of	Simtomax,	IgA-TTG	and	IgA-EMA	in	detecting	coeliac	disease	
in	symptomatic	patients	(group	one;	n=1000,	coeliac	disease	prevalence	4.1%).	
	
	 Simtomax		 IgA-TTG		 IgA-EMA	
Sensitivity	%	(95%	CI)	 82.9	(67.9-92.9)	 78.1	(62.4-89.4)	 70.7	(54.5-83.9)	
Specificity	%	(95%	CI)	 85.4	(83.0-87.6)	 96.3	(94.8-97.4)	 99.8	(99.3-100.0)	
PPV	%	(95%	CI)	 19.5	(16.5-23.0)	 47.1	(38.3-56.0)	 93.6	(78.2-98.3)	
NPV	%	(95%	CI)	 99.2	(98.4-99.6)	 99.0	(98.3-99.5)	 98.8	(98.0-99.2)	
Positive	likelihood	ratio	(95%	CI)	 5.7	(4.6-7.0)	 20.8	(14.5-30.0)	 339.2	(83.8-1373.2)	
Negative	likelihood	ratio	(95%	CI)	 0.2	(0.1-0.4)	 0.2	(0.1-0.4)	 0.3	(0.2-0.5)	
Accuracy	%	(95%	CI)	 85.3	(83.0-87.4)	 95.5	(94.0-96.7)	 98.6	(97.7-99.2)	
	
Table	7.	Group	1:	cross	tabulation	of	Simtomax	results	by	the	reference	standard.	
	 CD	 Not	CD	 	 CD	 Not	CD	 	 CD	 Not	CD	
Simtomax	+	 34	 140	 TTG	+	 32	 36	 EMA	+	 29	 2	
Simtomax	-	 7	 819	 TTG	-	 9	 923	 EMA	-	 12	 957	
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In	group	2,	70	patients	who	self-reported	gluten	sensitivity	were	recruited.	Nine	patients	who	
were	 on	 a	 self-imposed	 gluten	 free	 diet	 and	 declined	 a	 six-week	 gluten	 challenge	 prior	 to	
investigations	were	excluded	from	the	study.	A	total	of	61	patients	consuming	gluten	entered	
group	two	of	our	study.	There	were	51/61	females	(82.9%);	age	range	17-73,	median	age	35.		
	
Twenty-three	 patients	 who	were	 previously	 on	 a	 self-imposed	 gluten	 free	 diet	 underwent	 a	
gluten	challenge:	16	patients	managed	a	six-week	challenge	and	seven	could	only	tolerate	four	
weeks	of	gluten	challenge	at	which	point	the	serology	and	endoscopy	were	performed	due	to	
Figure	6.	Group	1	ROC	curve	for	Simtomax,	IgA-EMA	and	IgA-TTG	in	symptomatic	patients.	
Area	under	the	curve	(AUC)	for	each	test	were	0.842	(CI:	0.77-0.9),	0.853	(CI:	0.77-0.94)	and	
0.871	(CI:	0.8-0.95).		
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significant	symptoms.	The	remaining	38	patients	were	consuming	a	gluten	containing	diet	and	
continued	 to	do	so	at	 least	until	 the	 investigations	 took	place.	Eighteen	patients	were	 tested	
positive	for	EMA	by	their	general	practitioners.	The	vast	majority	(57/61=93.4%)	of	patients	had	
gastrointestinal	 symptoms,	 and	 10	 patients	 (10/61=16.4%)	 reported	 extra-gastrointestinal	
symptoms,	 predominantly	 neurological	 complaints	 (e.g.	 headache,	 paraesthesia,	 foggy	mind,	
ataxia,	lethargy,	tongue	tingling	and	arthralgia).		
	
Forty-two	patients	 (42/61=68.9%)	were	diagnosed	with	NCGS,	 17	 (17/61=27.9%)	with	 coeliac	
disease	and	two	(2/61=3.3%)	with	potential	coeliac	disease.	The	point	of	care	test	demonstrated	
a	sensitivity	and	NPV	of	100%	(vs	sensitivities	of	88.2%,	94.1%	and	NPV	of	91.8%,	97.77%	for	IgA-
TTG	and	IgA-EMA	respectively).	The	diagnostic	performance	of	Simtomax,	IgA-TTG	and	IgA-EMA	
for	group	two	are	displayed	in	tables	8	and	9.	ROC	curves	for	the	aforementioned	tests	for	group	
two	are	demonstrated	in	figure	7.	
Table	 8:	 The	 diagnostic	 accuracy	 of	 Simtomax,	 IgA-TTG	 and	 IgA-EMA	 in	 detecting	 coeliac	
disease	 in	 patients	who	 self-reported	 gluten	 sensitivity	 (group	 two;	 n=61,	 coeliac	 disease	
prevalence	27.9%).	
	
	 Simtomax		 IgA-TTG		 IgA-EMA	
Sensitivity	%	(95%	CI)	 100	(80.5-100)	 88.2	(63.6-98.5)	 94.1	(71.3-99.9)	
Specificity	%	(95%	CI)	 79.6	(64.7-90.2)	 93.2	(81.3-98.6)	 97.7	(88.0-99.9)	
PPV	%	(95%	CI)	 65.4	(51.3-77.2)	 83.3	(62.3-93.8)	 94.1	(69.6-99.1)	
NPV	%	(95%	CI)	 100	 91.8	(81.0-97.3)	 97.7	(86.5-99.6)	
Positive	likelihood	ratio	(95%	CI)	 4.9	(2.7-8.8)	 12.9	(4.3-39.1)	 41.4	(5.9-288.5)	
Negative	likelihood	ratio	(95%	CI)	 0		 0.1	(0-0.5)	 0.06	(0.01-0.4)	
Accuracy	%	(95%	CI)	 85.3	(73.8-93.0)	 91.8	(81.9-97.3)	 96.7	(88.7-99.6)	
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Table	9.	Group	2:	cross	tabulation	of	Simtomax	results	by	the	reference	standard.	
	 CD	 Not	CD	 	 CD	 Not	CD	 	 CD	 Not	CD	
Simtomax	+	 17	 9	 TTG	+	 15	 3	 EMA	+	 16	 1	
Simtomax	-	 0	 35	 TTG	-	 2	 41	 EMA	-	 1	 43	
	
Figure	7.	Group	2	ROC	curve	for	Simtomax,	IgA-EMA	and	IgA-TTG	in	patients	who	self-reported	
gluten	sensitivity.	AUC	for	each	test	were	0.898	(CI:	0.82-0.98),	0.959	(CI:	0.89-1.0)	and	0.907	
(CI:	0.81-1.0).		
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In	 regards	 to	 patient	 acceptability,	 Simtomax	 had	 significantly	 higher	 patient	 satisfaction	
compared	 to	 venepuncture.	 The	 difference	 in	 the	 scores	 between	 the	 two	 groups	 were	
statistically	 significant	 in	 all	 aspects	 of	 the	 acceptability	 questionnaire,	 and	 the	 effect	 size	
difference	between	the	two	groups	was	large	(r	=	0.506-0.656).	Table	10	shows	the	median	scores	
and	statistical	differences	in	both	groups	for	each	aspect	of	the	tests.	
Table	10:	Patient	acceptability	for	Simtomax	and	conventional	venepuncture.	Acceptability	was	
scored	with	a	Likert	scale	from	1-5,	with	1	being	a	negative	experience	and	5	being	a	positive	
experience.	
	
	 Simtomax	 Venepuncture	 Mann-Whitney	U	test	
Blood	collection	process:	 	 	 	
Score	for	comfort	level	of	the	test	 4.7	 3.3	 U=2988.5,	 Z=12.027,	
p<0.001,	r=0.506	
Score	for	speed	and	ease	of	the	test	 4.7	 3.3	 U=2182.5,	 Z=13.443,	
p<0.001,	r=0.566	
Convenience:	 	 	 	
Satisfaction	 score	 for	 having	 the	 test	
performed	during	the	consultation	(for	
Simtomax)	 vs	 separately	 from	 the	
consultation	by	the	phlebotomy	service	
(for	venepuncture)	
4.8	 2.9	 U=1086.5,	 Z=14.675,	
p<0.001,	r=0.617	
Quality	of	care:	 	 	 	
Satisfaction	 score	 for	 obtaining	 test	
results	 within	 10	 minutes	 (for	
Simtomax)	vs	a	few	days	to	a	week	(for	
venepuncture)	
4.8	 3.1	 U=583.5,	 Z=15.597,	
p<0.001,	r=0.656	
Satisfaction	 score	 for	 obtaining	 and	
discussing	 the	 test	 results	 with	 the	
clinician	within	 the	 same	 consultation	
(for	 Simtomax)	 vs	 at	 a	 later	 date	 (for	
venepuncture)	
4.8	 2.9	 U=	 988.0,	 Z=15.223,	
p<0.001,	r=0.64	
	
Preference:	 No.	of	patients		
Prefers	Simtomax	 452/500	(90.4%)	
Prefers	venepuncture	 14/500	(2.8%)	
No	preference	 34/500	(6.8%)	
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There	was	a	good	degree	of	inter-observer	agreement	on	Simtomax	result	interpretation,	with	a	
Fleiss	 Kappa	 coefficient	 of	 0.895	 overall.	 Sub-analysis	 revealed	 a	 high	 level	 of	 agreement	 for	
definite	red	bands	(Kappa	0.887)	and	absence	of	red	bands	(Kappa	0.956).	The	level	of	agreement	
dropped	 for	 faint	 red	 bands	 (Kappa	 0.781),	 where	 there	were	 31	 such	 cases	within	 the	 400	
assessed.	None	of	these	31	patients	had	coeliac	disease.	Only	solid	red	bands	were	classified	as	
a	positive	test	for	the	purpose	of	diagnostic	calculations	in	the	thesis,	and	faint	red	bands	were	
interpreted	as	negative.	Figure	8	illustrates	the	three	possible	outcomes	of	the	point	of	care	tests	
results.	
	
Figure	8:	Three	possible	outcomes	of	Simtomax	results.		
Red	band	A	indicates	a	positive	result,	red	band	B	indicates	the	presence	of	IgA,	red	band	CT	
is	the	control	line,	indicating	a	correctly	functioning	test.	Left:	A	solid	red	band	A	indicating	
a	positive	test;	Middle:	An	absence	of	a	red	band	A	indicating	a	negative	test;	Right:	A	faint	
pink	band	A	which	was	classified	as	a	negative	test,	as	none	of	the	patients	with	a	faint	band	
A	had	coeliac	disease	in	our	cohort.	
	
	
	
The	above	photographs	were	taken	by	myself.	
	 76	
4.5:	Discussion	
	
To	my	knowledge,	this	is	the	largest	study	to	date	evaluating	the	diagnostic	accuracy	of	Simtomax.	
This	is	also	the	first	study	to	explore	the	practicalities	of	this	point	of	care	test	including	patient	
acceptability	and	inter-observer	variability	of	test	result	interpretation.	
	
One	of	the	strengths	of	this	study	is	that	all	participants	had	duodenal	biopsies	taken,	irrespective	
of	 their	 coeliac	 antibodies	 or	 Simtomax	 results.	 This	 ensured	 that	 no	 false	 negative	 cases	 of	
coeliac	disease	would	be	missed.	This	methodology	contributed	to	a	major	difference	to	most	
point	of	care	test	studies	for	coeliac	disease,	where	only	patients	with	positive	antibodies	(either	
point	of	care	test	or	serology)	were	biopsied	(82,	88-90,	121,	122).	Additionally,	some	point	of	
care	test	studies	measured	the	sensitivities	against	serology	rather	than	duodenal	histology	as	
the	reference	standard	(82,	123,	124).	These	methodological	weaknesses	could	lead	to	a	positive	
ascertainment	bias,	thereby	falsely	elevating	the	reported	sensitivities.		
	
Another	 strength	 of	 this	 study	 is	 that	 the	 patient	 cohort	 had	 a	 coeliac	 disease	 prevalence	
consistent	 with	 real	 life	 case	 finding	 in	 patients	 with	 high	 risk	 symptoms,	 which	 have	 been	
reported	to	be	3-4.7%	(94,	95).	A	much	higher	coeliac	disease	prevalence	is	a	common	flaw	in	
previous	 point	 of	 care	 test	 studies	 	 (85,	 88,	 125).	 This	 tertiary	 referral	 bias	 restricts	 the	
generalisability	of	their	findings.	The	patient	characteristics	and	pre-test	probability	of	group	1	
allowed	a	more	accurate	reflection	of	the	diagnostic	performance	of	these	tests	when	used	in	
clinical	practice.	
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There	are	a	few	limitations	in	this	study.	Ideally,	the	measurement	of	laboratory	DGP	serology	
would	act	as	a	useful	comparison	of	the	sensitivities	between	DGP	detection	by	laboratory	assay	
and	 lateral	 flow	 immunochromatography.	 However,	 laboratory	 DGP	 serology	 is	 not	 widely	
available	in	the	UK	and	is	not	available	in	our	centre.	Therefore,	DGP	assays	were	not	performed.		
	
Another	limitation	is	the	evaluation	of	patient	acceptability	of	Simtomax.	I	devised	the	point	of	
care	test	acceptability	questionnaire	as	there	were	no	validated	questionnaires	for	point	of	care	
tests	 in	 the	 literature.	 Furthermore,	 the	 methodology	 of	 using	 a	 Likert	 scale	 provided	 a	
quantitative	 rather	 than	 qualitative	 measure	 of	 acceptability.	 Qualitative	 interviews	 would	
provide	 a	 more	 informative	 representation	 of	 patient	 acceptability.	 	 However,	 patient	
acceptability	was	a	secondary	outcome	and	not	the	main	focus	of	this	study.	
	
What	 is	 noteworthy	 is	 the	generally	 lower	 sensitivities	of	 IgA-TTG	and	 IgA-EMA	compared	 to	
previous	serological	studies	(126,	127).	There	are	several	potential	reasons	for	this.	Although	a	
systematic	 review	 in	2006	showed	that	 the	pooled	sensitivities	of	 IgA-TTG	and	 IgA-EMA	from	
published	data	were	93%	(range	70-100%)	and	specificities	were	>98%	(range	90-100%)	for	both,	
the	 authors	 indicated	 that	 these	 figures	were	 likely	 to	be	 falsely	 high	due	 to	methodological	
shortcomings	 in	 most	 studies	 (126).	 Firstly,	 many	 studies	 did	 not	 biopsy	 controls	 (i.e.	 take	
duodenal	 biopsies	 in	 seronegative	 patients),	 potentially	 missing	 false	 negative	 cases.	 In	 a	
subsequent	meta-analysis	of	the	diagnostic	accuracy	of	IgA-TTG	and	IgA-DGP	(127),	the	authors	
concluded	that	only	two	out	of	11	studies	biopsied	controls	(128,	129).	In	fact,	these	two	studies	
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demonstrated	 the	 sensitivities	 and	 specificities	 of	 IgA-TTG	 at	 78.3-95%	 and	 97.5-98.4%	
respectively.		
	
Second	of	all,	the	results	from	the	aforementioned	two	studies	still	may	not	have	reflected	their	
performance	 in	 real	 practice,	 as	 has	 been	 demonstrated	 previously	 (130),	 since	 the	 coeliac	
disease	prevalence	was	very	high	at	74%	for	both	studies.	This	again	could	have	falsely	increased	
the	sensitivity	and	PPV	of	IgA-TTG	due	to	positive	ascertainment	bias.		
	
Lastly,	the	lack	of	standardisation	of	IgA-TTG	laboratory	assays	could	also	lead	to	different	IgA-
TTG	sensitivities.	IgA-TTG	antibody	units	and	reference	ranges	are	arbitrary	and	method-specific.	
Furthermore,	over	30	different	 IgA-TTG	assay	kits	are	used	in	the	UK,	giving	different	 IgA-TTG	
titres.	A	recent	study	showed	that	even	when	the	same	IgA-TTG	ELISA	assay	kit	was	used,	there	
was	still	poor	agreement	among	laboratories	as	to	whether	the	sample	was	above	or	below	the	
defined	IgA-TTG	level	cut	off	point	for	Marsh	3	histology	using	a	ROC	curve	(131).	A	recent	head	
to	head	trial	of	three	different	TTG	serological	kits	also	found	widely	variable	sensitivities	and	
specificities,	ranging	from	71.1%-95.5%	and	82.6%-100%	respectively	(132).		
	
All	 these	 factors	 explain	 the	huge	 variability	of	 IgA-TTG	 sensitivities	 and	why	 the	 sensitivities	
appeared	 to	 be	 lower	 than	 average	 in	 this	 study,	where	 all	 patients	were	 biopsied	 including	
controls,	and	the	coeliac	disease	prevalence	being	much	lower	in	comparison	to	previous	studies.	
In	regards	to	the	prevalence	of	coeliac	disease	in	individuals	who	self-report	gluten	sensitivity,	
there	are	four	studies	in	the	literature	which	assessed	the	diagnostic	outcomes	of	this	cohort.	
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The	sample	sizes	ranged	from	93	to	238,	and	the	prevalence	of	coeliac	disease	varied	between	
2%	and	42.4%	(109,	133-135).	In	our	study,	the	coeliac	disease	prevalence	of	27.9%	in	the	self-
reported	gluten	sensitivity	cohort	lies	within	the	range	of	the	reported	data.	The	wide	variation	
in	 the	 reported	disease	prevalence	 is	 likely	due	 to	differences	 in	 the	 study	population,	 study	
design,	 recruitment	methods	 and	 diagnostic	 criteria.	 For	 example,	 our	 disease	 prevalence	 of	
27.9%	is	higher	than	the	7%	reported	by	Aziz	et	al.	which	was	derived	from	a	UK	population-
based	questionnaire	targeting	 individuals	with	 gluten	 related	 symptoms	 (109),	 as	 opposed	 to	
symptomatic	 individuals	 actively	 presenting	 to	 primary	 care	 who	 were	 then	 referred	 on	 to	
secondary	care	for	further	evaluation.	Our	group	2	patients’	gluten	related	symptoms	may	have	
prompted	 more	 proactive	 coeliac	 screening	 by	 their	 general	 practitioners,	 thus	 possibly	
explaining	 the	 higher	 prevalence	 of	 seropositive	 patients	 (18/61),	 giving	 a	 higher	 disease	
prevalence.	Nevertheless,	after	excluding	the	18	patients	who	were	referred	with	positive	EMA,	
the	sensitivity	and	NPV	of	Simtomax	remained	at	100%,	where	all	four	cases	of	coeliac	disease	
were	correctly	identified.	
	
Point	of	care	tests	for	other	laboratory	measurements	such	as	human	immunodeficiency	virus	
and	international	normalised	ratio	have	been	widely	adopted	in	national	practice	in	both	primary	
and	secondary	care	settings,	owing	to	their	clinical	effectiveness	and	good	patient	acceptability	
(136,	 137).	 Simtomax	 has	 been	 demonstrated	 to	 have	 favourable	 acceptability	 to	 patients	
compared	 to	venepuncture,	with	90.8%	patients	preferring	Simtomax	 to	venepuncture.	Most	
patients	generally	found	Simtomax	to	be	a	simple	and	quick	test	to	perform	(it	took	on	average	
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one	minute	to	perform	the	test,	and	10	minutes	for	the	results	to	become	available),	and	less	
painful	than	venepuncture.		
	
With	regards	to	the	diagnostic	performance	of	Simtomax,	the	sensitivity	was	comparable	to	IgA-
TTG	(82.9%	vs	78.1%).	In	the	group	1	cohort,	7.3%	(3/41)	of	the	newly	diagnosed	patients	had	
seronegative	 coeliac	 disease	 detected	 by	 Simtomax	 alone	 whilst	 IgA-TTG	 was	 negative.	 An	
increase	in	diagnostic	yield	was	also	demonstrated	by	Hoerter	et	al.	recently,	where	the	use	of	
IgA-DGP	 serology	 resulted	 in	 a	 15%	 increase	 in	 coeliac	 disease	detection	where	 IgA-TTG	was	
negative	(138).	However,	the	specificity	and	PPV	of	Simtomax	were	inferior	to	IgA-TTG	(85.4%	vs	
96.3%	 and	 19.5%	 vs	 47.1%	 respectively),	 due	 to	 a	 higher	 rate	 of	 false	 positives.	 This	 could	
potentially	 lead	 to	 unnecessary	 further	 investigations.	 A	 possible	 explanation	 of	 the	 low	
specificity	is	that	approximately	half	of	the	group	1	cohort	had	dyspepsia,	which	constituted	low	
risk	for	coeliac	disease,	and	hence	may	have	lowered	the	pre-test	probability	of	coeliac	disease	
and	hence	the	PPV.	On	the	other	hand,	when	Simtomax	was	used	in	higher	risk	groups,	such	as	
patients	who	self-reported	gluten	sensitivity	(group	2),	the	PPV	increased	to	65.4%,	with	a	100%	
sensitivity	and	NPV	in	detecting	coeliac	disease.		
	
The	advantages	of	Simtomax	over	conventional	serology	are	favourable	patient	acceptability	and	
rapidly	available	results	in	real	time.	Nevertheless,	despite	there	being	no	significant	difference	
in	the	overall	diagnostic	performance	between	Simtomax	and	serology	based	on	test	accuracy	
and	ROC	curve	analysis,	one	must	consider	the	clinical	impact	of	the	high	false	positive	rates	of	
Simtomax.	The	potential	burden	of	a	considerable	 increase	 in	unnecessary	 investigations	may	
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outweigh	the	benefits	of	a	sensitive	and	convenient	test.	As	a	case	finding	tool	in	the	secondary	
care	setting	where	the	coeliac	disease	prevalence	would	be	expected	to	be	approximately	4%,	as	
was	in	this	study	and	other	case	finding	studies	based	on	symptomatic	cohorts	(94),	Simtomax	
may	 not	 provide	 significant	 added	 value	 compared	 to	 conventional	 serology	 due	 to	 its	 low	
specificity,	albeit	its	similar	sensitivity	to	IgA-TTG.	
	
4.6:	Conclusion	
	
Simtomax	had	comparable	sensitivities	to	IgA-TTG	in	detecting	coeliac	disease	in	symptomatic	
patients,	and	correctly	identified	all	cases	of	coeliac	disease	in	a	gluten	sensitive	cohort	that	was	
consuming	gluten.	It	also	has	the	advantage	of	convenience,	rapid	result	availability,	and	good	
patient	acceptability.	However,	Simtomax	is	limited	by	its	low	specificity	which	may	increase	the	
number	of	unnecessary	investigations.	Simtomax	therefore	may	not	add	significant	value	when	
used	for	case	finding	in	secondary	care	in	patients	with	gastrointestinal	symptoms	or	risk	factors	
compared	to	conventional	serology.	
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Chapter	5:	The	role	of	a	point	of	care	test	in	iron	deficiency	anaemia	
at	endoscopy:	a	diagnostic	accuracy	and	a	cost	saving	model	
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5.1:	Abstract	
	
Background	
International	guidelines	recommend	coeliac	serology	in	iron	deficiency	anaemia,	and	duodenal	
biopsy	for	those	tested	positive	to	diagnose	coeliac	disease.	However,	pre-endoscopy	serology	is	
often	 unavailable,	 thus	 committing	 endoscopists	 to	 take	 routine	 duodenal	 biopsies.	 Some	
endoscopists	consider	duodenal	biopsy	mandatory	in	anaemia	to	exclude	other	pathologies.	It	is	
hypothesised	that	using	a	point	of	care	test	at	endoscopy	could	fill	this	gap,	by	providing	rapid	
results	to	target	which	anaemic	patients	require	biopsies,	and	save	costs	by	biopsy	avoidance.	
Three	key	aspects	to	this	hypothesis	were	thus	evaluated:	1)	to	establish	the	availability	of	pre-
endoscopy	serology	in	anaemia;	2)	to	determine	the	sensitivities	and	cost	effectiveness	of	pre-
endoscopy	coeliac	screening	with	Simtomax	in	anaemia;	3)	to	explore	whether	other	anaemia-
related	pathologies	could	be	missed	by	this	targeted-biopsy	approach.	
	
Methods	
Group	1:	pre-endoscopy	serology	availability	was	retrospectively	analysed	in	a	multicentre	cohort	
of	934	anaemic	patients	at	four	UK	hospitals.	Group	2:	the	sensitivities	of	Simtomax,	IgA-TTG	and	
IgA-EMA	were	compared	 in	133	prospectively	recruited	patients	with	 iron	deficiency	anaemia	
attending	for	a	gastroscopy.	The	sensitivities	were	measured	against	duodenal	histology	as	the	
reference	standard	in	all	patients.	The	cost	effectiveness	of	Simtomax	was	calculated	based	on	
the	number	of	biopsies	that	could	have	been	avoided	compared	to	an	all-biopsy	approach.	Group	
3:	the	duodenal	histology	of	153	patients	presenting	to	a	separate	iron	deficiency	anaemia	clinic	
were	retrospectively	reviewed.	
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Results	
In	group	1,	coeliac	serology	was	available	in	361	(33.8%)	patients.	In	group	2,	the	sensitivity	and	
NPV	were	100%	and	100%	for	Simtomax,	96.2%	and	98.9%	for	IgA-TTG,	and	84.6%	and	96.4%	for	
IgA-EMA	respectively.	In	group	3,	the	duodenal	histology	found	no	causes	for	anaemia	other	than	
coeliac	disease.	
	
Conclusion	
Simtomax	had	an	excellent	diagnostic	accuracy	in	iron	deficiency	anaemia	and	was	comparable	
to	conventional	serology.	Duodenal	biopsy	did	not	identify	any	causes	other	than	coeliac	disease	
for	 iron	deficiency	 anaemia,	 suggesting	 that	biopsy	 avoidance	 in	 Simtomax	negative	 anaemic	
patients	is	unlikely	to	miss	other	anaemia-related	pathologies.	Due	to	its	100%	NPV,	Simtomax	
could	reduce	unnecessary	biopsies	by	66%	if	only	those	with	a	positive	Simtomax	were	biopsied,	
potentially	saving	£3690/100	gastroscopies.		
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5.2:	Introduction	
	
One	of	the	common	presenting	symptoms	of	coeliac	disease	is	anaemia,	affecting	15-26.8%	of	
untreated	patients	(139,	140).	It	is	usually	caused	by	malabsorption,	leading	to	iron,	folate,	and	
B12	 deficiency	 (141).	 One	 way	 to	 increase	 the	 detection	 of	 coeliac	 disease	 is	 by	 screening	
individuals	with	 iron	deficiency	anaemia,	which	affects	2-5%	of	 the	general	population	 in	 the	
developed	world	 (142,	 143).	 	 At	 the	 endoscopy	 setting,	 2.6-8.7%	of	 patients	 presenting	with	
anaemia	are	diagnosed	with	coeliac	disease,	although	the	data	is	sparse	and	mainly	from	small	
cohorts	(140,	144-148).	The	current	BSG	iron	deficiency	anaemia	guidelines	recommend	routine	
screening	for	coeliac	disease	with	coeliac	serology,	and	a	gastroscopy	with	duodenal	biopsy	to	
confirm	the	diagnosis	of	coeliac	disease	if	serology	is	positive	(149).		
	
Anecdotally,	the	availability	and	utilisation	of	coeliac	serology	prior	to	endoscopy	appears	to	be	
highly	 variable,	 thus	 committing	 clinicians	 to	 take	 duodenal	 biopsies	 if	 serology	 results	 are	
unavailable	in	order	to	avoid	missing	the	diagnosis.	However,	this	is	an	expensive	way	of	case	
detection.	A	recent	Swedish	study	showed	that	routine	duodenal	biopsy	was	ineffective,	with	a	
number	 needed	 to	 biopsy	 of	 577	 to	 detect	 one	 case	 of	 coeliac	 disease,	 spending	more	 than	
€30,000	per	case	(140).	In	an	attempt	to	target	patients	who	require	a	duodenal	biopsy,	Hopper	
et	al.	devised	a	clinical	decision	tool	using	a	combination	of	pre-endoscopy	serological	testing	and	
symptom	assessment	(150).	This	validated	algorithm	resulted	in	a	100%	sensitivity	and	NPV	in	
detecting	coeliac	disease	when	applied	to	2000	prospectively	recruited	patients.	Yet,	the	lack	of	
serology	availability	prior	to	endoscopy	 in	real	 life	seemed	to	have	precluded	the	widespread	
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utilisation	of	this	effective	and	cost	saving	clinical	decision	tool.	One	method	of	filling	the	gap	of	
unavailable	serology	is	by	using	a	point	of	care	test	at	endoscopy.		
	
5.3:	Methods	
	
Aims:		
The	aim	of	this	study	was	to	evaluate	the	role	of	performing	a	pre-endoscopy	point	of	care	test	
in	iron	deficiency	anaemia	in	the	endoscopy	setting	as	a	cost	saving	model.		
	
Firstly,	 the	 rates	 of	 adherence	 to	 the	 BSG	 guidelines	 on	 coeliac	 screening	 in	 iron	 deficiency	
anaemia	 in	 clinical	 practice	 was	 reviewed,	 to	 demonstrate	 the	 pre-endoscopy	 availability	 of	
serology.		
	
Secondly,	the	diagnostic	performance	of	Simtomax	in	detecting	coeliac	disease	in	iron	deficiency	
was	ascertained,	and	the	economic	impact	of	using	Simtomax	as	a	screening	tool	to	target	biopsy	
taking	only	in	those	tested	positive	for	Simtomax	was	evaluated.		
	
Finally,	 a	 retrospective	 analysis	 was	 performed	 to	 explore	 whether	 routine	 duodenal	 biopsy	
would	yield	any	alternative	causes	for	iron	deficiency	anaemia	other	than	coeliac	disease,	in	order	
to	 assess	whether	 targeting	 biopsies	 only	 in	 Simtomax	 positive	 anaemic	 patients	would	miss	
other	duodenal	pathologies	causing	anaemia.		Figure	9	illustrates	a	flow	diagram	of	how	a	point	
of	care	test	in	endoscopy	would	fit	in.	
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Study	design	and	recruitment:		
Group	1	was	a	multicentre	retrospective	analysis	of	all	patients	with	anaemia	attending	 for	a	
gastroscopy	 with	 duodenal	 biopsy	 at	 four	 UK	 hospitals	 (Addenbrooke’s,	 Bradford,	 Hull	 and	
Figure	9:	A	 flow	diagram	of	how	a	point	of	 care	 test	 in	endoscopy	would	 fit	 in	within	 the	
endoscopy	setting.		
	
Starting	 from	 the	 top	 second	 left	 picture	 in	 a	 clockwise	 fashion:	 The	 patient	 enters	 the	
endoscopy	 unit,	 undertakes	 a	 Simtomax	 test	 performed	by	 a	 healthcare	 professional	 if	 iron	
deficiency	anaemia	is	present.	If	the	patient	has	a	positive	Simtomax,	the	endoscopist	would	
take	 duodenal	 biopsies	 to	 exclude	 coeliac	 disease.	 If	 the	 patient	 has	 a	 negative	 Simtomax,	
duodenal	biopsies	would	not	be	required.	
	
		
The	above	photographs	were	taken	by	Professor	Sanders.	
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Whipps	Cross)	over	a	12	month	period	 ranging	 from	2012	 to	2014.	The	availability	of	 coeliac	
serology	prior	to	gastroscopy	was	reviewed.		
	
Group	 2	 was	 a	 prospective	 study	 comparing	 the	 sensitivities	 of	 Simtomax	 to	 conventional	
serology	in	an	iron	deficient	cohort.	Patients	with	iron	deficiency	with	or	without	anaemia	were	
prospectively	 recruited.	 These	 patients	 attended	 for	 a	 gastroscopy	 at	 the	 Royal	 Hallamshire	
Hospital	 between	 2013	 and	 2015.	 All	 recruited	 patients	 were	 consented	 for	 the	 study,	 and	
undertook	 Simtomax,	 IgA-TTG,	 IgA-EMA,	 total	 IgA	 levels,	 and	 a	 gastroscopy	 with	 quadrantic	
duodenal	biopsy	from	the	second	part	of	the	duodenum	and	at	least	one	duodenal	bulb	biopsy.		
	
Group	3	was	a	retrospective	analysis	of	patients	attending	a	separate	non-coeliac	specialised	iron	
deficiency	 anaemia	 clinic	 at	 the	 Northern	 General	 Hospital	 in	 2013-2014.	 Their	 duodenal	
histology	and	hospital	case	notes	were	 reviewed	to	determine	 the	yield	of	alternative	causes	
other	than	coeliac	disease	in	the	context	of	iron	deficiency	anaemia.	The	decision	to	review	the	
duodenal	histology	of	patients	attending	a	non-coeliac	specialised	iron	deficiency	anaemia	clinic	
at	the	Northern	General	Hospital	was	so	that	the	results	would	represent	real	world	data	without	
tertiary	referral	bias.	
	
Inclusion	criteria	for	group	2:		
Patients	with	iron	deficiency	with	or	without	anaemia.		
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Exclusion	criteria	for	group	2:		
Patients	with	known	coeliac	disease,	 those	on	a	gluten	 free	diet,	patients	with	coagulopathy,	
active	gastrointestinal	bleeding	or	a	suspected	carcinoma	observed	during	the	examination	were	
excluded.		
	
Outcome	measures:		
The	primary	outcome	was	 to	assess	 the	diagnostic	accuracy	of	Simtomax	 in	detecting	coeliac	
disease	in	patients	with	anaemia.		
	
Secondary	 outcomes	 included	 an	 economic	 analysis	 of	 the	 cost	 savings	 achieved	 by	 only	
performing	duodenal	biopsies	 in	anaemic	patients	who	had	a	positive	Simtomax	compared	to	
routine	biopsies	for	all	anaemic	patients	attending	for	a	gastroscopy;	and	a	retrospective	analysis	
of	the	duodenal	histological	findings	in	a	separate	cohort	of	patients	with	iron	deficiency	anaemia.	
	
Economic	analysis:		
The	financial	impact	at	a	local	and	national	level	of	using	Simtomax	to	avoid	routine	duodenal	
biopsies	in	anaemia	was	evaluated.	In	the	UK,	the	Health	Resource	Group	(HRG)	tariff	(payment	
from	the	NHS	commissioners	to	hospitals	for	providing	a	service)	for	a	gastroscopy	with	duodenal	
biopsy	and	a	gastroscopy	alone	are	£382	and	£344	respectively.	This	means	that	£38	would	be	
saved	for	the	NHS	budget	if	duodenal	biopsy	was	avoided	for	each	gastroscopy	performed.	On	
the	other	hand,	there	is	cross	charging	between	departments	for	each	service	provided.	At	the	
Royal	 Hallamshire	 Hospital,	 the	 histopathology	 department	 charges	 the	 gastroenterology	
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department	£86	for	the	service	of	analysing	four	D2	biopsies	and	one	D1	biopsy	(local	tariff	may	
vary	among	different	trusts).		
	
Statistics:		
As	 the	 PPV	 and	 NPV	 of	 a	 test	 are	 influenced	 by	 the	 pre-test	 probability,	 positive	 (PLR)	 and	
negative	 likelihood	 ratios	 (NLR)	were	 also	 calculated	 as	 these	 are	 less	 prone	 to	 influence	 by	
disease	prevalence.		
	
Ethics	approval:		
The	 group	 2	 study	 protocol	 was	 approved	 by	 the	 Yorkshire	 and	 the	 Humber	 Research	 Ethics	
committee	 and	 registered	 with	 the	 local	 research	 and	 development	 department	 of	 Sheffield	
Teaching	Hospital	NHS	Foundation	Trust	under	the	registration	number	STH15416.	(See	appendix	7	
for	patient	information	sheet	and	appendix	8	for	consent	form)	
	
5.4:	Results	
	
In	group	1,	a	total	of	934	patients	with	anaemia	underwent	a	gastroscopy	with	duodenal	biopsy	
at	 four	 UK	 hospitals.	 Coeliac	 serology	 was	 only	 available	 in	 315	 patients	 (33.8%)	 prior	 to	
endoscopy.	Forty-four	(14%)	serology	samples	were	performed	in	primary	care.		
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In	group	2,	133	patients	(88	females,	66%)	with	iron	deficiency	attending	for	a	gastroscopy	at	the	
Royal	Hallamshire	Hospital	were	prospectively	 recruited	 (age	 range:	18-89	years,	median	53).	
Twenty-six	patients	(19.5%)	were	diagnosed	with	coeliac	disease.	Simtomax	correctly	identified	
all	cases	of	coeliac	disease,	defined	by	a	combination	of	positive	serology	(IgA-EMA/IgA-TTG)	and	
Marsh	3	villous	atrophy.	The	results	are	shown	in	tables	11	and	12.		There	was	one	case	of	a	38	
year	old	Zambian	lady	with	seronegative	villous	atrophy	secondary	to	tuberculosis.	A	comparison	
of	the	sensitivities	of	Simtomax,	IgA-TTG	and	IgA-EMA	are	shown	in	table	13.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	11:	Group	2	iron	deficient	patient	characteristics	and	corresponding	histology	results.	
	
	 Simtomax	
positive	
EMA	
positive	
TTG	
positive	
M*0	 M1	 M2	 M3a	 M3b	 M3c	 Coeliac	
disease	
Iron	
deficiency	
anaemia	
(n=81)	
30	 13	 19	 55	 7	 1	 2**	 5	 10	 16	
(19.8%)	
Iron	
deficiency	
without	
anaemia	
(n=52)	
15	 10	 15	 33	 8	 1	 2	 2	 6	 10	
(19.2%)	
	
*Marsh	grade	
**One	 patient	 had	 seronegative	 Marsh	 grade	 3a	 villous	 atrophy	 which	 was	 secondary	 to	
tuberculosis	instead	of	coeliac	disease.	
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In	group	3,	215	patients	with	iron	deficiency	anaemia	attended	a	separate	non-coeliac	specialised	
anaemia	clinic	at	the	Northern	General	Hospital	for	investigation	from	2013-2014.	A	total	of	175	
patients	 underwent	 a	 gastroscopy,	 and	 153	 of	 those	 had	 a	 duodenal	 biopsy.	 The	 duodenal	
histology	samples	of	these	153	patients	were	analysed.	Two	patients	had	Marsh	grade	3	villous	
atrophy	on	histology-	one	had	a	positive	coeliac	serology	and	hence	was	diagnosed	with	coeliac	
disease;	 the	 other	 patient	 was	 found	 to	 have	 a	 colonic	 tumour	 during	 the	 course	 of	 the	
investigation	and	subsequently	died.	He	never	had	coeliac	serology	or	HLA	genotyping	to	confirm	
the	diagnosis.	Assuming	the	latter	case	to	be	coeliac	disease,	the	prevalence	of	coeliac	disease	in	
group	3	would	be	1.3%.		
Table	13:	The	sensitivities	of	Simtomax,	IgA-TTG	and	IgA-EMA	in	group	2	in	iron	deficiency.	
	
	 Sensitivity	%	(95%	CI)	 Specificity	%	(95%	CI)	 PPV	%	(95%	CI)	 NPV	%	(95%	CI)	
Simtomax										100	(86.8-100.0)	 82.2	(73.7-89.0)	 57.8	(42.2-72.3)	 100	(95.9-100.0)	
IgA-TTG	 96.2	(80.4-99.9)	 91.5	(84.5-96.4)	 73.5	(55.6-87.1)	 99.0	(94.5-100.0)	
IgA-EMA	 84.6	(65.1-95.6)	 99.1	(94.9-100.0)	 95.7	(78.1-99.9)	 96.4	(91.0-99.0)	
 
Table	12:	Cross	tabulation	of	Simtomax	results	by	serology	and	duodenal	histology	results	
in	iron	deficiency.	
	
	 Simtomax	positive	 Simtomax	negative	
Coeliac	disease		 26	 0	
No	coeliac	disease		 19	 88	
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In	group	3,	92.2%	patients	(141/153)	had	normal	duodenal	histology.	Seven	patients	(4.6%)	had	
lymphocytic	duodenosis	 (Marsh	grade	1)	on	 their	histology,	all	of	whom	had	negative	coeliac	
serology.	Their	hospital	case	notes	were	reviewed	and	screened	for	drug	causes	for	lymphocytic	
duodenosis	 such	 as	 aspirin,	 proton	 pump	 inhibitors,	 olmesartan,	 non-steroidal	 anti-
inflammatories	and	chemotherapy;	autoimmune	associations	such	as	type	1	diabetes	and	thyroid	
disorders;	and	infections	such	as	Helicobacter	pylori,	Whipple’s,	Giardia	etc.	Six	of	these	patients	
had	 a	 cause	 for	 or	 association	 with	 lymphocytic	 duodenosis:	 vitiligo,	 autoimmune	
hypothyroidism,	multiple	sclerosis,	aspirin	use,	proton	pump	inhibitor	use	and	Helicobacter	pylori	
infection	 respectively.	 No	 attributable	 cause	 was	 found	 for	 lymphocytic	 duodenosis	 in	 the	
remaining	one	patient,	whose	helicobacter	status	was	unknown.	The	remaining	three	patients	
had	reactive	changes,	chronic	duodenitis	and	submucosal	haemangioma	respectively	on	 their	
duodenal	histology	which	were	not	the	cause	for	their	iron	deficiency	anaemia.	Table	14	shows	
a	breakdown	of	the	significant	findings	on	gastroscopy	in	the	group	3	cohort.	This	table	excludes	
hiatus	hernia,	mild	oesophagitis	(grade	A),	mild	or	non	Helicobacter	pylori	(HP)	related	gastritis	
or	 duodenitis,	 hyperplastic	 polyps,	 cystic	 fundal	 polyps	 and	 lipoma,	 as	 these	 are	 incidental	
findings	that	did	not	alter	clinical	management.	Significant	findings	that	contributed	to	anaemia	
formed	9.2%	(14/153)	of	the	cohort,	whilst	significant	findings	that	were	unrelated	to	anaemia	
constituted	7.8%	(12/153)	of	the	cohort.	Interestingly,	no	malignancy	was	found	on	gastroscopy	
in	this	cohort.	The	total	yield	of	significant	findings	on	gastroscopy	was	16.3%	(25/153).	
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Table	14.	Significant	findings	on	gastroscopy	in	the	group	3	cohort.	
Gastroscopy	findings	 No.	of	patients	(%)	 Cause	of	anaemia	
HP	related	gastritis	 9	(5.9%)	 Yes	
Peptic	ulcers	(both	positive	for	HP)	 2	(1.3%)	 Yes	
Oozing	telangiectasia	 1	(0.6%)	 Yes	
Duodenal	villous	atrophy	(coeliac	disease)	 2	(1.3%)	 Yes	
Barrett’s	oesophagus	 4	(2.6%)	 No	
Grade	B	or	above	oesophagitis	 3	(2%)	 No	
Pangastritis	(negative	for	HP)	 3	(2%)	 No	
Oesophageal	stricture	 1	(0.6%)	 No	
Gastric	tubular	adenoma	 1	(0.6%)	 No	
	
	
Cost	Saving	Economic	model	
In	the	group	2	cohort,	88	out	of	133	patients	had	a	negative	Simtomax	test.	Based	on	the	100%	
sensitivity	and	NPV	of	Simtomax,	a	duodenal	biopsy	could	have	been	avoided	in	these	88	patients	
(66.2%).	At	the	Royal	Hallamshire	Hospital,	the	cost	of	having	duodenal	biopsies	reported	(four	
D2	and	one	D1	biopsy)	is	£86,	and	the	price	of	each	Simtomax	test	kit	is	£20.	The	cost	saving	from	
avoided	biopsies	in	this	cohort	would	be	£7568	(£86x88).	After	taking	into	account	the	cost	of	
using	Simtomax	on	all	patients	(£20x133=£2660),	the	overall	cost	saving	in	this	cohort	would	be	
£4908	 (£7568-£2660)	 for	 the	 gastroenterology	 department.	 This	 equates	 to	 a	 potential	 cost	
saving	 of	 £3690	 per	 100	 gastroscopies.	 At	 a	 national	 level,	 the	 difference	 in	 the	 HRG	 tariff	
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between	 a	 gastroscopy	 alone	 and	 a	 gastroscopy	 with	 duodenal	 biopsy	 paid	 by	 the	 clinical	
commissioners	to	the	trust	is	£38.	This	equates	to	a	cost	saving	of	£2514	per	100	gastroscopies	
for	the	NHS	budget	(£38x88/133x100).	
	
	
5.5:	Discussion	
This	study	demonstrated	with	real	life	data	that	the	availability	of	coeliac	serology	in	anaemia	
prior	to	gastroscopy	was	low	(33.8%).	This	result	echoes	that	of	an	American	study	conducted	by	
Wiland	et	al.	 in	2013	demonstrating	that	only	one	third	of	patients	suspected	to	have	coeliac	
disease	had	serology	available	prior	to	endoscopy	(4).		
	
This	is	the	first	study	showing	that	Simtomax	had	100%	sensitivity	and	NPV	in	detecting	coeliac	
disease	 in	 iron	deficient	patients.	The	PLR	and	NLR	were	5.63	and	0	respectively,	 indicating	a	
negative	Simtomax	test	effectively	ruled	out	coeliac	disease	in	iron	deficient	patients.		
	
The	 group	 3	 duodenal	 histology	 analysis	 revealed	 no	 alternative	 causes	 for	 iron	 deficiency	
anaemia	other	 than	 villous	 atrophy	 secondary	 to	 coeliac	disease.	With	 a	100%	NPV,	 taking	 a	
duodenal	biopsy	in	patients	with	a	negative	Simtomax	test	would	be	highly	unlikely	to	yield	any	
other	diagnosis	for	iron	deficiency	in	routine	clinical	practice,	and	hence	duodenal	biopsies	could	
potentially	be	avoided.	
	
The	local	cost	saving	of	£3690/100	gastroscopies	was	based	on	the	coeliac	disease	prevalence	of	
19.5%	in	the	group	2	cohort.	In	a	lower	prevalence	population,	the	potential	cost	saving	would	
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be	greater.	By	basing	the	calculations	on	the	average	coeliac	disease	prevalence	of	5%	in	iron	
deficient	cohorts	(144-148),	the	potential	cost	saving	for	the	gastroenterology	department	would	
be	£5826/100	gastroscopies,	assuming	the	same	tariff	was	applied;	and	£3456/100	gastroscopies	
would	be	saved	at	a	national	level	for	the	NHS	budget.	This	is	excluding	a	wide	range	of	intangible	
savings	from	the	positive	knock	on	effects,	such	as	cost	savings	from	not	using	biopsy	pots	and	
forceps,	staff	time	and	workload	for	both	the	endoscopy	and	histopathology	departments.	
	
The	 strength	 of	 the	 prospective	 study	 (group	 2)	 is	 that	 the	 sensitivities	 of	 Simtomax	 were	
measured	 against	 duodenal	 histology	 rather	 than	 serology	 as	 the	 reference	 standard.	
Furthermore,	 in	 order	 to	 reduce	 selection	 bias,	 all	 patients	 underwent	 duodenal	 biopsies	
irrespective	of	their	serology	or	Simtomax	results.	This	sets	the	study	apart	from	the	three	out	of	
four	 published	 Simtomax	 studies	 (88-90),	 where	 only	 patients	 with	 a	 positive	 serology	 or	
Simtomax	 test	went	on	 to	have	duodenal	biopsies,	which	could	potentially	 lead	 to	a	positive	
ascertainment	bias	and	falsely	elevated	sensitivities.	This	drawback	is	also	common	in	previous	
studies	on	the	sensitivities	of	coeliac	serology	as	mentioned	in	the	previous	chapter.		
	
One	of	 the	 limitations	of	 the	study	 is	 the	 relatively	high	pre-test	probability	 in	group	2	being	
investigated	at	our	tertiary	referral	centre	for	coeliac	disease,	giving	a	coeliac	disease	prevalence	
of	19.5%.	This	referral	bias	may	falsely	increase	the	PPV	of	Simtomax,	although	the	weight	of	its	
NPV	may	 be	 strengthened,	 which	 is	 the	 focal	 feature	 of	 the	 point	 of	 care	 test	 that	 aims	 to	
confidently	exclude	coeliac	disease.	
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Another	 limitation	 is	 that	even	though	the	non-specialist	group	3	cohort	represented	real	 life	
data	where	no	other	causes	 for	anaemia	apart	 from	coeliac	disease	were	 found	on	duodenal	
histology,	it	is	a	relatively	small	cohort	and	may	not	be	representative	of	other	populations.	For	
instance,	 infective	 causes	 may	 be	 seen	 in	 other	 cohorts,	 and	 their	 prevalence	 varies	 from	
different	populations	and	geographical	regions.	Two	Turkish	studies	reported	a	2%	prevalence	of	
Giardiasis	found	on	duodenal	biopsies	in	their	cohorts	with	iron	deficiency	anaemia	(151,	152).	
In	 contrast,	 a	German	 study	only	 found	a	0.2%	prevalence	of	Giardiasis	 on	 routine	duodenal	
biopsy	in	1000	unselected	patients	attending	for	a	gastroscopy	(153),	and	a	study	from	America	
had	 a	 0.3%	 yield	 of	 Giardiasis	 on	 routine	 duodenal	 biopsy	 in	 300	 patients	 presenting	 with	
abdominal	pain	(154).	Therefore,	the	cost	saving	economic	model	through	biopsy	avoidance	in	
iron	deficient	patients	with	a	negative	Simtomax	test	may	not	be	applicable	to	populations	where	
parasitic	infections	are	common,	as	infective	diagnoses	may	be	missed.	
	
Of	note,	in	the	group	2	tertiary	centre	iron	deficient	cohort,	there	was	one	case	of	seronegative	
villous	atrophy	secondary	to	tuberculosis.	However,	this	is	a	rare	cause	of	seronegative	villous	
atrophy.	It	must	be	emphasised	that	the	group	2	cohort	does	not	reflect	what	is	normally	seen	in	
routine	clinical	practice,	as	the	Royal	Hallamshire	Hospital	is	a	tertiary	referral	centre	for	coeliac	
disease.	Apart	from	coeliac	disease	and	parasitic	infections,	rarer	malabsorptive	enteropathies	
with	villous	atrophy	have	been	reported	in	other	studies,	such	as	Whipple’s	disease	(155),	graft	
versus	 host	 disease	 (156),	 common	 variable	 immunodeficiency	 (157,	 158),	 autoimmune	
enteropathy	(159),	and	olmesartan	associated	enteropathy	(160).	The	literature	has	shown	that	
patients	with	gastrointestinal	parasitic	infections	and	other	rare	enteropathies	described	above	
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typically	present	with	significant	symptoms	such	as	diarrhoea,	abdominal	pain	and	malnutrition,	
rather	 than	 solely	 with	 iron	 deficency	 anaemia	 (154,	 157-159).	 	 Therefore,	 in	 iron	 deficient	
patients	where	there	is	a	high	index	of	suspicion	for	other	enteropathies,	such	as	malasborptive	
symptoms	or	high	risk	ethnicities,	the	threshold	for	taking	duodenal	biopsies	should	be	lowered	
in	spite	of	a	negative	Simtomax	test.	
	
This	study	demonstrated	excellent	sensitivity	and	NPV	of	Simtomax	 in	 iron	deficiency,	and	 its	
performance	was	comparable	to	both	IgA-EMA	and	IgA-TTG.	Although	the	results	were	based	on	
relatively	small	numbers,	they	are	consistent	with	two	other	studies	testing	Simtomax	in	high	risk	
groups	performed	by	Benkebil	et	al.	in	2013	(89)	(100%	sensitivity	for	coeliac	disease	in	a	high	
risk	population)	and	Bienvenu	et	al.	in	2014	(88)	(100%	sensitivity	and	NPV	for	coeliac	disease	in	
IgA	 deficient	 children,	 median	 age	 8.4).	 Larger	 studies	 would	 be	 helpful	 in	 confirming	 the	
diagnostic	accuracy	of	Simtomax	in	an	iron	deficient	cohort	in	order	to	validate	the	safety	of	a	
targeted	biopsy	approach.	
	
5.6:	Conclusion	
 
	
This	 is	 the	 first	 study	 that	 demonstrated	 excellent	 diagnostic	 accuracy	 of	 Simtomax	 in	 iron	
deficiency,	which	was	comparable	to	conventional	serological	 testing.	With	a	100%	sensitivity	
and	 NPV,	 Simtomax	 could	 be	 used	 judiciously	 by	 clinicians	 as	 an	 effective	 and	 cost	 saving	
screening	 test	 for	 coeliac	disease	 in	 the	endoscopic	 setting,	by	avoiding	duodenal	biopsies	 in	
patients	presenting	with	iron	deficiency	with	a	negative	Simtomax	test	(96).	
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Chapter	6:	The	role	of	a	point	of	care	test	in	coeliac	disease	follow	up:	
predicting	histological	remission	in	patients	with	known	coeliac	
disease	on	a	gluten	free	diet	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 100	
6.1:	Abstract	
	
Introduction:	Mucosal	healing	is	important	in	coeliac	disease	for	the	prevention	of	complications.	
However,	obtaining	duodenal	biopsies	 is	 invasive,	and	there	 is	currently	no	reliable	surrogate	
marker	for	histological	remission	in	clinical	practice.	The	aim	was	to	assess	the	role	of	a	point	of	
care	test,	Simtomax,	in	detecting	persistent	villous	atrophy	in	coeliac	disease.	
	
Methods:	Patients	with	known	coeliac	disease	attending	for	a	gastroscopy	for	the	assessment	of	
histological	remission	were	prospectively	recruited.	All	patients	had	Simtomax,	IgA-EMA,	and	IgA-
TTG	performed,	and	completed	a	validated	dietary	adherence	questionnaire.	A	gastroscopy	was	
performed	in	all	patients,	with	four	biopsies	taken	from	the	second	part	of	the	duodenum	and	
one	from	the	duodenal	bulb.	The	diagnostic	performance	of	the	surrogate	markers	was	measured	
against	duodenal	histology	as	the	reference	standard.	
	
Results:	A	total	of	217	patients	with	coeliac	disease	(70%	female,	age	range	16-83,	median	age	
53)	on	a	gluten	free	diet	(median	duration	six	years)	were	recruited	from	2013-2017.	Eighty-five	
(39.2%)	patients	had	persistent	villous	atrophy.	The	sensitivities	of	Simtomax,	IgA-TTG,	IgA-EMA	
and	 the	 adherence	 score	 in	 detecting	 villous	 atrophy	 were	 67.1%,	 44.7%,	 37.7%	 and	 24.7%	
respectively	 (Simtomax	 vs	 IgA-TTG	p=0.0005).	 	 The	 combination	 of	 Simtomax	 and	 adherence	
score	only	marginally	increased	the	sensitivity	to	70.6%	(59.7-80.0%).	
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Conclusion:	 The	 sensitivity	 of	 Simtomax	 was	 higher	 than	 the	 other	 surrogate	 markers	 in	
predicting	 villous	 atrophy.	 Simtomax	may	 provide	 the	 additional	 advantage	 of	 an	 immediate	
objective	assessment	of	mucosal	healing	at	the	time	of	an	office	based	follow-up	consultation.	
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6.2:	Introduction	
	
A	 gluten	 free	 diet	 remains	 the	 only	 treatment	 for	 coeliac	 disease	 at	 present.	 Strict	 dietary	
adherence	is	often	challenging	given	the	ubiquity	of	gluten	in	Westernised	diets	and	processed	
foods,	with	 adherence	 rates	 reported	 to	 vary	 between	 42%	 and	 91%	 (43,	 161,	 162).	 Dietary	
transgression	is	the	commonest	cause	for	non-responsive	coeliac	disease	(42,	46,	163),	which	can	
lead	 to	 gastrointestinal	 and	 extra-gastrointestinal	 symptoms,	 persistent	 villous	 atrophy,	
complications	such	as	osteoporosis	and	malabsorption,	and	a	worse	quality	of	life	(164).	A	meta-
analysis	based	on	over	3000	patients	showed	that	irritable	bowel	type	symptoms	were	twice	as	
common	in	patients	who	were	non-adherent	compared	to	those	who	achieved	dietary	adherence	
(pooled	odds	ratio	2.62,	95%	CI	0.75-9.56)	(165).		
	
	
Histological	remission	is	not	always	achieved	in	adults,	with	remission	rates	ranging	from	34%-
65%	at	two	years	after	diagnosis	(166-168).	This	is	an	important	point	because	persistent	villous	
atrophy	may	increase	the	risk	of	lymphoproliferative	malignancies	(58)	and	hip	fractures	(169).	
Consequently,	the	logical	approach	for	disease	monitoring	would	be	histological	assessment	of	
the	duodenum	for	mucosal	healing.	However,	this	method	is	invasive,	costly,	and	carries	risks	of	
complications	such	as	bleeding,	perforation	and	cardiopulmonary	complications	from	sedation	
(170,	171).	Furthermore,	there	is	little	consensus	for	routine	follow	up	biopsy,	and	the	timing	of	
re-biopsy	vary	among	individual	practice	and	national	guidelines	(35,	36,	172,	173).	
	
There	 is	 certainly	an	unmet	need	 for	a	 reliable	 surrogate	marker	 for	histological	 remission	 in	
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coeliac	disease.	A	myriad	of	novel	markers	such	as	serum	intestinal	fatty	acid-binding	protein	(I-
FABP)	levels	(174),	urinary	and	faecal	gluten	immunogenic	peptide	(175),	citrulline	(176),	faecal	
fat	 excretion	 (177),	 urinary	 lactulose-to-mannitol	 excretion	 ratios	 (178),	 	 and	 the	 maximum	
concentration	of	simvastatin	in	the	small	intestine	(179)	have	been	studied,	but	none	of	them	
are	currently	used	in	routine	clinical	practice.		
	
At	present,	a	combination	of	dietetic	evaluation,	symptom	assessment	and	serological	titres	are	
used	during	follow	up	to	determine	the	necessity	for	a	repeat	duodenal	biopsy.	However,	these	
non-invasive	 surrogate	markers	 have	 been	 shown	 to	 correlate	 poorly	 with	 persistent	 villous	
atrophy.	It	is	well	established	that	serology	is	inadequate	in	detecting	ongoing	villous	atrophy,	
with	sensitivities	of	IgA-TTG	and	IgA-EMA	reported	to	be	41-52%	and	26-31%	respectively	(166,	
167,	 180,	 181).	 Symptoms	have	 also	not	 been	 shown	 to	 associate	with	histological	 recovery,	
where	62%	of	patients	with	symptomatic	improvement	were	still	found	to	have	persistent	villous	
atrophy	(166).	Dietary	assessment	by	a	specialist	dietitian	may	currently	be	the	optimal	method	
of	measuring	adherence	(182),	although	the	method	of	assessment	is	not	standardised.		
	
For	all	these	reasons,	a	simple	and	reliable	method	of	assessment	to	measure	dietary	adherence	
is	 needed.	 A	 dietary	 assessment	 questionnaire	 was	 devised	 by	 Biagi	 and	 colleagues,	 which	
contains	four	simple	questions	based	on	the	patients’	strategy	for	gluten	avoidance	rather	than	
assessing	 the	 amount	 of	 gluten	 ingested.	 Biagi	 et	 al.	 concluded	 that	 the	 adherence	 score	
identified	patients	in	histological	remission,	with	a	PPV	of	35.7%	and	NPV	of	86.7%	(183).	Further	
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studies	are	required	to	validate	the	utility	of	this	questionnaire.	
	
There	is	an	abundance	of	studies	investigating	the	performance	of	different	point	of	care	tests	in	
the	diagnosis	of	untreated	coeliac	disease,	with	sensitivities	of	point	of	care	tests	(Biocard,	Celiac	
Quick	Test	and	Stick	CD1	and	2)	 reported	 to	be	58-100%	 (82,	84,	87-89,	121,	123,	125,	184).	
Conversely,	 there	 is	 a	 paucity	 of	 data	 examining	 the	 role	 of	 point	 of	 care	 tests	 in	 disease	
monitoring.	Previous	studies	showed	the	sensitivities	were	found	to	be	78.9%	for	Simtomax	(89),	
and	77.8%	(using	whole	blood)	and	93.5%	(using	serum)	for	Celiac	Quick	Test	in	measuring	dietary	
adherence	 in	known	coeliac	disease	 (184).	However,	 these	results	should	be	 interpreted	with	
caution	as	they	did	not	use	the	presence	of	villous	atrophy	as	the	marker	for	non-adherence,	but	
instead	compared	the	point	of	care	tests	against	TTG.			
	
6.3:	Methods	
	
Aims:		
To	 evaluate	 the	 diagnostic	 performance	 of	 Simtomax,	 IgA-TTG,	 IgA-EMA	 and	 the	 adherence	
questionnaire	 devised	 by	 Biagi	 et	 al.	 in	 predicting	 persistent	 villous	 atrophy	 in	 patients	with	
coeliac	disease	on	a	gluten	free	diet.	
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Study	design	and	recruitment:		
The	study	took	place	at	the	Royal	Hallamshire	Hospital,	Sheffield,	U.K.,	from	March	2013-January	
2017.	Patients	with	biopsy	proven	coeliac	disease	on	a	gluten	free	diet	who	were	being	assessed	
for	 histological	 remission	were	 prospectively	 recruited.	 All	 patients	were	 concurrently	 tested	
with	 Simtomax,	 IgA-TTG,	 IgA-EMA,	 total	 IgA	 levels.	 A	 health	 questionnaire	 regarding	 their	
symptoms	 (appendix	 9)	 and	 a	 dietary	 adherence	 questionnaire	 devised	 by	 Biagi	 et	 al.	 (183)	
(appendix	 10)	 were	 completed	 in	 the	 endoscopy	 unit.	 A	 gastroscopy	 with	 one	 D1	 and	 four	
quadrantic	D2	biopsies	was	then	performed	in	all	patients.			
	
Inclusion	criteria:		
Patients	with	known	coeliac	disease	who	were	symptomatic,	non-adherent	to	their	gluten	free	
diet	 or	 those	with	 raised	 serological	 titres	were	 recruited.	 Patients	who	were	 asymptomatic,	
adherent	 to	 their	 diet	 and	 with	 negative	 serology	 were	 not	 routinely	 referred	 for	 a	 repeat	
duodenal	biopsy	in	our	centre.	
	
Exclusion	criteria:		
Gastrointestinal	bleeding	or	evidence	of	cancer	found	on	endoscopy.	
	
Outcome	measures:		
The	primary	outcome	was	to	determine	the	diagnostic	accuracy	of	Simtomax,	IgA-EMA	and	IgA-
TTG	in	detecting	persistent	villous	atrophy	in	patients	with	known	coeliac	disease.		
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The	 secondary	outcome	was	 to	perform	an	economic	 analysis	 comparing	 the	 cost	 of	 routine	
duodenal	biopsy	for	coeliac	disease	follow	up	against	that	of	using	Simtomax,	IgA-EMA	and	IgA-
TTG	to	target	biopsy	for	those	with	a	positive	result.	
	
Statistics:		
Sensitivities	of	 the	 surrogate	markers	were	compared	using	 the	McNemar	 test	 for	 correlated	
proportions.		
ROC	curves	were	constructed	with	paired	sensitivities	and	specificities	of	each	surrogate	marker,	
and	the	AUC	was	determined.		
	
Ethics	approval:		
The	study	protocol	was	approved	by	the	Yorkshire	and	the	Humber	Research	Ethics	committee	
and	 registered	 with	 the	 local	 research	 and	 development	 department	 of	 Sheffield	 Teaching	
Hospital	NHS	Foundation	Trust	under	the	registration	number	STH15416.	Written	consent	was	
obtained	from	all	patients.	 	 (See	appendix	7	for	patient	 information	sheet	and	appendix	8	for	
consent	form)	
	
Economic	analysis:	
An	economic	analysis	was	performed	comparing	the	cost	of	routine	duodenal	biopsy	against	that	
of	using	Simtomax,	IgA-EMA	and	IgA-TTG	to	target	biopsy	for	those	with	a	positive	result.		
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The	costs	of	each	item	is	as	follows:	Simtomax=	£20;	TTG=	£22.71;	EMA=	£13.41;	combination	
price	of	TTG+EMA=	£27.96;	 immunoglobulins=	£14.12;	processing	four	D2	and	1	D1	biopsies=	
£86;	formalin	biopsy	pot=	£0.17,	biopsy	forceps=	£4.85;	total	cost	of	gastroscopy	with	duodenal	
biopsies	(£344+	£86+	£0.17x2+	£4.85)	=	£435.19	(D1	and	D2	biopsies	were	placed	in	2	separate	
pots,	hence	£0.17x2).	Immunoglobulins	were	routinely	measured	alongside	IgA-TTG	and	IgA-EMA	
to	identify	those	with	IgA	deficiency	during	follow	up,	as	previous	IgA	levels	may	not	always	be	
available,	 especially	 in	 cases	 where	 the	 patient	 was	 referred	 from	 outside	 our	 local	 area.	
Therefore,	the	cost	of	immunoglobulins	was	taken	into	account	when	calculating	the	cost	of	using	
IgA-TTG	and	IgA-EMA	for	the	purpose	of	the	analysis.	Since	Simtomax	detects	both	IgA	DGP	and	
IgG	DGP,	there	is	no	need	to	check	immunoglobulins	for	IgA	deficiency	when	using	Simtomax	as	
IgG-DGP	would	be	detected.	Therefore,	the	cost	of	immunoglobulins	was	not	included	in	the	cost	
analysis	for	Simtomax.	
	
6.4:	Results	
 
A	total	of	217	patients	with	biopsy	proven	coeliac	disease	on	a	gluten	free	diet	were	recruited	
from	2013-2017	 (70%	 female,	 age	 range	16-83,	median	age	53).	 The	median	duration	of	 the	
gluten	 free	 diet	 was	 six	 years	 (76.5	 months;	 range:	 6-900	 months).	 Patient	 characteristics	
including	their	gender,	race,	median	duration	of	gluten	free	diet	in	the	villous	atrophy	group	and	
no	 villous	 atrophy	 group	 are	 illustrated	 in	 table	 15.	 There	 was	 no	 significant	 difference	 in	
symptoms	or	patient	demographics	between	the	two	groups.		
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Table	15:	Patient	characteristics	in	the	villous	atrophy	and	no	villous	atrophy	groups.	
	 Villous	atrophy	
group	
%	 No	villous	
atrophy	group	
%	 P	value	
Total	 number	 of	
patients	
82	 n/a	 128	 n/a	 n/a	
Male	 24	 29.3	 41	 32.0	 0.6726	
Race:	Caucasian	 76	 92.7	 120	 93.8	 0.7623	
Race:	Asian	 4	 4.9	 8	 6.3	 0.6760	
Race:	Afrocarribean	 2	 2.4	 0	 0	 0.0758		
Median	 gluten	 free	
diet	duration	
72	months	(6	
years)	
n/a	 72	months	(6	
years)	
n/a	 n/a	
Normal	bowel	habit	 42	 51.2	 71	 55.5	 0.5468	
Constipation	 12	 14.6	 20	 15.6	 0.8455	
Diarrhea	 15	 18.3	 15	 11.7	 0.1841	
Alternating	
constipation/	
diarrhea	
12	 14.6	 22	 17.2	 0.7389	
Nocturnal	diarrhea	 7	 8.5	 11	 8.6	 0.9885	
Urgency	 16	 19.5	 30	 23.4	 0.5022	
Steatorrhea	 20	 24.4	 31	 24.2	 0.9774	
Bloating	 37	 45.1	 69	 53.9	 0.2142	
Weight	loss	 21	 25.6	 22	 17.2	 0.1401	
Energy	 level:	
normal	
29	 35.4	 43	 33.6	 0.7918	
Energy	level:	low	 53	 64.6	 85	 66.4	 0.7918	
	
	 109	
			
	
	
	
	
Eighty-five	(39.2%)	patients	had	persistent	villous	atrophy	as	defined	by	Marsh	grade	3	histology.	
Tables	17	and	18	and	figures	10	to	13	illustrate	the	diagnostic	performance	and	the	ROC	curves	
for	the	surrogate	markers	respectively.	The	sensitivities	of	Simtomax,	IgA-TTG,	IgA-EMA	and	the	
adherence	score	in	detecting	villous	atrophy	were	67.1%,	44.7%,	37.7%	and	24.7%	respectively,	
where	 Simtomax	 had	 a	 significantly	 higher	 sensitivity	 than	 IgA-TTG	 (Simtomax	 vs	 IgA-TTG	
Surrogate	markers	 correctly	 testing	
negative	for	villous	atrophy.	
Surrogate	 markers	 correctly	 testing	
positive	for	villous	atrophy.	
Table	16:	The	number	of	patients	for	each	Marsh	grade,	and	the	number	and	proportion	of	
patients	whose	surrogate	markers	correctly	identified	the	presence	(Marsh	3a-c	histology)	or	
absence	(Marsh	0-2	histology)	of	persistent	villous	atrophy.	
	
	 Marsh	
0	
Marsh	
1	
Marsh	
2	
Marsh	
0-2	
Marsh	
3a	
Marsh	
3b	
Marsh	
3c	
Marsh	
3a-c	
No.	 of	
patients	
78	 37	 17	 132	 38	 24	 23	 85	
Simtomax	 48	
(61.5%)	
23	
(62.2%)	
7	
(41.2%)	
78	
(59.1%)	
21	
(55.3%)	
21	
(87.5%)	
15	
(65.2%)	
57	
(67.1%)	
IgA-TTG	 73	
(93.6%)	
30	
(81.1%)	
15	
(88.2%)	
118	
(89.4%)	
9	
(23.7%)	
12	
(50.0%)	
11	
(47.8%)	
32	
(37.6%)	
IgA-EMA	 70	
(89.8%)	
30	
(81.1%)	
14	
(82.4%)	
114	
(86.5%)	
9	
(23.7%)	
16	
(66.7%)	
13	
(56.5%)	
38	
(44.7%)	
Adherence	
score	
69	
(88.5%)	
31	
(83.8%)	
14	
(82.4%)	
114	
(86.4%)	
4	
(10.5%)	
9	
(37.5%)	
8	
(34.8%)	
21	
(24.7%)	
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p=0.0005).		The	combination	of	Simtomax	and	the	adherence	score	only	marginally	increased	the	
sensitivity	to	70.6%	(59.7-80.0%).	An	economic	analysis	of	using	Simtomax,	IgA-TTG	and	IgA-EMA	
in	coeliac	disease	monitoring	is	shown	in	table	18.		
	
	
Table	17:	The	diagnostic	performance	of	Simtomax,	IgA-TTG,	IgA-EMA	and	the	adherence	score	in	
detecting	persistent	villous	atrophy,	measuring	against	duodenal	histology.	
	
	
		 Sensitivity	 %	
(CI)	
Specificity	 %	
(CI)	
PPV	%	(CI)	 NPV	%	(CI)	 P	value	
(Simtomax	
vs	each	
surrogate	
marker)	
Simtomax	 67.1	(56.0-76.9)	 59.1	(50.2-67.6)	 51.4	(45.0-57.6)	 73.6	(66.6-79.6)	 n/a	
IgA-TTG	 44.7	(33.9-55.9)	 86.4	(79.3-91.7)	 67.9	(56.4-77.5)	 70.8	(66.5-74.8)	 0.0005	
IgA-EMA	 37.7	(27.4-48.8)	 89.4	(82.9-94.1)	 69.6	(56.5-80.1)	 69.0	(65.1-72.6)	 <0.0001	
Adherence	
score	
24.7	(16.0-35.3)	 86.4	(79.3-91.7)	 53.9	(39.8-67.3)	 64.0	(60.8-67.2)	 <0.0001	
	
Table	18:	The	diagnostic	performance	of	Simtomax	in	combination	with	IgA-TTG,	IgA-EMA	and	the	
adherence	 score	 respectively	 in	 detecting	 persistent	 villous	 atrophy,	measuring	against	 duodenal	
histology.	
	
	
		 Sensitivity	%	(CI)	 Specificity	%	(CI)	 PPV	%	(CI)	 NPV	%	(CI)	
Simtomax	+	IgA-TTG	 71.8	(61.0-81.0)	 55.5	(46.4-64.0)	 50.8	(45.1-56.6)	 75.3	(67.7-81.5)	
Simtomax	+	IgA-EMA	 71.8	(61.0-81.0)	 56.1	(47.2-64.7)	 51.3	(45.4-57.1)	 75.5	(68.0-81.7)	
Simtomax+	
adherence	score	
70.6	(59.7-80.0)	 52.3	(43.4-61.0)	 48.8	(43.2-54.4)	 73.4	(65.7-79.9)	
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	Table	19:	Cost	analysis	of	using	Simtomax,	IgA-TTG,	IgA-EMA	and	duodenal	biopsies	in	coeliac	
disease	monitoring	in	our	cohort.		
	
	 Cost	for	detecting	villous	
atrophy	(VA)	
Cost	to	detect	one	case	
of	villous	atrophy	(VA)	
Cost	saving	for	
detecting	one	
case	of	villous	
atrophy	vs	routine		
re-biopsy	
Duodenal	
biopsy	
routinely	for	
all	patients	
(n=217)	
£435.19	x217	(total	cost	of	
gastroscopy	with	duodenal	
biopsies	for	all	patients)	=	
£94436.23		
There	were	85	cases	of	
VA	detected	by	routine	
duodenal	biopsies.		
£94436.23/85=	
£1111.01		
n/a	
Duodenal	
biopsy	for	
positive	IgA-
TTG	patients	
only	(n=56)	
£22.71	x217	(cost	of	TTG	for	all	
patients)	+	£14.12	x	217	(cost	
of	immunoglobulins	for	all	
patients)	+	£435.19	x56	(total	
cost	of	gastroscopy	with	
duodenal	biopsies	for	positive	
TTG	patients)	=	£32362.75		
There	were	38	cases	of	
VA	detected	by	positive	
TTG.		
	
£32362.75/38	=	£851.65			
£1111.01-£851.65	
=	£259.36		
Duodenal	
biopsy	for	
positive	IgA-
EMA	patients	
only	(n=46)	
£13.41	x217	(cost	of	EMA	for	
all	patients)	+	£14.12	x217	
(cost	of	immunoglobulins	for	
all	patients)	+	£435.19	x46	
(total	cost	of	gastroscopy	with	
duodenal	biopsies	for	positive	
EMA	patients)	=	£25992.75		
There	were	29	cases	of	
VA	detected	by	positive	
EMA.		
	
£25992.75/29=	£896.30		
£1111.01-	£896.30	
=	£214.71		
Duodenal	
biopsy	for	
positive	IgA-
EMA	and/or	
IgA-TTG	
patients	only	
(n=56)	
£27.96	x217	(cost	of	
combination	price	of	TTG+EMA	
for	all	patients)	+	£14.12	x	217	
(cost	of	immunoglobulins	for	
all	patients)	+	£435.19	x56	
(total	cost	of	gastroscopy	with	
duodenal	biopsies	for	positive	
TTG+/-	EMA	patients)	=	£33502		
There	were	38	cases	of	
VA	detected	by	positive	
TTG	and/or	EMA.		
	
£33502/38=	£881.63		
£1111.01-	881.63	
=	£229.38		
Duodenal	
biopsy	for	
positive	
Simtomax	
patients	only	
(n=111)	
£20	x217	(cost	of	Simtomax	for	
all	patients)	+	£435.19	x111	
(total	cost	of	gastroscopy	with	
duodenal	biopsies	for	positive	
Simtomax	patients)	=	
£52646.09		
There	were	57	cases	of	
VA	detected	by	positive	
Simtomax.		
	
£52646.09/57=	£923.62		
£1111.01-	923.62	
=	£187.39		
Footnote:	Simtomax=	£20;	TTG=	£22.71;	EMA=	£13.41;	combination	price	of	TTG+EMA=	£27.96;	
immunoglobulins=	£14.12;	diagnostic	gastroscopy=£344;	processing	4	D2	and	1	D1	biopsies=	£86;	
formalin	biopsy	pot=	£0.17,	biopsy	forceps=	£4.85;	total	cost	of	gastroscopy	with	duodenal	biopsies	
(£344+	£86+	£0.17x2+	£4.85)	=	£435.19	(D1	and	D2	biopsies	were	placed	in	2	separate	pots,	hence	
£0.17x2)	
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Figure	 10:	 ROC	 curve	 for	 Simtomax	 for	 predicting	 persistent	 villous	 atrophy	 in	 known	
coeliac	disease	on	a	gluten	free	diet.	AUC=0.631	(CI:	0.56-0.71).	
	
Figure	11:	ROC	curve	for	IgA-TTG	for	predicting	persistent	villous	atrophy	in	known	coeliac	
disease	on	a	gluten	free	diet.	AUC=0.663	(CI:	0.59-0.74).	
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Figure	12:	ROC	curve	 for	 IgA-EMA	 for	predicting	persistent	villous	atrophy	 in	known	coeliac	
disease	on	a	gluten	free	diet.	AUC=0.635	(CI:	0.56-0.71).	
	
	
Figure	13:	ROC	curve	for	the	Biagi	adherence	score	for	predicting	persistent	villous	atrophy	in	
known	coeliac	disease	on	a	gluten	free	diet.	AUC=0.555	(CI:	0.48-0.64).	
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6.5:	Discussion	
	
This	 is	 currently	 the	 largest	 study	 evaluating	 Simtomax	 in	 disease	 monitoring,	 showing	 that	
Simtomax	 had	 a	 higher	 sensitivity	 than	 conventional	 serology	 and	 the	 adherence	 score	 in	
detecting	ongoing	villous	atrophy.		
	
One	 of	 the	 strengths	 of	 this	 study	 is	 that	 duodenal	 biopsies	 were	 taken	 from	 all	 patients	
irrespective	of	 their	 coeliac	antibody	or	adherence	 score	 results,	 ensuring	 that	 false	negative	
cases	 would	 be	 taken	 into	 account	 when	 calculating	 the	 sensitivities	 and	 specificities	 of	 the	
surrogate	markers.	The	only	other	published	study	investigating	the	role	of	Simtomax	in	disease	
monitoring	was	performed	by	Benkebil	et	al.	(89).	The	authors	tested	Simtomax	and	IgA-TTG	in	
46	 patients	with	 known	 coeliac	 disease,	 but	 only	 those	with	 a	 positive	 IgA-TTG	 serology	 had	
duodenal	biopsies	taken.	The	sensitivity	and	specificity	of	Simtomax	were	reported	to	be	78.9%	
and	95.7%	respectively.	However,	these	results	are	unlikely	to	reflect	the	actual	performance	of	
Simtomax	in	disease	monitoring,	as	only	patients	with	a	positive	IgA-TTG	were	biopsied.	
	
Laboratory	DGP	serology	has	been	shown	in	several	studies	to	be	useful	for	disease	monitoring	
in	coeliac	disease,	and	appeared	to	be	superior	to	TTG	in	this	respect	(185-188).	Spatola	et	al.	
showed	 that	 IgG-DGP	 was	 an	 effective	 surrogate	 marker	 for	 histological	 recovery,	 with	 a	
sensitivity	and	specificity	of	87%	and	89%	(at	a	positive	threshold	of	12U/ml),	versus	33%	and	
100%	 for	 IgA-TTG	 (at	 a	 positive	 threshold	 of	 5U/ml)	when	 tested	 in	 60	 patients	with	 known	
coeliac	disease	who	were	strictly	adherent,	of	which	15	(20%)	had	persistent	villous	atrophy.	ROC	
curve	analysis	 showed	 that	 IgG-DGP	substantially	outperformed	 IgA-TTG	with	an	AUC	of	0.94	
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versus	0.61	(186).	Similar	results	were	replicated	by	de	Chaisemartin’s	group	subsequently,	with	
a	 ROC	 curve	 analysis	 demonstrating	 AUC	 of	 0.817	 for	 IgG-DGP	 in	 detecting	 ongoing	 villous	
atrophy	(188).		
	
It	is	not	clear	why	there	is	such	marked	difference	between	the	performance	of	Simtomax	and	
laboratory	 IgG-DGP	 serology	 as	 previously	 reported	 (186,	 188).	 It	 is	 conceivable	 that	 the	
threshold	 for	 the	 generation	 of	 a	 positive	 result	 in	 Simtomax	 is	 not	 appropriate	 for	 disease	
monitoring	purposes,	and	the	cut	off	value	cannot	be	adjusted	like	laboratory	serological	titres	
to	identify	the	optimal	cut	off	numerical	value.	Furthermore,	different	DGP	peptides	are	used	for	
different	DGP	assays,	thereby	possibly	giving	different	levels	of	sensitivities.	It	would	have	been	
useful	to	measure	laboratory	DGP	assay	alongside	Simtomax	in	this	study.	However,	as	previously	
mentioned,	DGP	assays	are	not	widely	available	 in	 the	UK,	and	 is	not	available	 in	our	centre.	
Therefore,	DGP	assays	were	not	performed,	which	is	a	limitation	of	this	study.		
	
Another	 limitation	of	 this	 study	 is	 the	 study	 cohort-	 the	 recruited	patients	were	 referred	 for	
duodenal	 biopsies	 to	 evaluate	 for	 histological	 recovery	 due	 to	 persistence	 or	 recurrence	 of	
symptoms,	positive	serology	and/or	issues	with	dietary	adherence.	Although	duodenal	biopsy	is	
the	gold	standard	for	the	assessment	of	disease	remission,	it	is	not	routinely	performed	in	clinical	
practice	due	to	the	cost	and	invasiveness	of	a	gastroscopy	unless	there	is	a	clinical	need	for	it.		
This	means	that	it	is	likely	that	there	would	be	a	higher	proportion	of	patients	with	persistent	
villous	atrophy	in	our	study	cohort	compared	to	the	general	coeliac	population,	which	may	mean	
that	the	reported	diagnostic	performance	of	Simtomax	may	not	be	reflective	of	 its	use	 in	the	
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general	coeliac	population	who	have	no	clinical	suspicion	of	disease	relapse.	Assuming	that	there	
will	be	fewer	cases	of	persistent	villous	atrophy	in	the	general	coeliac	cohort,	the	sensitivities	
may	fall.	
	
Although	Simtomax	performed	significantly	better	than	the	other	surrogate	markers,	a	sensitivity	
of	67%	is	not	adequate	for	it	to	be	used	in	isolation	during	follow	up,	nor	is	it	adequate	to	replace	
duodenal	biopsy.	Combining	Simtomax	with	the	dietary	adherence	score	only	moderately	raised	
the	sensitivity	to	70%.	Where	there	is	a	clinical	suspicion	of	persistent	villous	atrophy,	relying	on	
using	 Simtomax	 alone	 to	 determine	 the	 need	 for	 a	 repeat	 biopsy	may	miss	 cases	 of	 villous	
atrophy,	leading	to	potential	complications.		
	
On	the	other	hand,	one	could	look	at	it	from	a	different	perspective:	Currently,	we	do	not	have	a	
good	surrogate	marker	for	mucosal	healing	at	hand.	This	study	demonstrates	that	this	simple	
point	of	care	test	provides	a	stepwise	increase	in	the	diagnostic	accuracy	of	a	surrogate	marker	
for	persistent	villous	atrophy	to	an	acceptable	level	in	our	search	for	a	better	test.	Alongside	the	
usual	dietetic	evaluation	and	symptom	assessment,	Simtomax	could	serve	as	a	useful	adjunct	to	
provide	 instant	 DGP	 results	 during	 a	 follow	 up	 consultation,	 not	 only	 for	 the	 benefit	 of	 the	
clinicians,	but	also	as	an	immediate	feedback	for	the	patients	which	they	highly	value.	With	the	
use	of	a	point	of	care	 test	during	a	clinic	consultation,	a	 face	 to	 face	discussion	between	 the	
clinician	and	the	patient	making	a	joint	decision	regarding	the	need	for	re-biopsy	is	made	possible.		
	
The	low	sensitivity	of	44.7%	for	IgA-TTG	in	detecting	persistent	villous	atrophy	in	this	study	is	in	
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line	with	what	has	been	reported	in	the	literature.	For	instance,	Kaukinen	et	al.	reported	the	IgA-
TTG	sensitivity	to	be	41%	(180),	and	more	recently	43.6%	by	Sharkey’s	group	(167).	The	even	
lower	sensitivity	of	37.7%	for	IgA-EMA	also	mirrors	the	26%	sensitivity	reported	by	Kaukinen	et	
al.	(180).	The	poor	association	between	serological	titres	and	persistent	villous	atrophy	could	be	
explained	by	the	fact	that	serological	testing	reflects	the	adaptive	immune	response	rather	than	
directly	measuring	intestinal	inflammation.	
	
The	dietary	adherence	questionnaire	was	quick	and	simple	to	administer,	but	its	performance	in	
identifying	patients	with	ongoing	villous	atrophy	was	disappointing	in	this	study.	Recent	work	by	
Bannister	et	al.	evaluated	this	adherence	questionnaire	and	found	that	the	adherence	score	had	
a	similarly	low	correlation	to	villous	atrophy,	with	a	sensitivity,	specificity,	PPV	and	NPV	of	33%,	
89%,	13%	and	97%	respectively	(189).	The	sensitivity	and	specificity	of	the	adherence	score	were	
consistent	 with	 our	 results	 of	 24.7%	 and	 86.4%,	 however	 the	 PPV	 and	 NPV	 were	 strikingly	
different	from	our	findings.	This	could	be	due	to	the	significantly	lower	prevalence	of	persistent	
villous	atrophy	 in	Bannister’s	paediatric	 cohort	 (5.3%)	 compared	 to	our	adult	 cohort	 (39.2%),	
where	a	low	prevalence	population	could	lead	to	a	higher	NPV	for	a	diagnostic	test.			
	
Indeed,	previous	follow	up	studies	have	demonstrated	a	slower	and	more	incomplete	mucosal	
healing	in	adults	with	coeliac	disease	treated	with	a	gluten	free	diet	(168,	190-192)	compared	to	
children.	Potential	reasons	for	the	low	sensitivity	of	the	adherence	questionnaire	include	reliance	
on	the	patient’s	understanding	of	what	foods	contain	gluten	and	how	forthcoming	they	were	
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regarding	their	adherence.		
	
An	 economic	 analysis	 was	 performed	 for	 each	 surrogate	 marker	 and	 the	 gold	 standard	 of	
duodenal	biopsy	for	the	assessment	of	histological	remission	(see	table	18).	Routine	re-biopsy	
was	found	to	be	most	expensive,	costing	£94436.23	in	our	cohort,	compared	to	taking	biopsies	
only	in	patients	with	a	positive	serology	or	Simtomax,	ranging	from	£25992.75-£52646.09.	The	
detection	of	persistent	villous	atrophy	differed	using	different	methods,	with	the	gold	standard	
of	routine	re-biopsy	detecting	all	cases	of	villous	atrophy	(n=85),	followed	by	Simtomax	(57/85	=	
67%),	IgA-TTG	(38/85	=	44.7%)	and	IgA-EMA	(29/85	=	34%).	When	taking	this	into	consideration,	
the	cost	to	detect	one	case	of	villous	atrophy	was	most	expensive	with	routine	re-biopsy	and	
cheapest	 with	 IgA-TTG	 (£1111.01,	 £923.62,	 £896.30	 and	 £851.65	 for	 routine	 re-biopsy,	
Simtomax,	IgA-EMA	and	IgA-TTG	respectively).	Overall,	Simtomax	was	shown	to	be	cheaper	than	
routine	re-biopsy	although	slightly	more	expensive	than	conventional	serology.	Nevertheless,	it	
is	 important	for	clinicians	to	consider	not	only	the	cost,	but	also	the	efficacy	of	the	surrogate	
markers	and	the	invasiveness	of	a	gastroscopy	as	a	whole	when	deciding	which	method	should	
be	used	for	disease	monitoring	in	coeliac	disease.	
	
6.6:	Conclusion	
	
To	conclude,	this	study	showed	for	the	first	time	that	the	commercially	available	DGP	based	point	
of	 care	 test,	 Simtomax,	 had	 a	 superior	 sensitivity	 in	 detecting	 persistent	 villous	 atrophy	 in	
patients	with	known	coeliac	disease,	compared	to	the	adherence	score	and	conventional	coeliac	
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serology	 (IgA-TTG	 and	 IgA-EMA)	which	 are	 routinely	 used	 for	 disease	monitoring	 at	 present.	
Simtomax	 could	 help	 streamline	 the	 follow	 up	 process	 by	 providing	 DGP	 results	 during	 the	
consultation,	 and	 facilitate	 the	 joint	 decision	 making	 between	 the	 clinician	 and	 the	 patient	
regarding	the	onward	management	plan	such	as	the	necessity	of	follow	up	duodenal	biopsy.	
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7.1	Summary	of	key	findings	and	recommendations	for	future	research	
	
In	this	body	of	research	that	I	have	undertaken,	I	have	assessed	the	diagnostic	accuracy	and	utility	
of	Simtomax	in	various	clinical	settings,	including	case	finding	in	primary	care,	secondary	care,	
pre-endoscopy	and	coeliac	disease	assessment	at	follow	up.	Despite	the	early	promising	results	
for	Simtomax	with	the	 initial	published	reports,	 this	was	not	borne	out	 in	 the	studies	which	 I	
undertook.	For	example,	point	of	care	testing	in	community	pharmacies	produced	a	low	yield	for	
case	detection,	even	though	the	sensitivity	of	Simtomax	was	in	fact	comparable	to	TTG	serology.	
The	low	yield	in	primary	care	is	unlikely	to	be	due	to	sensitivity	issues.	A	previous	point	of	care	
test	case	finding	study	by	Urwin	et	al.	based	 in	15	pharmacies	across	England	(97)	also	had	a	
similar	 Simtomax	 positive	 rate,	 indicating	 that	 the	 low	 yield	 in	 primary	 care	 is	 probably	 not	
confined	to	our	local	area	but	beyond.	Disappointingly,	the	limitation	of	Simtomax	lies	in	its	low	
specificity.	On	balance,	the	high	false	positive	rate	outweighs	the	advantage	of	providing	rapid	
and	 sensitive	 antibody	 results	 in	 real	 time,	 due	 to	 the	 high	 number	 patients	 who	would	 be	
subjected	 to	 undergo	 unnecessary	 investigations.	 Given	 the	 above	 findings,	 I	 consider	 that	
Simtomax	cannot	be	recommended	as	a	suitable	test	for	general	case	finding	in	both	primary	and	
secondary	care	in	the	NHS.	Nonetheless,	it	is	important	to	point	out	that	point	of	care	testing	for	
coeliac	disease	may	be	of	value	in	a	different	healthcare	system.	For	instance,	two	case	finding	
studies	based	in	Brazil	found	that	the	use	of	a	point	of	care	test	for	coeliac	disease	was	far	more	
effective	and	cost	saving	than	conventional	serology,	due	to	limited	facilities	and	the	high	cost	of	
laboratory	based	tests	in	a	low	income	country	(193,	194).	
	
It	 is	 intriguing	that	 laboratory	DGP	serology	has	been	shown	to	have	a	higher	specificity	 than	
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sensitivity,	whereas	the	opposite	was	observed	for	Simtomax.	A	systematic	review	reported	a	
pooled	sensitivity,	specificity,	PPV	and	NPV	of	combined	IgA/IgG-DGP	serology	to	be	87-98.3%	
(median	 95.2%),	 98.8-100%	 (median	 96%),	 98.3-100%	 (median	 99%)	 and	 97-98.8%	 (median	
97.9%)	respectively	(195).	One	should	bear	in	mind	that	these	values	are	much	higher	than	our	
data	as	the	coeliac	disease	prevalence	in	these	studies	were	very	high,	ranging	from	39.1-44.3%,	
compared	to	4%	in	our	cohort	in	chapter	4.	Nevertheless,	it	is	not	clear	why	the	specificity	and	
PPV	of	 Simtomax	 from	 chapter	 4	 are	 substantially	 lower	 than	 the	published	data.	Diagnostic	
performance	 is	considerably	 influenced	by	a	wide	range	of	factors.	Methodological	disparities	
such	 as	 study	 design,	 inclusion	 criteria,	 disease	 prevalence,	 reference	 standard	 and	 disease	
spectrum	 (severity	 of	 villous	 atrophy)	 are	 well	 known	 to	 affect	 diagnostic	 performance.	
Additionally,	 specific	 to	 Simtomax,	 the	 difference	 in	 the	method	 of	 DGP	 testing	 (lateral	 flow	
immunochromatography	vs	ELISA)	also	plays	a	role	in	the	incongruent	results	to	DGP	serology.	A	
combination	of	two	specific	DGP	peptides	which	were	shown	to	provide	superior	performance	
were	selected	for	Simtomax	based	on	a	study	by	Schwertz	et	al.	(92).	These	DGP	peptides	may	
differ	from	those	used	for	laboratory	DGP	serology	that	were	studied	(Quanta	Lite	Gliadin	II	IgG	
and	IgA;	Inova	Diagnostics,	San	Diego,	CA,	USA)	and	hence	giving	different	results.	Furthermore,	
there	is	a	mechanical	filter	in	the	Simtomax	device	that	separates	whole	blood	by	removing	red	
blood	cells	and	nucleated	cells	to	allow	the	serum	proteins	to	be	analysed	using	antigen	direct	
sandwich	assay	technique,	which	is	very	similar	to	ELISA.	It	is	plausible	that	the	filtering	process	
may	 cause	a	 low	degree	of	haemolysis	which	would	adversely	 affect	 the	plasma	 flow	due	 to	
increased	turbidity,	and	thereby	increasing	background	noise,	hence	affecting	precision	of	the	
test.	 Moreover,	 it	 is	 also	 conceivable	 that	 the	 wicking	 rate	 and	 adsorption	 control	 of	 the	
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nitrocellulose	 membrane	 of	 the	 device	 where	 the	 assay	 binding	 occurs	 may	 play	 a	 part	 in	
influencing	sensitivities.		
	
As	 for	 the	 assessment	 of	 disease	 remission,	 even	 though	 Simtomax	 was	 the	 most	 sensitive	
marker	for	predicting	persistent	villous	atrophy	compared	to	serology	and	a	dietary	adherence	
questionnaire,	its	sensitivity	of	67%	is	still	considerably	inadequate	to	be	solely	relied	upon,	and	
cannot	replace	repeat	duodenal	biopsies.	For	now,	Simtomax	may	be	used	as	an	adjunct	in	follow	
up	clinics	to	help	determine	the	need	for	repeat	duodenal	biopsies,	but	I	think	it	will	soon	be	
superseded	by	other	more	promising	surrogate	markers	such	as	gluten	immunogenic	peptides.	
	
Undoubtedly,	there	is	a	demand	for	point	of	care	tests	in	clinical	practice,	and	a	good	example	is	
point	 of	 care	 tests	 for	 INR	 which	 has	 been	 well	 established	 in	 its	 role	 in	 both	 primary	 and	
secondary	care	in	the	last	decade.	The	successful	implementation	of	INR	point	of	care	testing	by	
healthcare	 professionals	 was	 based	 on	 acceptable	 diagnostic	 performance	 compared	 to	
laboratory	INR	testing.	A	systematic	review	in	2012	analysing	20	studies	found	the	correlation	
coefficient	of	CoaguCheck	XS	varied	from	0.81	to	0.98,	whilst	that	of	INRatio	and	ProTime	varied	
between	 0.73	 and	 0.95	 when	 compared	 to	 laboratory	 INR	 as	 the	 reference	 standard	 (196).	
However,	uncertain	cost	effectiveness	based	on	conflicting	results	from	previous	studies	(136)	
meant	 that	 INR	point	of	 care	 testing	has	not	been	approved	 for	 routine	patient	use	 for	 self-
monitoring.	 Deriving	 from	 this	 example,	 I	 have	 demonstrated	 that	 Simtomax	 not	 only	 had	
comparable	diagnostic	accuracy	to	conventional	serology,	but	also	cost	effectiveness	when	used	
in	the	pre-endoscopy	setting	for	patients	with	iron	deficiency	anaemia.	Therefore,	I	believe	the	
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area	of	potential	for	Simtomax	is	within	this	setting.	With	the	100%	NPV,	Simtomax	could	be	used	
as	a	cost	saving	screening	tool	 through	biopsy	avoidance	 in	a	cohort	where	routine	duodenal	
biopsy	is	common	practice.		
	
Despite	 this,	 I	 think	 there	 are	 barriers	 to	 overcome	 at	 multiple	 levels	 before	 this	 could	 be	
implemented	within	the	NHS.	First	of	all,	the	study	sample	size	was	relatively	small	(chapter	5)	
(n=144),	therefore	the	results	will	have	to	be	rigorously	validated	with	a	 larger	or	multicentre	
study	before	being	approved	by	the	NHS.	Whilst	INR	POCT	has	clinician	‘buy	in’,	I	do	not	think	
(based	 on	my	 own	 experience	 of	 presenting	 the	 data	widely)	 that	 Gastroenterology	 doctors	
regard	this	coeliac	POCT	in	the	same	way.	One	of	the	reasons	I	would	suggest	is	that	this	is	due	
to	the	poor	specificity	of	the	test.		
	
Finances	 and	 time	 pressures	 also	 play	 a	 negative	 role	 from	 the	 endoscopy	 directorate’s	
perspective.	Using	Simtomax	in	endoscopy	involves	training	nurses	to	perform	the	test.	Nurses	
may	be	reluctant	to	take	it	on	as	it	consumes	more	time	and	effort	during	the	pre-assessment	
process,	 where	 time	 constraint	 is	 commonplace	 within	 the	 existing	 healthcare	 system.	
Additionally,	having	to	pay	for	the	Simtomax	kits	upfront	before	any	potential	longer	term	cost	
savings	are	apparent	may	also	deter	the	directorate	from	taking	the	risk	to	invest	in	this	economic	
model.	This	cost	saving	model	was	based	on	routine	duodenal	biopsy	for	anaemic	patients,	but	
biopsy	 practice	may	 differ	 in	 other	 hospitals,	 and	 this	 could	 also	 be	 influenced	 by	 their	 pre-
endoscopy	availability	of	coeliac	serology	results.	Although	we	have	demonstrated	that	only	30%	
of	patients	with	anaemia	had	serology	performed	prior	to	endoscopy	in	four	UK	hospitals,	the	
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pre-endoscopy	serology	availability	will	 vary	amongst	different	hospitals.	 	 If	we	consider	HRG	
tariffs,	a	gastroscopy	with	biopsy	 is	remunerated	at	a	higher	 level	than	a	gastroscopy	without	
biopsy.	So	although	Simtomax	may	reduce	biopsy	rates,	the	local	NHS	manager	may	view	that	
this	results	in	paying	for	the	cost	of	the	test	as	well	as	reducing	revenue	for	their	directorate.	
	
Moreover,	 the	 endoscopists	 may	 disregard	 the	 Simtomax	 test	 results,	 whether	 it	 be	 due	 to	
clinical	reasons,	hesitance	in	relying	on	the	accuracy	of	Simtomax,	or	inertia	to	change	practice,	
and	hence	the	cost	saving	potential	in	reality	may	differ	from	the	estimated	calculations	I	made.	
On	 the	 other	 hand,	 from	 the	 histopathology	 department’s	 standpoint,	 even	 though	 biopsy	
avoidance	would	 reduce	 their	workload,	 they	may	 see	 this	as	a	 reduction	of	 revenue	 for	 the	
department.	 The	 histopathology	 department	 is	 funded	 on	 units	 of	 work	 irrespective	 of	 the	
complexity	of	the	work.	Controversially,	looking	at	it	from	a	human	factor	or	work	intensity	angle,	
one	 may	 prefer	 having	 to	 process	 and	 report	 straightforward	 normal	 duodenal	 biopsies	 to	
evaluating	more	complex	abnormal	histological	samples	as	the	bulk	of	their	daily	work.	These	
potential	obstacles	may	arise	and	have	to	be	overcome	in	order	to	successfully	implement	the	
use	of	Simtomax	in	practice.		
	
Overall,	Simtomax	fits	the	criteria	for	being	an	excellent	test	in	many	ways,	including	comparable	
sensitivity	 to	 TTG	 serology,	 convenience,	 rapid	 result	 availability	 and	 high	 user	 satisfaction.	
Unfortunately,	its	low	specificity	presents	a	major	setback	and	needs	to	be	addressed.	A	recent	
study	reported	on	a	novel	gliadin	peptide	known	as	8-mer	gliadin	peptide	 that	 is	 released	by	
gliadin	degrading	metalloproteinases	in	the	duodenal	mucosa	found	only	in	patients	with	coeliac	
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disease.	The	specificity	of	this	peptide	antibody	was	found	to	be	98.8%	(197).	Further	research	
such	as	this	may	help	to	enhance	the	diagnostic	performance	of	a	point	of	care	test	for	coeliac	
disease	by	integrating	highly	accurate	peptide	sequences	in	a	lateral	flow	format.	
	
	
7.2	Conclusion	
	
Simtomax	has	been	shown	to	have	comparable	sensitivities	and	practical	advantages	to	serology.	
However,	 its	 low	 specificity	 represents	 a	 major	 limitation,	 as	 its	 use	 in	 a	 general	 cohort	 of	
symptomatic	patients	may	lead	to	a	rise	in	unnecessary	investigations.	In	regards	to	predicting	
histological	remission,	Simtomax	had	a	significantly	higher	sensitivity	compared	to	TTG	serology.	
However,	its	sensitivity	is	not	reliable	enough	to	replace	duodenal	biopsies.	I	believe	Simtomax	
may	be	best	suited	to	be	used	in	the	pre-endoscopy	setting	for	anaemic	patients	in	hospitals	that	
would	derive	cost	saving	benefits	from	it.	
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Appendix	1:	A	Supplementary	Table	of	All	the	Studies	on	the	Commercially	Available	point	of	
care	tests.	
Test	 Reference	 Country	 n	 Population	
CD	
prevalence	
Sensitivity	 Specificity	 Study	Limitations	
Biocard		
(123)	
Nemec	
2006	
Italy	 151	
Adult	 &	
Paediatric	
33.8%	 90.2%	 100%	
Only	 positive	
POCT/serology	biopsied.	
High	pre-test	probability.	
Biocard	
(82)	 Raivio	
2006	
Hungary	
and	
Finland	
150	 Paediatric	 30%	 95.5%	 97.1%	
Only	 positive	
POCT/serology	biopsied.	
Sensitivities	 compared	
against	serology.	
High	pre-test	probability.	
Biocard	
(121)	
Korponay-
Szabo	2007	
Finland	 43	 Adults	 43%	 91.7%	 78.9%	 High	pre-test	probability.	
Biocard	
(121)		
Korponay-
Szabo	2007	
Hungary	 2676	 Paediatric	 1.2%	 78.1%	 100%	
Only	 positive	
POCT/serology	biopsied.	
Biocard		
(194)	
Crovella	
2007	
Brazil	 1074	 Adult	 0.84%	 No	data	
100%	 in	
urban,	
76%	 in	
suburban	
Only	 positive	
POCT/serology	biopsied.	
Biocard	
(83)	 Raivio	
2008	
Finland	 242	 Paediatric	 57.4%	 93%	 94%	 High	pre-test	probability.	
Biocard	
(193)	 Kotze	
2009	
Brazil	 300	
Adult	 &	
Paediatric	
4.7%	 No	data	 No	data		
Only	 positive	 POCT	 or	
high	 suspicion	 of	 CD	
biopsied.	
Biocard	
(124)	
Laadhar	
2011	
Tunisia	 57	 Paediatric	 no	data	 100%	 96.4%	
Sensitivities	 compared	
against	TTG.	
Biocard	
(198)	
Pichler	
2011	
	UK	 196	
Adult	 &	
Paediatric	
1.5%	 No	data		 No	data		
Only	 positive	 POCT	
biopsied.	
Biocard	
(16)	Alarida	
2011	
Libya	 2920	 Paediatric	 0.79%	 58%	 40%	
Only	 positive	
POCT/serology	biopsied.	
Biocard	
(199)	
Oliviera	
2012	
Portugal	 268	 Adult	 2.6%	 No	data	 No	data	
Only	 positive	 POCT	
biopsied.	
Biocard	
(200)	 Hariz	
2011	
Tunisia	 2064	 Paediatric	 0.24-0.34%	 100%	 100%	
Only	 positive	
POCT/serology	biopsied.	
Biocard	
(201)	
Karagiozogl
u-
Lampoudi	
2013	
Greece	 1136	 Paediatric	 0.65%	 No	data		 No	data		
Only	 those	with	positive	
POCT	 went	 on	 to	 have	
EMA	and	TTG.		
Only	 positive	 serology	
biopsied.	
Biocard	
(202)	 Popp	
2013	
Romania		 148	
Adult	 &	
Paediatric	
6%		 92.3%	 100%	
Only	 positive	
POCT/serology	biopsied.	
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Biocard	
(84)	
Mooney	
UK	 576	 Adult	 22.4%	 70.1%	 96.6%	 High	pre-test	probability.	
Biocard	
(203)	 Costa	
2014	
Italy	 206	 Adult	 44.%	
90%	 98.7%	
Only	 positive	
POCT/serology	biopsied.	
High	pre-test	probability.	
Biocard	
(203)	 Costa	
2014	
Italy	 85	 Paediatric	 11.80%	 97.1%	 94.1%	
Only	 positive	
POCT/serology	biopsied.	
Slightly	 high	 pre-test	
probability.	
Biocard	
(203)	 Costa	
2014	
Italy	 3559	 Paediatric	 0.50%	
No	data		 No	data		 Only	 positive	
POCT/serology	biopsied	
Biocard	
(203)	 Costa	
2014	
Slovenia	 1480	 Paediatric	 0.47%	
No	data		 No	data		 Only	 positive	
POCT/serology	biopsied	
Biocard	
(203)	 Costa	
2014	
Turkey	 785	 Paediatric	 0.13%	
No	data		 No	data		 Only	 positive	
POCT/serology	biopsied	
Biocard	
(85)	 Singh	
2014	
India	 124	 Paediatric	 64.70%	 83.6%	 90%	 High	pre-test	probability.	
Biocard	
(87)	
Mooney	
2015	 UK	 55	 Adults	 65.40%	 72.2%	 No	data	
Sensitivities	 compared		
against	 EMA.	 High	 pre-
test	probability.	
Biocard	
(204)	
Ceylan	
2016	 Turkey	 1003	 Paediatric	 0.3%	 No	data	 No	data	
None	of	the	patients	had	
biopsies.	
Prevalence	 based	 on	
positive	POCT.	
Stick	CD1		
(205)	Ferre-
Lopez	2004	 Spain	 286	 Paediatric	 53.5%	 97.1%	 99%	 High	pre-test	probability.	
Stick	CD2	
(205)	Ferre-
Lopez	2004	 Spain	 49	 Adult	 61.2%	 83.3%	 100%	 High	pre-test	probability.	
Stick	CD1	 (123)	
Nemec	
2006	 Italy	 329	
Adult	 &	
Paediatric	 34.7%	 100%		 94.9%		
Only	 positive	
POCT/serology	biopsied.	
Sensitivities	 compared	
against	TTG.	
High	pre-test	probability.	
Stick	CD1	
(125)	
Baviera	
2007	
Spain	
and	Latin	
America	 185	 Paediatric	 61.1%	 96.5%	 98.6%	
	High	 pre-test	
probability.	
Stick	CD2	
(125)	
Baviera	
2007	
Spain	
and	Latin	
America	 185	 Paediatric	 61.1%	 94.5%	 98.6%	
	High	 pre-test	
probability.	
Stick	CD1	
(194)	
Crovella	
2007	
Brazil	 1074	 Adult	 0.84%	 No	data	
100%	 in	
urban,	
76%	 in	
suburban	
Only	 positive	 POCT	
biopsied.	
Simple	
CD1WB		
(122)	
Almazan	
2015	 Spain	 198	 Paediatric	 3%		 16.6%	 98.9%	
Only	 positive	
POCT/serology	biopsied.	
Simple	
CD2WB		
(122)	
Almazan	
2015	 Spain	 198	 Paediatric	 	3%	 100%	 89.1%	
	Only	 positive	
POCT/serology	biopsied.	
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Celiac	
Quick	Test	
(184)	
George	
2014	 UK	 80	
Adults	 with	
known	CD*	 100%	
Predicting	
remission	
93.5%	
(serum)		
	
Predicting	
remission	
94.9%	
(serum)		
Only	 symptomatic,	 non-
compliant	 or	 positive	
serology	biopsied.		
Sensitivities	 compared	
against	serology.	
	Celiac	
Quick	Test	
(184)	
George	
2014	 UK	 80	
Adults	 with	
known	CD*	 	100%	
Predicting	
remission	
77.8%	
(whole	
blood)	
Predicting	
remission	
100%		
(whole	
blood)	
Only	 symptomatic,	 non-
compliant	 or	 positive	
serology	biopsied.		
Sensitivities	 of	 POCT	
compared	 against	
serology.	
Celiac	
Quick	Test	
(87)	
Mooney	
2015	 UK	 55	 Adults	 65.40%	 77.8%	 no	data	
Sensitivities	 compared	
against	 EMA.	 High	 pre-
test	probability.	
Simtomax	
(90)	
Bienvenu	
2012	 France	 250	 Paediatric	 9.6%	 95%	 93.1%	
Only	 positive	 TTG	
biopsied.		
Sensitivities	 compared	
against	serology.	
High	risk/CD	symptoms	
Simtomax	
(89)	
Benkebil	
2013	
Switzerla
nd	 66	
Adult	 &	
Paediatric	
12%	 100.%	 93.1%	
Only	 positive	
POCT/serology	 biopsied.	
Slightly	 high	 pre-test	
probability.	
FDR	and	CD	symptoms	
Simtomax	
(89)	
Benkebil	
2013	
Switzerla
nd	 46	
Adult	 &	
Paediatric	
100%	
Predicting	
remission	
78.9%		
Predicting	
remission	
95.7%		
Only	 positive	
POCT/serology	biopsied.	
Sensitivities	 compared	
against		serology.	
Simtomax	
(88)	
Bienvenu	
2014	 France	 45	 Paediatric	 17.8%	 100.%	 89.2%	
Only	 positive	
POCT/serology	biopsied.	
High	pre-test	probability.	
Retrospective	 Simtomax	
test	 on	 IgA	 def,	 some	
missing	 data	 as	
retrospective	
Simtomax	
(87)	
Mooney	
2015	 UK	 55	 Adults	 65.40%	 94.4%	 no	data	 High	pre-test	probability.	
Simtomax	
(87)	
Mooney	
2015	 UK	 508	 Adults	 13.40%	 92.7%	 85.2%	
Slightly	 high	 pre-test	
probability.	
Simtomax	
(200)	
Polanco	
2017	 Spain	 100	 Paediatric	 48%	 95.8%	 98.1%	
High	 prevalence.	
Reference	 standard	 for	
POCT	 based	 on	 new	
ESPGHAN	guidelines.	
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Appendix	2:	Participant	questionnaire	(Chapter	3)	
	
Participant	questionnaire	
1. Are	you	under	18	years	of	age?	
2. Have	you	been	diagnosed	with	coeliac	disease?	
3. Have	you	previously	been	or	are	you	currently	being	investigated	for	coeliac	disease?	
If	your	answers	are	no	to	all	3	questions	above,	please	continue	to	question	4	and	5.		
If	any	of	your	above	answers	is	yes,	you	are	not	eligible	to	take	part	in	the	study.	
4. Do	you	suffer	from	any	of	the	following?	
- Persistent	 unexplained	 gastrointestinal	 symptoms	 (bloating,	 abdominal	 pain	 or	
discomfort,	diarrhoea,	constipation,	urgency,	nausea/vomiting,	indigestion)	
- Prolonged	fatigue	
- Unexpected	weight	loss	
- Severe	or	persistent	mouth	ulcers	
- Unexplained	iron,	vitamin	B12	or	folate	deficiency	
- Type	1	diabetes	
- Autoimmune	thyroid	disease	
- Irritable	bowel	syndrome		
- Osteoporosis	or	osteomalacia	
- Unexplained	 neurological	 symptoms	 (particularly	 numbness	 and	 tingling	 in	 your	
extremeties,	or	problems	with	your	balance)	
- Unexplained	fertility	problems	or	recurrent	miscarriage	
- Persistently	abnormal	liver	blood	tests		
- Dental	 enamel	defects	 (discoloured,	 grooves	and	pits	or	 yellow/brown	 spots	on	 teeth	
surfaces;	irregular	shaped	teeth)		
5. Do	you	have	any	first	degree	relatives	with	coeliac	disease?	
	
If	any	of	your	answers	is	yes	to	question	4	or	5,	you	will	be	eligible	to	take	part	in	the	study.	
	
Demographic	details:	
Name:	 	 	 	 	 	 Gender:	 	 DOB:	
Contact	number:	
Address	
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Appendix	3:	Study	recruitment	poster	for	pharmacy	customers	(Chapter	3)	
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Appendix	4:	Patient	information	sheet	(Chapter	3)	
	
	
Participant	information	sheet		
	
Study	title:	Case	Finding	for	Coeliac	Disease	using	a	Point	of	Care	Test	in	a	Pharmacy	Setting:	A	
Feasibility	Study	
	
Invitation:	We	would	like	to	invite	you	to	take	part	in	our	research	study.		Before	you	decide	we	
would	like	you	to	understand	why	the	research	is	being	done	and	what	it	would	involve	for	you.		
One	of	the	team	will	go	through	the	information	sheet	with	you	and	answer	any	questions	you	
have.		This	should	take	about	five	to	ten	minutes.		Talk	to	others	about	the	study	if	you	wish.		Ask	
us	if	there	is	anything	that	is	not	clear.			
	
What	is	the	purpose	of	the	study?	
Coeliac	disease	 is	an	autoimmune	condition	 in	which	 the	body	attacks	 the	 lining	of	 the	small	
bowel.	The	immune	reaction	is	triggered	by	gluten,	a	protein	found	in	wheat,	barley	and	rye.		
Coeliac	disease	affects	approximately	1	in	100	people	and	is	treated	with	a	gluten-free	diet.		
However,	coeliac	disease	is	underdiagnosed-	for	every	patient	known	to	have	coeliac	disease,	5	
patients	 remain	 undiagnosed.	 Undiagnosed	 individuals	 could	 suffer	 from	 long	 term	 health	
complications	and	a	reduced	quality	of	life.	
A	new	rapid	antibody	test	kit	for	coeliac	disease	has	become	available,	producing	coeliac	antibody	
results	within	10	minutes.	This	study	aims	to	assess	whether	using	this	 test	kit	 in	pharmacies	
would	help	to	increase	the	detection	of	coeliac	disease.	Those	with	positive	test	results	will	be	
advised	to	visit	their	GP	to	be	referred	for	a	gastroscopy	to	confirm	the	diagnosis.		
	
Why	have	I	been	invited?	
You	have	been	invited	because	you	may	have	risk	factors	for	or	symptoms	due	to	coeliac	disease.		
	
Do	I	have	to	take	part?	
No.	It	is	up	to	you	whether	or	not	you	decide	to	take	part	in	this	study.		If	you	do	decide	to	take	
part,	you	will	be	given	this	information	sheet	to	keep	and	asked	to	sign	a	consent	form.		If	you	
choose	not	to	take	part,	you	do	not	need	to	give	a	reason	and	your	care	will	not	be	affected	in	
any	way.	
	
What	will	happen	to	me	if	I	take	part?	
You	will	have	a	finger	prick	test	at	the	pharmacy	to	assess	if	you	potentially	have	coeliac	disease.	
The	test	results	will	be	available	within	10	minutes.		
	
If	the	test	result	is	positive,	you	will	be	advised	to	visit	your	GP	to	be	referred	for	a	gastroscopy	
(camera	test)	at	the	Royal	Hallamshire	Hospital.	This	is	to	obtain	biopsies	from	your	small	bowel	
to	confirm	the	diagnosis	of	coeliac	disease	as	per	usual	practice.	The	chance	of	being	diagnosed	
with	coeliac	disease	with	a	positive	finger	prick	test	is	about	50%	after	further	investigation	with	
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a	gastroscopy.	The	accuracy	of	this	finger	prick	test	is	high,	and	is	comparable	to	the	conventional	
blood	tests	we	currently	use	to	detect	coeliac	disease.	
A	gastroscopy	is	a	procedure	where	a	thin,	flexible	tube	called	an	endoscope	is	used	to	look	inside	
the	oesophagus,	stomach	and	first	part	of	the	small	intestine.	A	gastroscopy	often	takes	less	than	
10	minutes.	Before	the	procedure,	your	throat	will	be	numbed	with	a	local	anaesthetic	spray.	You	
can	also	choose	to	have	a	sedative,	if	you	prefer.	The	endoscope	will	enter	the	back	of	your	mouth	
and	 it	 will	 then	 be	 guided	 down	 your	 oesophagus	 into	 your	 stomach.	 Tiny	 samples	 will	 be	
obtained	from	your	small	intestine.	A	diagnostic	gastroscopy	is	a	very	safe	procedure.	Possible	
complications	that	can	occur	include:	a	reaction	to	the	sedative,	which	can	cause	problems	with	
your	breathing,	heart	rate	and	blood	pressure,	internal	bleeding	(usually	minor	and	self-limiting	
if	it	occurs),	and	very	rarely,	tearing	of	the	gut	lining	(perforation),	occurring	in	less	than	1	in	3,000	
cases.	
If	the	test	result	is	negative,	you	most	probably	do	not	have	coeliac	disease.	You	do	not	need	to	
do	anything	and	a	gastroscopy	is	not	required	for	a	negative	finger	prick	test.	If	your	symptoms	
persist,	please	consult	your	GP.	
		
When	do	I	have	to	decide?	
It	is	up	to	you.	You	can	decide	now,	or	think	about	it	and	let	us	know	at	a	later	date	as	long	as	the	
study	is	running.		
	
Will	this	affect	my	existing	treatment?	
No.	This	study	does	not	involve	administration	of	medications.	
	
What	are	the	possible	disadvantages	and	risks	of	taking	part?	
The	 finger	 pin-prick	 test	 is	minimally	 uncomfortable,	 and	will	 take	 10	minutes	 to	 obtain	 the	
results.		
	
What	are	the	possible	benefits	of	taking	part?	
For	 those	 who	 are	 diagnosed	with	 coeliac	 disease,	 you	 will	 benefit	 from	 an	 early	 diagnosis,	
meaning	that	you	will	receive	treatment	early,	preventing	long	term	complications	and	have	an	
improved	quality	of	life.	
	
For	those	in	whom	coeliac	disease	has	been	ruled	out,	you	may	not	have	a	direct	benefit	from	
the	study,	but	your	contribution	will	help	us	provide	the	best	care	for	patients	in	the	future.	
	
How	long	will	the	study	last?	
The	study	will	last	approximately	18	months.		
	
Will	my	taking	part	in	the	study	be	kept	confidential?	
Yes,	your	data	will	be	kept	confidential.		It	will	be	governed	by	the	Data	Protection	Act	(1998)	and	
has	Research	Ethics	Committee	approval.		Information	will	be	completely	anonymised	if	it	is	to	
be	analysed	or	published	outside	the	research	team.		Only	the	research	team	will	be	able	to	see	
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your	personal	information.		The	information	that	can	identify	you	personally	will	NEVER	be	given	
to	anyone	else	or	published.		Only	relevant	sections	of	your	medical	notes	will	be	looked	at	by	
the	research	team,	from	regulatory	authorities	or	from	your	NHS	Trust.		Personal	data	will	only	
be	 stored	 on	 NHS	 password	 protected	 computers	 and	 when	 this	 is	 pseudonymised	 the	
identification	list	will	be	kept	separate	located	on	the	NHS	system.		
	
What	will	happen	if	I	don’t	want	to	carry	on	with	the	study?	
You	can	withdraw	your	consent	at	any	time	in	the	future	without	giving	a	reason.		If	you	withdraw	
your	consent	or	become	unable	to	continue	to	give	informed	consent,	any	information	collected	
with	 consent	will	 remain	 and	be	 used	 in	 the	 study.	 	No	 further	 information	 however	will	 be	
collected	and	a	record	will	be	kept	that	you	withdrew	consent	or	were	unable	to	continue	to	
provide	consent.		Your	care	will	not	be	affected	in	any	way	if	you	change	your	mind	and	withdraw	
from	the	study.	
	
What	if	there	is	a	problem?	
Any	complaints	about	the	way	you	have	been	dealt	with	during	the	study	or	any	possible	harm	
you	might	suffer	will	be	addressed.		Detailed	information	on	who	to	contact	are	given	at	the	end	
of	this	information	sheet.		
	
What	will	happen	to	the	results	of	the	research	study?	
We	intend	to	publish	the	results	of	the	research	in	peer	reviewed	journals,	and	to	present	them	
at	scientific	meetings.	Professor	Sanders	holds	an	honorary	post	as	the	medical	advisor	to	Coeliac	
UK	and	regularly	speaks	at	their	meetings.	No	identifiable	data	will	be	published.	
	
Will	my	general	practitioner	(GP)	be	contacted?		
Your	GP	will	be	informed	if	you	have	a	positive	finger	prick	test,	in	order	to	take	it	forward	by	
referring	you	for	a	gastroscopy	to	confirm	the	diagnosis	of	coeliac	disease.	
	
Who	is	organising	and	funding	the	research?	
The	study	is	funded	by	Professor	Sanders’	research	funds.	Tillotts	Pharma	is	providing	the	point	
of	care	test	kits.	
	
Who	has	reviewed	the	study?	
All	research	in	the	NHS	is	looked	at	by	an	independent	group	of	people,	called	a	Research	Ethics	
Committee,	to	protect	your	interests.		This	study	has	been	reviewed	and	given	favourable	opinion	
by	the	Research	Ethics	Committee	and	the	Sheffield	Teaching	Hospitals	NHS	Foundation	Trust	
R&D	Department	(Clinical	Research	Office).	
	
Thank	you	for	taking	the	time	to	read	this	information	sheet	and	for	considering	taking	part	in	
this	study.	
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Further	information	and	contact	details:	
If	you	want	further	general	or	specific	information	about	the	research,	advice	as	to	whether	to	
participate	 or	 who	 to	 approach	 if	 you	 are	 unhappy	 with	 the	 study	 or	 want	 to	 take	 part	 or	
withdraw	consent	please	contact:	
	
Dr.	Michelle	Lau	
Clinical	Research	Fellow	in	Gastroenterology	
Michelle.lau3@sth.nhs.uk	
	
If	you	have	any	complaints	that	you	would	like	to	be	dealt	with	independently,	please	contact:	
The	Patient	Services	Team	
Email:	pst@sth.nhs.uk		
Telephone:	0114	2712400		
Or	write	to:	The	Medical	Director	
8	Beech	Hill	Rd	
Sheffield		
S10	2SB	
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Letter	to	the	General	Practitioner	
	
Date:___________________	
	
Dear	colleague,	
	
Professor	David	Sanders’	research	team	is	currently	running	a	case	finding	study	for	adult	coeliac	
disease	using	a	Point	of	Care	Test	in	pharmacies	across	Sheffield.	Participants	with	risk	factors	for	
or	symptoms	suggestive	of	coeliac	disease	are	offered	a	Point	of	Care	Test	at	pharmacies.		
	
The	 Point	 of	 Care	 Test,	 Simtomax,	 detects	 coeliac	 disease	 associated	 IgA	 and	 IgG	 antibodies	
against	a	unique	combination	of	deamidated	gliadin	peptides	(DGP)	as	well	as	the	total	level	of	
IgA.	 This	 ensures	 results	 are	 not	 influenced	 by	 patients	 with	 IgA	 deficiency,	 which	 is	 more	
common	 in	 people	with	 coeliac	 disease	 than	 the	 general	 population.	 Preliminary	data	 shows	
excellent	and	comparable	sensitivities	of	Simtomax	to	conventional	serology	TTG	and	EMA.	
	
Participant	____________________________	has	been	tested	positive.	We	would	be	grateful	if	
you	could	refer	him/her	directly	to	Professor	Sanders	for	a	gastroscopy	by	the	research	team	at	
the	 Royal	 Hallamshire	 Hospital,	 to	 obtain	 duodenal	 biopsies	 for	 histological	 confirmation	 of	
coeliac	disease.			
	
If	 you	 have	 any	 queries	 or	would	 like	 further	 information	 about	 the	 research,	 please	 do	 not	
hesitate	to	contact:	
	
Dr.	Michelle	Lau	
Clinical	Research	Fellow	in	Gastroenterology	
Michelle.lau3@sth.nhs.uk	
	
Yours	faithfully,	
	
	
	
	
Dr.	Michelle	Lau	
Clinical	Research	Fellow	in	Gastroenterology	
Royal	Hallamshire	Hospital	
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Appendix	5:	Patient	consent	form	(Chapter	3)	
	
Study	Number:	STH	19172	
Participant	Identification	Number	for	this	trial:	
CONSENT	FORM	
Title	of	Project:	Can	a	point	of	care	test	increase	the	detection	of	coeliac	disease	in	a	pharmacy	
setting?	
Name	of	Researcher:	Professor	David	Sanders,	Dr.	Michelle	Lau	
Please	initial	box		
1. I	confirm	that	I	have	read	the	information	sheet	dated	9/11/15	(version	2.0)	for	the	
above	study.	I	have	had	the	opportunity	to	consider	the	information,	ask	questions	and	have	
had	these	answered	satisfactorily.	
2. I	understand	that	my	participation	is	voluntary	and	that	I	am	free	to	withdraw	at	any	time	
without	giving	any	reason,	without	my	medical	care	or	legal	rights	being	affected.	
3. I	understand	that	relevant	sections	of	my	medical	notes	and	data	collected	during	
the	study	may	be	looked	at	by	individuals	from	regulatory	authorities	or	
from	the	NHS	Trust,	where	it	is	relevant	to	my	taking	part	in	this	research.	I	give	permission	for	
these	individuals	to	have	access	to	my	records.		
4. I	consent	to	provide	a	blood	sample	for	this	study.	I	understand	that	my	blood	sample	
will	be	discarded	after	the	test	result	is	obtained.		
5. I	understand	that	the	information	collected	about	me	will	be	used	to	support	
other	research	in	the	future,	and	may	be	shared	anonymously	with	other	researchers.		
6. I	agree	to	my	General	Practitioner	being	informed	of	my	participation	in	the	study.		
7. I	agree	to	take	part	in	the	above	study.	
	
	
	
	 	 	 	 	 	 	 	 	 	 	 	 	
Name	of	Participant	 	 	 Date	 	 	 	 Signature	
	
	 	 	 	 	 	 	 	 	 	 	 	 	
Name	of	Person	taking	consent	 	 Date	 	 	 	 Signature	
	 150	
Appendix	6:	Acceptability	questionnaires	for	point	of	care	test	and	venepuncture	(Chapter	4)	
 
 
 
 
 
 
 
Acceptability	 questionnaire	 for	 patients	 in	 the	
intervention	arm:	
	
Strongly	
disagree	
Disagree	 Neither	 Agree	 Strongly	
agree	
1. Blood	collection	process:	 	 	 	 	 	
a. The	finger	prick	was	not	painful.	 	 	 	 	 	
b. The	finger	prick	was	quick	and	easy.	 	 	 	 	 	
2. Convenience:	 	 	 	 	 	
a. I	 am	 satisfied	 that	 I	 can	 have	 the	 test	
done	 within	 the	 same	 consultation	
which	saves	me	from	having	to	make	a	
separate	 trip	 to	 the	 GP	 surgery	 or	
hospital	to	have	my	blood	taken.	
	 	 	 	 	
b. I	find	it	helpful	to	know	the	results	within	
10	minutes	so	it	saves	me	from	having	to	
travel	 for	 a	 second	 consultation	 to	
obtain	the	results.	
	 	 	 	 	
3. Quality	of	care:	 	 	 	 	 	
a. I	 am	 satisfied	 that	 the	 test	 results	 are	
available	 immediately	 rather	 than	
having	to	wait	for	a	few	days	or	weeks.	
	 	 	 	 	
b. I	 find	it	useful	to	be	able	to	discuss	the	
results	with	the	doctor	within	the	same	
consultation.	
	 	 	 	 	
4. Preference:	 	 	 	 	 	
I	prefer	a	finger	prick	test	to	a	standard	blood	
test	taken	from	a	vein.	
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Acceptability	questionnaire	for	venepuncture	
	
Strongly	
disagree	
Disagree	 Neither	 Agree	 Strongly	
agree	
1. Blood	collection	process:	 	 	 	 	 	
a. The	blood	test	was	not	painful.	 	 	 	 	 	
b. The	blood	test	was	quick	and	easy.	 	 	 	 	 	
2. Convenience:	 	 	 	 	 	
a. I	 don’t	 mind	 having	 to	 wait	 in	 line	 to	
have	my	blood	taken	in	the	phlebotomy	
department	after	seeing	the	doctor.	
	 	 	 	 	
b. I	 don’t	 mind	 having	 to	 travel	 for	 a	
second	 consultation	 to	 obtain	 the	
results.	
	 	 	 	 	
3. Quality	of	care:	 	 	 	 	 	
a. I	 am	 satisfied	 that	 the	 test	 results	 are	
available	 within	 a	 few	 days	 to	 a	 few	
weeks.	
	 	 	 	 	
b. I	don’t	mind	having	to	wait	for	the	next	
consultation	to	discuss	the	results	with	
the	doctor.			
	 	 	 	 	
4. Preference:	 	 	 	 	 	
I	prefer	a	standard	blood	test	taken	from	a	
vein	to	a	finger	prick	test.		
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Appendix	7:	Patient	information	sheet	(Chapters	4-6)	
	
Patient	Information	Sheet	
	
Study:	 Pre-endoscopy	 serological	 testing	 for	 coeliac	 disease;	 a	 novel	 approach	 using	 rapid	
antibody	testing.	
	
Investigators:	Professor	David	Sanders,	Dr.	Michelle	Lau,	William	White	
	
We	would	 like	 to	 invite	 you	 to	 take	part	 in	a	 research	 study.	Before	you	decide	you	need	 to	
understand	why	the	research	is	being	done	and	what	it	would	involve	for	you	
Ask	us	if	you	there	is	anything	that	is	not	clear	or	if	you	would	like	more	information.	Take	time	
to	decide	whether	you	would	like	to	participate	or	not.	If	you	do	decide	to	participate	you	will	be	
given	an	information	sheet	and	a	copy	of	the	signed	consent	form	to	keep.	
	
What	is	the	purpose	of	the	study?	
Coeliac	disease	 is	an	autoimmune	condition	 in	which	 the	body	attacks	 the	 lining	of	 the	small	
bowel.	The	 immune	reaction	 is	 triggered	by	gluten,	a	protein	found	 in	wheat,	barley	and	rye.	
Coeliac	disease	affects	approximately	1%	of	the	population	and	is	treated	with	a	gluten-free	diet.	
It	is	diagnosed	by	taking	a	biopsy	of	the	small	bowel	at	endoscopy.	It	is	important	that	people	
with	a	high	risk	for	coeliac	disease	have	biopsies	taken.	Currently	routine	laboratory	blood	tests	
are	used	to	identify	people	at	risk	of	coeliac	disease.	However,	the	results	are	not	always	available	
at	the	time	of	gastroscopy.	A	new	test	has	become	available	that	uses	a	pinprick	of	blood	from	
the	 finger.	A	 result	 is	 available	within	 ten	minutes.	 This	 test	 could	potentially	be	used	 in	 the	
endoscopy	department	to	identify	those	people	requiring	biopsy.	This	study	aims	to	assess	the	
accuracy	of	this	test	in	the	users	of	the	endoscopy	department	to	see	if	it	could	provide	a	faster,	
more	convenient	alternative	to	the	traditional	blood	test.	
	
Why	have	I	been	invited?	
Your	doctor	has	requested	that	you	have	a	gastroscopy	with	biopsies	and	standard	blood	tests	
for	coeliac	disease	as	part	of	your	routine	medical	care.		
	
Do	I	have	to	take	part?	
It	is	up	to	you	to	decide.	We	would	ask	you	to	sign	a	consent	form	to	show	that	you	have	agreed	
to	take	part.	You	are	free	to	withdraw	at	any	time	without	giving	a	reason.	This	would	not	affect	
the	standard	of	care	you	receive.	
	
What	will	happen	to	me	if	I	take	part?	
At	one	of	your	routine	appointments	either	in	the	outpatient	clinic	or	in	endoscopy,	you	will	have	
a	 blood	 test.	 This	 is	 the	 test	 under	 evaluation	 and	 the	 results	 produced	 have	 not	 yet	 been	
validated	(that	is	the	purpose	of	this	study).	For	this	reason,	you	will	not	be	told	the	result.	The	
result	of	your	test	has	no	bearing	on	the	care	that	you	will	receive.	
	
	
	 153	
What	are	the	possible	disadvantages	and	risks	of	taking	part?	
The	blood	test	is	minimally	uncomfortable.	
	
What	are	the	possible	benefits	of	taking	part?	
As	an	individual	you	will	not	benefit	directly	from	the	study	but	your	contribution	will	help	us	
provide	the	best	care	for	patients	in	the	future.	
	
What	if	there	is	a	problem?	
If	you	have	concerns	about	any	aspect	of	the	study	you	should	ask	to	speak	to	Dr	Michelle	Lau,	
clinical	research	fellow	on	01142261179.	She	will	do	her	best	to	answer	any	questions.	 If	you	
remain	unhappy	and	wish	to	complain	 formally,	you	can	do	this	 through	the	NHS	Complaints	
Procedure.	Details	can	be	obtained	from	the	hospital.	
	
Will	my	taking	part	in	this	study	be	kept	confidential?	
Identifiable	details	will	not	form	any	part	of	the	database.	Manual	files	are	stored	 in	a	 locked	
room	with	access	only	available	to	researchers.	Files	on	NHS	computers	will	require	individual	log	
on	 and	 password	 identification	 in	 keeping	 with	 standard	 Trust	 confidentiality	 practices.	
Databases	 will	 only	 be	 accessible	 by	 the	 research	 team	who	 will	 also	 have	 have	 access	 to	
participants'	personal	data.	Consent	would	be	sought	should	monitors	or	auditors	from	the	NHS	
require	access.	In	the	final	analysis	no	identifiable	data	will	be	used.	The	database	will	be	kept	
for	5	years	after	which	time	in	would	be	destroyed	in	line	with	current	practice.	
	
What	will	happen	to	any	samples	I	give?	
The	pin	prick	test	is	a	‘once	only’	test	and	generates	no	storable	sample.		
	
What	will	happen	to	the	results	of	the	research	study?	
It	 is	 intended	to	publish	the	results	of	 the	research	 in	peer	reviewed	 journals,	and	to	present	
them	 at	 scientific	meetings.	 Professor	 Sanders	 holds	 an	 honorary	 post	 as	medical	 advisor	 to	
Coeliac	UK	and	regularly	speaks	at	their	meetings.	No	identifiable	data	will	be	published.	
	
Who	is	organising	and	funding	the	research?	
The	study	is	sponsored	by	Professor	Sanders’	research	funds.	Tillotts	is	providing	the	testing	kits.	
	
Who	has	reviewed	the	study?	
All	research	in	the	NHS	is	looked	at	by	an	independent	group	called	a	Research	Ethics	Committee	
to	protect	 your	 safety,	 rights,	wellbeing	and	dignity.	 This	 study	has	been	 reviewed	and	given	
favourable	opinion	by	Hull	and	East	Riding	Research	Ethics	Committee.	
	
Further	information	and	contact	details	
If	 you	 have	 any	 questions	 about	 this	 study	 please	 contact	 Dr	Michelle	 Lau,	 Clinical	 Research	
Fellow	on	0114	2261179	or	michelle.lau3@sth.nhs.uk	
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Appendix	8:	Patient	consent	form	(Chapters	4-6)	
	
Consent	Form	
	
Title	of	project:	Pre-endoscopy	serological	testing	for	coeliac	disease;	a	novel	approach	using	
rapid	antibody	testing.	
	
Investigators:	Professor	David	Sanders,	Dr.	Michelle	Lau,	William	White	
	
Patient	ID	number:	
	
Please	initial	each	box	with	respect	to	the	following:	
	
										I	confirm	that	I	have	read	and	understand	the	information	sheet	for	the	above	study.	I	have	
had	the	opportunity	to	consider	the	information,	ask	questions	and	have	had	these	answered	
satisfactorily.	
	
										I	understand	that	my	participation	is	voluntary	and	that	I	am	free	to	withdraw	at	any	time,	
without	giving	any	reason,	without	my	medical	care	or	legal	rights	being	affected.	
	
										I	understand	that	relevant	sections	of	data	collected	during	the	study	may	be	looked	at	by	
responsible	 individuals	 from	 Sheffield	 Teaching	 Hospitals	 NHS	 Trust,	 or	 from	 regulatory	
authorities	where	 it	 is	 relevant	 to	my	 taking	part	 in	 this	 research.	 I	 give	permission	 for	 these	
individuals	to	have	access	to	the	data	I	have	contributed.		
	
										I	agree	to	take	part	in	the	above	study.		
	
	
1	copy	for	patient	and	1	for	researcher	file	
	
	
_____________________________________________________________________	
Name	of	patient																																							Signature																																																	Date	
	
	
_____________________________________________________________________																					
Name	of	person	taking	consent																Signature																																														Date	
	
	
_____________________________________________________________________	
Researcher																																																Signature																																																		Date	
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Appendix	9:	Health	dietary	adherence	questionnaire	for	patients	with	known	coeliac	disease	
on	a	gluten	free	diet	(Chapter	6)	
	
Date																																										
Name																																																								
Date	of	Birth																																										
	
Race/Ethnicity:	 	
White/Caucasian												Afro-Caribbean												Asian													Other	……………																								
	
1.	Compared	to	people	of	your	own	age,	how	would	you	rate	your	overall	health?					
											Excellent																	Good															Fair																	Poor																			Very	poor			
	
2.	Are	you	on	a	Gluten	Free	Diet			Yes	/	No			If	yes	:	
	 Self-imposed		 	 	 Dietician	advised				
	
3.	How	would	you	describe	your	bowel	habit?	
															Regular/Normal															Constipated																			Diarrhoea/Looseness	
	 	
	 Alternating	constipation	diarrhoea		
	
4.	On	average	how	often	do	you	open	your	bowels?	
Twice	per	week	or	less	 	 Alternate	days	
	
Once	per	day	 	 Twice	per	day	 											More	than	twice	per	day		
	
5.	Do	you	currently	have	any	of	these	symptoms?	
	 Flatulence	 	 	 Bloating			 				 Floating	stools				
														
											 Mucus	in	stools		 	 Urgency		
	 	
	 Nocturnal	diarrhoea		 Weight	loss	
	
6.	Any	other	symptoms?	
………………………………………………………………………………………………………………………………………………	
	
7.	With	regard	to	your	energy	level,	do	you	feel:	
			Less	tired	than	the	people	around	you	
			Similar	energy	to	the	people	around	you	
			More	tired	than	the	people	around	you	
			Tired	all	the	time	
How	long	have	you	been	on	a	
gluten	free	diet?		
 
_________ 
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Appendix	10:	Biagi	dietary	adherence	questionnaire	for	patients	with	known	coeliac	disease	
on	a	gluten	free	diet	(Chapter	6)	
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